molecule,virus,reference,type,SMILES,PubChem ID,target,Similarity Calculated,Activity Type,Activity (nM),Drug Status,ZINC ID,Drugbank ID,OBabel Canonical Smiles,Notes and Description
Remdesivir,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,121304016,,1,,,,,DB14761,CCC(COC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,
Chloroquine,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,2719,,1,,,,,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,
Nitazoxanide,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-],41684,,1,,,,,,CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+](=O)[O-],
Nafamostat,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,4413,,1,,,,,,NC(=Nc1ccc(cc1)C(=O)Oc1ccc2c(c1)ccc(c2)C(=N)N)N,
penciclovir,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,135398748,,1,,,,,,OCC(CCn1cnc2c1nc(N)[nH]c2=O)CO,
nafamostat,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,4413,,1,,,,,,NC(=Nc1ccc(cc1)C(=O)Oc1ccc2c(c1)ccc(c2)C(=N)N)N,
favipiravir,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,C1=C(N=C(C(=O)N1)C(=O)N)F,492405,,1,,,,,,Fc1c[nH]c(=O)c(n1)C(=O)N,
Loratadine,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,3957,Nsp6,1,Histamine 1 receptor antagonist,IC50 = 4000,Approved (Antihistamine),ZINC537931,,CCOC(=O)N1CCC(=C2c3ccc(cc3CCc3c2nccc3)Cl)CC1,
Daunorubicin,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,30323,Orf9c,1,Topoisomerase inhibitor,Ki = 70,Approved (Cancer),ZINC3917708,,COc1cccc2c1C(=O)c1c(C2=O)c(O)c2c(c1O)C(OC1CC(N)C(C(O1)C)O)CC(C2)(O)C(=O)C,
Midostaurin,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC,9829523,Orf9b,1,Multi-targeted protein kinase inhibitor,"KD = 100, 23",Approved (Cancer),ZINC100013130,,COC1C(CC2OC1(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O)N(C(=O)c1ccccc1)C,
Ponatinib,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,24826799,Nsp12,1,RIPK1 inhibitor,IC50 = 12,Approved (Cancer),ZINC000036701290,,CN1CCN(CC1)Cc1ccc(cc1C(F)(F)F)NC(=O)c1ccc(c(c1)C#Cc1cnc2n1nccc2)C,
Silmitasertib,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4,24748573,N,1,CK2 inhibitor,IC50 = 1,Approved (Cancer),ZINC58638454,,Clc1cccc(c1)Nc1nc2cc(ccc2c2c1ccnc2)C(=O)O,
Valproic Acid,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CCCC(CCC)C(=O)O,3121,Nsp5,1,HDAC2 inhibitor,Ki = 5,"Approved (CNS disease, Cancer)",ZINC3008621,,CCCC(C(=O)O)CCC,
Haloperidol,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,3559,Nsp6 Orf9c,1,Sigma 1/2 modulator,Ki = 2-12,Approved (CNS diseases),ZINC537822,,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl,
Metformin,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CN(C)C(=N)N=C(N)N,4091,Nsp7/Orf9c,1,MRC 1 inhibitor (indirect),na,Approved (Diabetes),ZINC12859773,,CN(C(=N)N=C(N)N)C,
Migalastat,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1C(C(C(C(N1)CO)O)O)O,176077,Nsp14,1,a-Gal inhibitor,IC50 = 40,Approved (Fabry disease),ZINC1636704,,OCC1NCC(C(C1O)O)O,
S-verapamil,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,92305,Orf9c,1,"Calcium channel, drug efflux transporter inhibitior",Ki = 113,Approved (Hypertension),ZINC3812888,,COc1ccc(cc1OC)CCN(CCCC(c1ccc(c(c1)OC)OC)(C(C)C)C#N)C,
Indomethacin,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,3715,Nsp7,1,Prostaglandin E2 synthase inhibitor,IC50 = 750,"Approved (Inflammation, Pain)",ZINC601283,,COc1ccc2c(c1)c(CC(=O)O)c(n2C(=O)c1ccc(cc1)Cl)C,
Ruxolitinib,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,25126798,Orf9b,1,Multi-targeted protein kinase inhibitor,MARK1 KD = 660 MARK3 KD > 10000,Approved (Myelofibrosis),ZINC43207851,,N#CCC(n1ncc(c1)c1ncnc2c1cc[nH]2)C1CCCC1,
Mycophenolic acid,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O,446541,Nsp14,1,IMPDH inhibitor,IC50 = 20,Approved (Organ rejection),ZINC000000001758,,COc1c(CC=C(CCC(=O)O)C)c(O)c2c(c1C)COC2=O,
Entacapone,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N,5281081,Nsp7,1,COMT inhibitor,IC50 = 151,Approved (Parkinson's disease),ZINC35342787,,CCN(C(=O)C(=Cc1cc(O)c(c(c1)[N+](=O)[O-])O)C#N)CC,
Ribavirin,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,37542,Nsp14,1,IMPDH inhibitor,IC50 = 100-250,Approved (Viral infection),ZINC1035331,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,
E-52862,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1=CC(=NN1C2=CC3=CC=CC=C3C=C2)OCCN4CCOCC4,44247568,Nsp6,1,Sigma 1 antagonist,IC50 = 17,Clinical Trial,ZINC95000617,,Cc1cc(nn1c1ccc2c(c1)cccc2)OCCN1CCOCC1,
Merimepodib,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)OC3CCOC3)C4=CN=CO4,153241,Nsp14,1,IMPDH inhibitor,Ki = 10,Clinical Trial,ZINC3975663,,COc1cc(ccc1c1cnco1)NC(=O)Nc1cccc(c1)CNC(=O)OC1COCC1,
RVX-208,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1=CC(=CC(=C1OCCO)C)C2=NC3=C(C(=CC(=C3)OC)OC)C(=O)N2,135564749,E,1,BRD2/4 inhibitor,IC50 = 50-1800,Clinical Trial,ZINC43199551,,OCCOc1c(C)cc(cc1C)c1nc2cc(OC)cc(c2c(=O)[nH]1)OC,
XL413,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1CC(NC1)C2=NC3=C(C(=O)N2)OC4=C3C=C(C=C4)Cl,135564632,Orf8,1,CDC7 inhibitor,IC50 = 3.4,Clinical Trial,ZINC84668615,,Clc1ccc2c(c1)c1nc([nH]c(=O)c1o2)C1CCCN1,
AC-55541,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC(=NNC(=O)C(C1=NNC(=O)C2=CC=CC=C21)NC(=O)C3=CC=CC=C3)C4=CC(=CC=C4)Br,9589606,Orf9c,1,PAR agonist,pEC50 = 6.7,Pre-clinical,ZINC13302309,,Brc1cccc(c1)C(=NNC(=O)C(c1n[nH]c(=O)c2c1cccc2)NC(=O)c1ccccc1)C,
Apicidin,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CCC(C)C1C(=O)N2CCCCC2C(=O)NC(C(=O)NC(C(=O)N1)CC3=CN(C4=CC=CC=C43)OC)CCCCCC(=O)CC,6918328,Nsp5,1,HDAC inhibitor,IC50 = 120,Pre-clinical,ZINC17654900,,CCC(=O)CCCCCC1NC(=O)C2CCCCN2C(=O)C(NC(=O)C(NC1=O)Cc1cn(c2c1cccc2)OC)C(CC)C,
AZ3451,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC(C1CCCCC1)N2C3=C(C=C(C=C3)C(=O)NC4=CC=C(C=C4)C#N)N=C2C5=CC6=C(C=C5Br)OCO6,126961335,Orf9c,1,PAR2 negative allosteric modulator,pKD = 15,Pre-clinical,ZINC914431341,,N#Cc1ccc(cc1)NC(=O)c1ccc2c(c1)nc(n2C(C1CCCCC1)C)c1cc2OCOc2cc1Br,
AZ8838,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CCCC1=C(C=CC(=C1)F)C(C2=NC=CN2)O,126961334,Orf9c,1,PAR antagonist,IC50 = 344,Pre-clinical,ZINC914431265,,CCCc1cc(F)ccc1C(c1ncc[nH]1)O,
Bafilomycin A1,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)C2(CC(C(C(O2)C(C)C)C)O)O)O)OC)C,6436223,Nsp6,1,ATPase inhibitor,IC50 = 100,Pre-clinical,ZINC000169647947,,COC1C=CC=C(C)CC(C)C(O)C(C=C(C=C(C(=O)OC1C(C(C(C1(O)CC(O)C(C(O1)C(C)C)C)C)O)C)OC)C)C,
CCT 365623,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CS(C1=CC(S(C2=CC=C(CN)S2)(=O)=O)=CC(C3=CC=CC=C3)=C1)(=O)=O,,Orf8,1,LOXL2 inhibitor,IC50 = 1500,Pre-clinical,ZINC1776011385,,NCc1ccc(s1)S(=O)(=O)c1cc(cc(c1)S(=O)(=O)C)c1ccccc1,
GB110,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CCC(C)C(C(=O)NCC1=CC(=CC=C1)C(=O)N2CCC(CC2)CN)NC(=O)C(CC3CCCCC3)NC(=O)C4=CC=NO4,49843508,Orf9c,1,PAR2 agonist,EC50 = 280,Pre-clinical,ZINC64527010,,NCC1CCN(CC1)C(=O)c1cccc(c1)CNC(=O)C(C(CC)C)NC(=O)C(NC(=O)c1ccno1)CC1CCCCC1,
H-89,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1=CC2=C(C=CN=C2)C(=C1)S(=O)(=O)NCCNCC=CC3=CC=C(C=C3)Br,449241,Nsp13,1,Protein kinase A inhibitor,KD = 48,Pre-clinical,ZINC2043204,,Brc1ccc(cc1)C=CCNCCNS(=O)(=O)c1cccc2c1ccnc2,
JQ1,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C,46907787,E,1,BRD inhibitor,IC50 = 4-120,Pre-clinical,ZINC57318556,,O=C(OC(C)(C)C)CC1N=C(c2ccc(cc2)Cl)c2c(n3c1nnc3C)sc(c2C)C,
PB28,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,COC1=CC=CC2=C1CCCC2CCCN3CCN(CC3)C4CCCCC4,10474335,Nsp6/Orf9c,1,Sigma 1/2 modulator,IC50 = 15,Pre-clinical,ZINC22931094,,COc1cccc2c1CCCC2CCCN1CCN(CC1)C1CCCCC1,
PD-144418,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CCCN1CCC=C(C1)C2=CC(=NO2)C3=CC=C(C=C3)C,9817231,Nsp6,1,Sigma 1 antagonist,Ki = 0.8,Pre-clinical,,,CCCN1CCC=C(C1)c1onc(c1)c1ccc(cc1)C,
RS-PPCC,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,Cc1ccc(cc1)C2(CC2CN3CCC(CC3)(c4ccccc4)O)C(=O)OC,,Nsp6,1,Sigma 1 agonist,Ki = 1.5,Pre-clinical,ZINC28635556,,COC(=O)C1(CC1CN1CCC(CC1)(O)c1ccccc1)c1ccc(cc1)C,
TMCB,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CN(C)C1=NC2=C(N1CC(=O)O)C(=C(C(=C2Br)Br)Br)Br,46943415,N,1,Multi-targeted protein kinase inhibitor,Ki = 21,Pre-clinical,ZINC000058638742,,OC(=O)Cn1c(nc2c1c(Br)c(Br)c(c2Br)Br)N(C)C,
UCPH-101,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,COC1=CC=C(C=C1)C2C(=C(OC3=C2C(=O)CC(C3)C4=CC=CC5=CC=CC=C54)N)C#N,25223366,M,1,EAAT1 inhibitor,IC50 = 660,Pre-clinical,ZINC000040914195,,COc1ccc(cc1)C1C2=C(OC(=C1C#N)N)CC(CC2=O)c1cccc2c1cccc2,
ZINC1775962367,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,Cc1nc2c([N+](=O)[O-])c(Cl)c(Cl)cc2n1Cc1ccc([B-]23OC(=O)C[N+]2(C)CC(=O)O3)cc1,,Orf9b,1,dCTPase inhibitor,IC50 = 47,Pre-clinical,ZINC1775962367,,O=C1C[N+]2([B-](O1)(OC(=O)C2)c1ccc(cc1)Cn1c(C)nc2c1cc(Cl)c(c2[N+](=O)[O-])Cl)C,
ZINC4326719,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,COc1ccc(-c2nn3c(-c4ccco4)nnc3s2)cc1OC,661498,Orf9b,1,DCTPP1 inhibitor,IC50 = 19,Pre-clinical,ZINC4326719,,COc1cc(ccc1OC)c1nn2c(s1)nnc2c1ccco1,
ZINC4511851,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,COC1=C(C=C(C=C1)C2=NN3C(=NN=C3S2)C4=CC=CS4)OC,3163969,Orf9b,1,dCTPase inhibitor,IC50 = 20,Pre-clinical,ZINC4511851,,COc1cc(ccc1OC)c1nn2c(s1)nnc2c1cccs1,
ZINC95559591,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,O=C(NCCCNc1nc(Nc2ccc(N3CCOCC3)cc2)ncc1C1CC1)C1CCC1,44465558,Orf9b Nsp13,1,Multi-targeted protein kinase inhibitor,MARK3 IC50 = 12 TBK1 IC50 = 6,Pre-clinical,ZINC95559591,,O=C(C1CCC1)NCCCNc1nc(ncc1C1CC1)Nc1ccc(cc1)N1CCOCC1,
4E2RCat,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1=CC=C(C=C1)CN2C(=O)C(=CC3=CC=C(O3)C4=CC(=C(C=C4)Cl)C(=O)O)SC2=S,2287236,,1,eIF4E/G PPI inhibitor,IC50 = 13500,Pre-clinical,ZINC7018722,,S=C1SC(=Cc2ccc(o2)c2ccc(c(c2)C(=O)O)Cl)C(=O)N1Cc1ccccc1,
ABBV-744,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CCNC(=O)C1=CC2=C(N1)C(=O)N(C=C2C3=C(C=CC(=C3)C(C)(C)O)OC4=C(C=C(C=C4C)F)C)C,132010322,E,1,BRD inhibitor,Kd = 2.1,Clinical Trial,ZINC1250228389,,CCNC(=O)c1cc2c([nH]1)c(=O)n(cc2c1cc(ccc1Oc1c(C)cc(cc1C)F)C(O)(C)C)C,
Camostat,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N,2536,,1,Serine protease 1 inhibitor,IC50 < 1000,Approved (Pancreatitis),ZINC3871842,,CN(C(=O)COC(=O)Cc1ccc(cc1)OC(=O)c1ccc(cc1)N=C(N)N)C,
Captopril,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC(CS)C(=O)N1CCCC1C(=O)O,44093,,1,ACE inhibitor,Ki = 3,Approved (Hypertension),ZINC57001,,SCC(C(=O)N1CCCC1C(=O)O)C,
CB5083,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1=CC2=C(C=CC=C2N1C3=NC4=C(COCC4)C(=N3)NCC5=CC=CC=C5)C(=O)N,73051434,Orf10,1,p97 inhibitor,IC50 = 11,Clinical Trial,ZINC208076131,,NC(=O)c1cccc2c1cc(n2c1nc(NCc2ccccc2)c2c(n1)CCOC2)C,
Chloramphenicol,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1=CC(=CC=C1C(C(CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],5959,,1,mitochondrial ribosome inhibitor,IC50 = 7400,Approved (Bacterial infection),ZINC113382,,OCC(C(c1ccc(cc1)[N+](=O)[O-])O)NC(=O)C(Cl)Cl,
Chloroquine,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,2719,Nsp6,1,Sigma 1 binder,Ki = 100,Approved (Malaria),ZINC19144231,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,
Compound 10,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,COC=C(C1=CC=CC=C1OC2=CC(=O)NC=N2)C(=O)OO,139595720,,1,PI4K-IIIß inhibitor,IC50 = 3.4,Pre-clinical,,,COC=C(c1ccccc1Oc1nc[nH]c(=O)c1)C(=O)OO,
Compound 2,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,O=C([C@@H]1CCCN(C([C@H](C)NC([C@H](C(C)C)N2)=O)=O)N1)O[C@H](CCNC(OC(C)(C)C)=O)C3=CC=CC(/C=C/CC[C@@H](OC)[C@@H](C)C2=O)=C3,,,1,Cyclophilin inhibitor,Kd = 24,Pre-clinical,,,CO[C@@H]1CC/C=C/c2cccc(c2)[C@@H](CCNC(=O)OC(C)(C)C)OC(=O)[C@H]2NN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1C)C(C)C)C)CCC2,
CPI-0610,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1=NOC2=C1C3=CC=CC=C3C(=NC2CC(=O)N)C4=CC=C(C=C4)Cl,57389999,E,1,BRD inhibitor,BRD2 IC50 = 25 BRD4 IC50 = 18,Clinical Trial,ZINC200480149,,NC(=O)CC1N=C(c2ccc(cc2)Cl)c2c(c3c1onc3C)cccc2,
Dabrafenib,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,44462760,Nsp9,1,NEK9 nhibitor,IC50 = 1,Approved (Cancer),ZINC68153186,,Nc1nccc(n1)c1sc(nc1c1cccc(c1F)NS(=O)(=O)c1c(F)cccc1F)C(C)(C)C,
DBeQ,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)NCC4=CC=CC=C4,676352,Orf10,1,p97 inhibitor,Ki = 3200,Pre-clinical,ZINC39389,,c1ccc(cc1)CNc1nc(NCc2ccccc2)c2c(n1)cccc2,
dBET6,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)NCCCCCCCCNC(=O)COC4=CC=CC5=C4C(=O)N(C5=O)C6CCC(=O)NC6=O)C7=CC=C(C=C7)Cl)C,121427831,E,1,Degrades BRD proteins,IC50 < 10000,Pre-clinical,,,O=C(COc1cccc2c1C(=O)N(C2=O)C1CCC(=O)NC1=O)NCCCCCCCCNC(=O)CC1N=C(c2ccc(cc2)Cl)c2c(n3c1nnc3C)sc(c2C)C,
IHVR-19029,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,O[C@H]1[C@H](O)[C@@H](O)CN(CCCCCCN(C2CCCCC2)C(NC(C)(C)C)=O)[C@@H]1CO,,,1,antiviral activity,IC50 = 1200,Clinical Trial,,,OC[C@H]1N(CCCCCCN(C(=O)NC(C)(C)C)C2CCCCC2)C[C@@H]([C@H]([C@@H]1O)O)O,
Linezolid,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,441401,,1,mitochondrial ribosome inhibitor,IC50 = 16000,Approved (Bacterial infection),ZINC2008866,,CC(=O)NCC1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,
Lisinopril,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O,5362119,,1,ACE inhibitor,Ki = 0.27,Approved (Hypertension),ZINC3812863,,NCCCCC(C(=O)N1CCCC1C(=O)O)NC(C(=O)O)CCc1ccccc1,
Minoxidil,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,4201,Orf8,1,PLOD inhibitor,indirect mechanism,Approved (Hair loss),ZINC1735,,Nc1cc(nc(=N)n1O)N1CCCCC1,
ML240,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,COC1=CC=CC2=C1N=C(N=C2NCC3=CC=CC=C3)N4C5=CC=CC=C5N=C4N,49830258,Orf10,1,p97 inhibitor,IC50 = 100,Pre-clinical,ZINC96021026,,COc1cccc2c1nc(nc2NCc1ccccc1)n1c(N)nc2c1cccc2,
MZ1,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1=C(C2=C(N3C(C)=NN=C3[C@@H](N=C2C4=CC=C(C=C4)Cl)CC(NCCOCCOCCOCC(N[C@@H](C(C)(C)C)C(N5C[C@@H](C[C@H]5C(NCC6=CC=C(C7=C(N=CS7)C)C=C6)=O)O)=O)=O)=O)S1)C,,E,1,Degrades BRD proteins,Kd = 120-228,Pre-clinical,,,O[C@@H]1C[C@H](N(C1)C(=O)[C@H](C(C)(C)C)NC(=O)COCCOCCOCCNC(=O)C[C@@H]1N=C(c2ccc(cc2)Cl)c2c(n3c1nnc3C)sc(c2C)C)C(=O)NCc1ccc(cc1)c1scnc1C,
Nafamostat,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,4413,,1,Serine protease 1 inhibitor,IC50 = 100,Approved (Anticoagulant),ZINC3874467,,NC(=Nc1ccc(cc1)C(=O)Oc1ccc2c(c1)ccc(c2)C(=N)N)N,
Pevonedistat,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1CC2=CC=CC=C2C1NC3=C4C=CN(C4=NC=N3)C5CC(C(C5)O)COS(=O)(=O)N,16720766,Orf10,1,NEDD8-activating enzyme inhibitor,IC50 = 4.7,Clinical Trial,ZINC58660702,,OC1CC(CC1COS(=O)(=O)N)n1ccc2c1ncnc2NC1CCc2c1cccc2,
PS3061,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC(C)C[C@@H]1NC(=O)[C@@H](CCC#N)OC(=O)[C@H](C)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN(CC3=CC=C(Br)C=C3)C3=C2C=CC=C3)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C1=O,,,1,Sec61 inhibitor,IC50 = 20-500,Pre-clinical,,,N#CCC[C@H]1OC(=O)[C@H](C)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2cn(c3c2cccc3)Cc2ccc(cc2)Br)N(C(=O)[C@@H](NC(=O)[C@@H](N(C(=O)[C@@H](NC1=O)CC(C)C)C)CC(C)C)CC(C)C)C,
Rapamycin (Sirolimus),SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,5284616,N Nsp2 Orf8,1,mTOR inhibitor,IC50 =2.0,Approved (Organ rejection),ZINC169289388,,COC1CC(CCC1O)CC(C1OC(=O)C2CCCCN2C(=O)C(=O)C2(O)OC(CCC2C)CC(OC)C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)C1)C)C)O)OC)C)C)C)C,
Sanglifehrin A,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CCC1CC(C2(C(C(C(C(O2)CC(C(C)CCC=CC=C(C)C3CC=CC=CC(C(C(C(C(=O)NC(C(=O)NC(C(=O)N4CCCC(N4)C(=O)O3)CC5=CC(=CC=C5)O)C(C)C)CCC(=O)C)O)C)O)O)C)O)C)NC1=O)C,5388925,Nsp14,1,PPIA-IMPDH2 modulator,PPIA Kd = 0.2 IPDH2 Binding EC50 = 11.5 (with PPIA),Pre-clinical,,,CCC1CC(C)C2(NC1=O)OC(CC(C(CCC=CC=C(C1CC=CC=CC(O)C(C)C(O)C(CCC(=O)C)C(=O)NC(C(=O)NC(C(=O)N3NC(C(=O)O1)CCC3)Cc1cccc(c1)O)C(C)C)C)C)O)C(C(C2C)O)C,
Sapanisertib (INK128/MlN128),SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC(C)[N]1N=C(C2=CC3=C(OC(=N3)N)C=C2)C4=C(N)N=CN=C14,,N,1,mTOR inhibitor,IC50 = 1,Clinical Trial,ZINC73069271,,Nc1oc2c(n1)cc(cc2)c1nn(c2c1c(N)ncn2)C(C)C,
FK-506 (Tacrolimus),SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,445643,Orf8,1,FKBP inhibitor,,Approved (Organ rejection),ZINC85537027,,C=CCC1C=C(C)CC(C)CC(OC)C2OC(O)(C(CC2OC)C)C(=O)C(=O)N2C(C(=O)OC(C(C(CC1=O)O)C)C(=CC1CCC(C(C1)OC)O)C)CCCC2,
Ternatin 4 (DA3),SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,O=C([C@H](CC(C)C)N(C([C@@H](N(C([C@H](NC([C@H](NC([C@H]1CCCCN1C([C@H](C)N2C)=O)=O)[C@@H](C(C)C)O)=O)[C@@H](C)CC)=O)C)C)=O)C)N[C@@H](C[C@@H](C)C=C)C2=O,,,1,eEF1A inhibitor,IC50 = 71,Pre-clinical,,,C=C[C@@H](C[C@@H]1NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C)N(C)C(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H]2N(C(=O)[C@@H](N(C1=O)C)C)CCCC2)[C@@H](C(C)C)O)[C@H](CC)C)C,
Tigecycline,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC(C)(C)NCC(=O)NC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C,54686904,,1,mitochondrial ribosome inhibitor,IC50 = 3300,Approved (Bacterial infection),ZINC14879972,,O=C(Nc1cc(N(C)C)c2c(c1O)C(=C1C(C2)CC2C(C1=O)(O)C(=C(C(=O)C2N(C)C)C(=O)N)O)O)CNC(C)(C)C,
Tomivosertib (eFT-508),SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,CC1=C2N(C(=O)C(=C1)NC3=NC=NC(=C3)N)C4(CCCCC4)NC2=O,,,1,MNK1/2 inhibitor,IC50 = 2.4,Clinical Trial,ZINC575623807,,Nc1ncnc(c1)Nc1cc(C)c2n(c1=O)C1(CCCCC1)NC2=O,
Verdinexor,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,C1=CC=NC(=C1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,71492799,Nsp4/9/Orf6,1,XPO1/nuclear export inhibitor,IC50 = 960,Clinical Trial,ZINC205957597,,O=C(C=Cn1cnc(n1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)NNc1ccccn1,
WDB002,SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,O=C([C@]1([H])CCCCN1C2=O)O[C@@H](/C=C/C/C=C/C[C@@H](C)[C@H](O)[C@@H](C)[C@@]3([H])O[C@](C2=O)(O)[C@H](C)CC3)[C@H](CC)CC4=CC=CC=C4,,Nsp13,1,CEP250 inhibitor (with FKBP),Kd = 0.29,Clinical Trial,,,CC[C@@H]([C@@H]1/C=C/C/C=C/C[C@@H](C)[C@H](O)[C@H]([C@H]2O[C@](C(=O)C(=O)N3[C@H](C(=O)O1)CCCC3)(O)[C@H](C)CC2)C)Cc1ccccc1,
Zotatifin (eFT226),SARS-CoV-2,10.1101/2020.03.22.002386v1,Experimental,N#CC1=CC=C([C@@]2(O3)[C@@](C4=C3C=C(OC)N=C4OC)(O)[C@H](O)[C@H](CN(C)C)[C@H]2C5=CC=CC=C5)C=C1,,Nsp2,1,EIF4a inhibitor,IC50 = 1.5,Clinical Trial,,,COc1nc(OC)cc2c1[C@]1(O)[C@H](O)[C@@H]([C@H]([C@@]1(O2)c1ccc(cc1)C#N)c1ccccc1)CN(C)C,
Camostat,MERS,10.3390/v10120721,Experimental,CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N,2536,,1,"could completely block syncytium formation, but only partially block virus entry",,,,,CN(C(=O)COC(=O)Cc1ccc(cc1)OC(=O)c1ccc(cc1)N=C(N)N)C,
Chloroquine,MERS,10.3390/v10120721,Experimental,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,2719,,1,inhibited MERS-CoV replication and blocked infection,,,,,CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C,
Chlorpromazine,MERS,10.3390/v10120721,Experimental,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2,2726,,1,inhibited MERS-CoV replication at both early and post-entry stages,,,,,CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C,
Ouabain,MERS,10.3390/v10120721,Experimental,CC1C(C(C(C(O1)OC2CC(C3(C4C(CCC3(C2)O)C5(CCC(C5(CC4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O,439501,,1,inhibit MERS-CoV entry,,,,,OCC12C(O)CC(CC2(O)CCC2C1C(O)CC1(C2(O)CCC1C1=CC(=O)OC1)C)OC1OC(C)C(C(C1O)O)O,
bufalin,MERS,10.3390/v10120721,Experimental,CC12CCC(CC1CCC3C2CCC4(C3(CCC4C5=COC(=O)C=C5)O)C)O,9547215,,1,inhibit MERS-CoV entry,,,,,OC1CCC2(C(C1)CCC1C2CCC2(C1(O)CCC2c1ccc(=O)oc1)C)C,
Dihydrotanshinone,MERS,10.3390/v10120721,Experimental,CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C(C=CC=C43)C,5316743,,1,showed a decimal reduction and antiviral effects,,,,,CC1COC2=C1C(=O)C(=O)c1c2ccc2c1cccc2C,
Disulfiram,MERS,10.3390/v10120721,Experimental,CCN(CC)C(=S)SSC(=S)N(CC)CC,3117,,1,allosteric inhibitor,,,,,CCN(C(=S)SSC(=S)N(CC)CC)CC,
6TG (6-thioguanine),MERS,10.3390/v10120721,Experimental,NC1=NC(=S)C2=C(N1)N=CN2,,,1,inhibit MERS-CoV papain-like protease,,,,,Nc1nc(=S)c2c([nH]1)nc[nH]2,Tioguanine
MPA (mycophenolic acid),MERS,10.3390/v10120721,Experimental,COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C,,,1,inhibit MERS-CoV papain-like protease,,,,,COc1c(C/C=C(/CCC(=O)O)\C)c(O)c2c(c1C)COC2=O,
Promethazine,MERS,10.3390/v10120721,Experimental,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,4927,,1,inhibitors of cell–cell fusion,,,,,CN(C(CN1c2ccccc2Sc2c1cccc2)C)C,
fluphenazine,MERS,10.3390/v10120721,Experimental,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,3372,,1,inhibitors of cell–cell fusion,,,,,OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F,
Ribavirin,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,37542,,1,,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,
Lopinavir,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,92727,,1,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
ritonavir,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,392622,,1,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,
Penciclovir,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,135398748,,1,,,,,,OCC(CCn1cnc2c1nc(N)[nH]c2=O)CO,
Nitazoxanide,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-],41684,,1,,,,,,CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+](=O)[O-],
Chloroquine,SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,2719,,1,,,,,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,
Remdesivir (GS- 5734),SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1,,,1,,,,,,CCC(COC(=O)[C@@H](N[P@@](=O)(Oc1ccccc1)OC[C@H]1O[C@@]([C@@H]([C@@H]1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,
Favipiravir (T-705),SARS-CoV-2,10.1038/s41422-020-0282-0,Experimental,C1=C(N=C(C(=O)N1)C(=O)N)F,492405,,1,,,,,,Fc1c[nH]c(=O)c(n1)C(=O)N,
Ribavirin,SARS,10.3201/eid1004.030458,Experimental,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,37542,,1,Inhibited CPE in SARS-CoV infected vero E6 cells,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,
Oseltamivir,SARS,10.3201/eid1004.030458,Experimental,CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC,65028,,1,,,,,,CCOC(=O)C1=CC(C(C(C1)N)NC(=O)C)OC(CC)CC,
Foscarnet,SARS,10.3201/eid1004.030458,Experimental,OC(=O)P(O)(O)=O,3415,,1,,,,,,OC(=O)P(=O)(O)O,
EGCG Palmitate,SARS,10.2174/1871528114666151022150122,Experimental,OC1=CC(O)=C2C[C@@H](OC(=O)C3=CC(O)=C(O)C(O)=C3)[C@H](OC2=C1)C1=CC(O)=C(O)C(O)=C1,,,1,Used in compounding. Inhibitory strategies against pathogenic viruses,,,,,Oc1cc(O)c2c(c1)O[C@@H]([C@@H](C2)OC(=O)c1cc(O)c(c(c1)O)O)c1cc(O)c(c(c1)O)O,
"glycoside glycyrrhizic acid (glycyrrhizin, GL)",SARS,10.1021/jm0493008,Experimental,O=C(O)[C@H]7O[C@@H](O[C@@H]6[C@@H](O)[C@H](O)[C@H](O[C@@H]6O[C@@H]2C(C)(C)[C@@H]3CC[C@@]1(C)[C@]5(C(=C/C(=O)[C@@H]1[C@@]3(C)CC2)\[C@@H]4C[C@](C(=O)O)(C)CC[C@]4(C)CC5)C)C(=O)O)[C@H](O)[C@@H](O)[C@@H]7O,,,1,"antitumoral, antiinflammatory, and antiviral",,,,,O[C@@H]1[C@@H](O[C@@H]2O[C@H](C(=O)O)[C@H]([C@@H]([C@H]2O)O)O)[C@H](O[C@@H]([C@H]1O)C(=O)O)O[C@H]1CC[C@]2([C@H](C1(C)C)CC[C@@]1([C@@H]2C(=O)C=C2[C@@]1(C)CC[C@@]1([C@H]2C[C@](C)(CC1)C(=O)O)C)C)C,
zanamivir,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N,60855,,1,neuraminidase inhibitor,,,,,OCC(C(C1OC(=CC(C1NC(=O)C)N=C(N)N)C(=O)O)O)O,
oseltamivir,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC,65028,,1,neuraminidase inhibitor,,,,,CCOC(=O)C1=CC(C(C(C1)N)NC(=O)C)OC(CC)CC,
arbidol,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3,131411,,1,fusion peptide,,,,,CCOC(=O)c1c(CSc2ccccc2)n(c2c1c(CN(C)C)c(O)c(c2)Br)C,
Lamivudine,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,C1C(OC(S1)CO)N2C=CC(=NC2=O)N,60825,,1,RNA synthesis inhibitor,,,,,Nc1ccn(c(=O)n1)C1CSC(O1)CO,
lopinavir,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,92727,,1,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
ritonavir,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,392622,,1,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,
Umifenovir,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3,131411,,1,Arbidol chemical name,,,,,CCOC(=O)c1c(CSc2ccccc2)n(c2c1c(CN(C)C)c(O)c(c2)Br)C,
hydroxychloroquine,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,3652,,1,,,,,,OCCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,Clinical Trial
chloroquine,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,2719,,1,,,,,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,Clinical Trial
remdesivir,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,121304016,,1,,,,,,CCC(COC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,Clinical Trial
arbidol,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3,131411,,1,,,,,,CCOC(=O)c1c(CSc2ccccc2)n(c2c1c(CN(C)C)c(O)c(c2)Br)C,Clinical Trial
lopinavir,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,92727,,1,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,Clinical Trial
ritonavir,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,392622,,1,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,Clinical Trial
darunavir,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,213039,,1,,,,,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1COC2C1CCO2)O)C,Clinical Trial
cobicistat,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,25151504,,1,,,,,,O=C(NC(Cc1ccccc1)CCC(Cc1ccccc1)NC(=O)C(NC(=O)N(Cc1csc(n1)C(C)C)C)CCN1CCOCC1)OCc1cncs1,Clinical Trial
favipiravir,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,C1=C(N=C(C(=O)N1)C(=O)N)F,492405,,1,,,,,,Fc1c[nH]c(=O)c(n1)C(=O)N,Clinical Trial
thalidomide,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,5426,,1,,,,,,O=C1CCC(C(=O)N1)N1C(=O)c2c(C1=O)cccc2,Clinical Trial
vitamin C,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,C(C(C1C(=C(C(=O)O1)O)O)O)O,54670067,,1,,,,,,OCC(C1OC(=O)C(=C1O)O)O,Clinical Trial
methylpredinsone,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,,,1,,,,,,OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)CC(=O)[C@H]1[C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)C,Clinical Trial
pirfenidone,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,40632,,1,,,,,,Cc1ccc(=O)n(c1)c1ccccc1,Clinical Trial
bromhexine hydrochloride,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CN(CC1=C(C(=CC(=C1)Br)Br)N)C2CCCCC2.Cl,5702220,,1,,,,,,Brc1cc(CN(C2CCCCC2)C)c(c(c1)Br)N.Cl,Clinical Trial
Fingolimod,SARS-CoV-2,10.5582/bst.2020.01020,Experimental,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N,107970,,1,,,,,,CCCCCCCCc1ccc(cc1)CCC(CO)(CO)N,Clinical Trial
INSC-1,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1(F)ccc(CN2CCC3(CC2)NC(=O)c2c([C@H](NS(=O)(=O)c4ccccc4)C)ccn32)c(CN2CCN(C(=O)CC)CC2)c1,,,1,,,,,,CCC(=O)N1CCN(CC1)Cc1cc(F)ccc1CN1CCC2(CC1)NC(=O)c1n2ccc1[C@H](NS(=O)(=O)c1ccccc1)C,
INSC-2,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(C)[C@@H](NC(=O)c1nn(c2cccc(F)c2)c2c1CCC2)C(=O)NC1CCN(C[C@@H](C)c2cccc(F)c2)CC1,,,1,,,,,,Fc1cccc(c1)[C@@H](CN1CCC(CC1)NC(=O)[C@@H](C(C)C)NC(=O)c1nn(c2c1CCC2)c1cccc(c1)F)C,
INSC-3,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(C)[C@@H](CNC(=O)C[C@]1(NC(=O)Nc2cccc(c2)C2(N)CC2)CCOc2ccccc12)NC(=O)c1cc(sc1)C,,,1,,,,,,O=C(C[C@@]1(CCOc2c1cccc2)NC(=O)Nc1cccc(c1)C1(N)CC1)NC[C@H](C(C)C)NC(=O)c1csc(c1)C,
INSC-4,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C(N)(C(=O)Nc1cccc2c1NC(=O)N1CCN(C(=O)c3c(cccc3C)F)C[C@H]21)(C)C,,,1,,,,,,O=C1Nc2c(cccc2[C@@H]2N1CCN(C2)C(=O)c1c(C)cccc1F)NC(=O)C(N)(C)C,
INSC-5,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,COc1cccc([C@@H]2CC3(CN(c4ccc(C(=O)N5CCN(c6ccc(cc6)F)C(=O)C5)c(C)c4)C3)NS2(=O)=O)c1,,,1,,,,,,COc1cccc(c1)[C@@H]1CC2(NS1(=O)=O)CN(C2)c1ccc(c(c1)C)C(=O)N1CCN(C(=O)C1)c1ccc(cc1)F,
INSC-6,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C(Nc1ccc(c2c(CN3CCC(CC3)(F)F)cc[nH]c2=O)cc1)[C@H](NS(=O)(=O)c1ccc(cc1)F)c1ccccc1,,,1,,,,,,Fc1ccc(cc1)S(=O)(=O)N[C@H](c1ccccc1)C(=O)Nc1ccc(cc1)c1c(cc[nH]c1=O)CN1CCC(CC1)(F)F,
INSC-7,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,N(CS(=O)(=O)Nc1cccc(NC(=O)c2cn(C[C@@H](O)c3ccc(C(F)(F)F)cc3)c3ccccc23)c1)C,,,1,,,,,,CNCS(=O)(=O)Nc1cccc(c1)NC(=O)c1cn(c2c1cccc2)C[C@H](c1ccc(cc1)C(F)(F)F)O,
INSC-8,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C[C@@]1(c2ccc(C(=O)N3CCC4(CC3)C[C@@H](c3ccc(O)c(c3)C)C(=O)N4)cc2)NC(=O)N(Cc2ccc(c(F)c2)C)C1=O,,,1,,,,,,O=C(c1ccc(cc1)[C@]1(C)NC(=O)N(C1=O)Cc1ccc(c(c1)F)C)N1CCC2(CC1)C[C@H](C(=O)N2)c1ccc(c(c1)C)O,
INSC-9,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C[C@@]1(c2cc(c(C(=O)N3CCC4(CC3)C[C@@H](c3ccc(O)cc3)C(=O)N4)cc2)C)NC(=O)N(Cc2cccc(O)c2)C1=O,,,1,,,,,,Oc1ccc(cc1)[C@@H]1CC2(NC1=O)CCN(CC2)C(=O)c1ccc(cc1C)[C@]1(C)NC(=O)N(C1=O)Cc1cccc(c1)O,
INSC-10,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1cc(sc1C(=O)CCN1CC[C@@]21C(=O)Nc1c(N3C(=O)c4[nH]nc(c5cccc(F)c5)c4C3)ccn21)C,,,1,,,,,,Fc1cccc(c1)c1n[nH]c2c1CN(C2=O)c1ccn2c1NC(=O)[C@@]12CCN1CCC(=O)c1ccc(s1)C,
INSC-11,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1(C)ccc(NS(=O)(=O)c2ccc([C@H]3NC(=O)N(C[C@@H](C)c4cccc5occc45)C43CCN(CC4)C)cc2)cc1,,,1,,,,,,CN1CCC2(CC1)[C@H](NC(=O)N2C[C@H](c1cccc2c1cco2)C)c1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)C,
INSC-12,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C(Nc1ccc(c2c(CN3CCCCC3)cc[nH]c2=O)cc1)[C@H](NS(=O)(=O)c1ccc(cc1)F)c1ccccc1F,,,1,,,,,,Fc1ccc(cc1)S(=O)(=O)N[C@H](c1ccccc1F)C(=O)Nc1ccc(cc1)c1c(cc[nH]c1=O)CN1CCCCC1,
INSC-13,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,NCC[C@H](C(=O)Nc1ccc(CN2C(=O)CCC2=O)c(c2ccnc(C)c2)c1)c1ccc(cc1)F,,,1,,,,,,NCC[C@@H](c1ccc(cc1)F)C(=O)Nc1ccc(c(c1)c1ccnc(c1)C)CN1C(=O)CCC1=O,
INSC-14,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C[C@H](N)C(=O)Nc1cccc2c1NC(=O)C1CN(C(=O)c3ccc(c4ccc(F)cc4)s3)CCN21,,,1,,,,,,O=C([C@@H](N)C)Nc1cccc2c1NC(=O)C1N2CCN(C1)C(=O)c1ccc(s1)c1ccc(cc1)F,
INSC-15,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,COCc1cccc(c2n[nH]c3c2CN(C(=O)N[C@@H](C)C[C@H](N)c2scnc2C(C)C)C3=O)c1O,,,1,,,,,,COCc1cccc(c1O)c1n[nH]c2c1CN(C2=O)C(=O)N[C@H](C[C@@H](c1scnc1C(C)C)N)C,
INSC-16,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=S1(=O)N=C(c2ccc(cc2)C)NC2=C1[C@@](C1CCN(C[C@H]3CN(c4nc5ccccc5[nH]4)CCC3)CC1)(CC2)C,,,1,,,,,,Cc1ccc(cc1)C1=NS(=O)(=O)C2=C(N1)CC[C@]2(C)C1CCN(CC1)C[C@@H]1CCCN(C1)c1nc2c([nH]1)cccc2,
INSC-17,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1cc(S(=O)(=O)Nc2cc(C(F)(F)F)ccc2N2CCc3[nH]c([C@H]4CC[C@@H]4C(=O)OCCN)nc3C2)cnc1C,,,1,,,,,,NCCOC(=O)[C@H]1CC[C@@H]1c1nc2c([nH]1)CCN(C2)c1ccc(cc1NS(=O)(=O)c1ccc(nc1)C)C(F)(F)F,
INSC-18,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,NC(=O)[C@@H](c1cc2c(O)ccc(C(=O)Nc3cccc(O)c3)c2[nH]1)N1CCC2(CC1)NC(=O)c1ccccc1O2,,,1,,,,,,Oc1cccc(c1)NC(=O)c1ccc(c2c1[nH]c(c2)[C@@H](N1CCC2(CC1)NC(=O)c1c(O2)cccc1)C(=O)N)O,
INSC-19,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,COc1ccsc1C(=O)CCN1CC[C@H]2Cc3c(c4cc(F)cc(O)c4)n[nH]c3[C@@H]2C1=O,,,1,,,,,,COc1ccsc1C(=O)CCN1CC[C@@H]2[C@@H](C1=O)c1[nH]nc(c1C2)c1cc(O)cc(c1)F,
INSC-20,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(C)C(=O)NC1CCN([C@]2(Cc3cc(F)ccc3O)CC[C@H]2C[C@H]2Nc3ccccc3S(=O)(=O)N2C)CC1,,,1,,,,,,O=C(C(C)C)NC1CCN(CC1)[C@@]1(CC[C@H]1C[C@H]1Nc2ccccc2S(=O)(=O)N1C)Cc1cc(F)ccc1O,
INSC-21,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1(cc(cc(c1)[C@@H](CN1C[C@@]2(c3c(C1=O)cccc3)C(=O)Nc1c(C2)ccc(c1)NS(=O)(=O)CC)O)O)C,,,1,,,,,,CCS(=O)(=O)Nc1ccc2c(c1)NC(=O)[C@@]1(C2)CN(C[C@H](c2cc(C)cc(c2)O)O)C(=O)c2c1cccc2,
INSC-22,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1nc(sc1C(=O)CCCNC(=O)N1C(=O)c2[nH]nc(c3cc(F)cc(OC)c3)c2CC1(C)C)C,,,1,,,,,,COc1cc(F)cc(c1)c1n[nH]c2c1CC(C)(C)N(C2=O)C(=O)NCCCC(=O)c1cnc(s1)C,
INSC-23,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,NC(=O)C1=C2O[C@@H](CCCc3ccc(F)cc3)C(=O)N2CN1C(=O)c1cc2ccccc2s1,,,1,,,,,,Fc1ccc(cc1)CCC[C@@H]1OC2=C(C(=O)N)N(CN2C1=O)C(=O)c1cc2c(s1)cccc2,
INSC-24,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,Cc1nc2c(n1c1ccc(NC(=O)CC)cc1)C(=O)N[C@@H](C1=COC[C@@H](c3cccc(F)c3)C1)N2C,,,1,,,,,,CCC(=O)Nc1ccc(cc1)n1c(C)nc2c1C(=O)N[C@H](N2C)C1=COC[C@H](C1)c1cccc(c1)F,
INSC-25,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,Cc1[nH]c(C2CCC(CNS(=O)(=O)[C@H](CO)c3cccnc3)CC2)nc1c1cccc(O)c1C,,,1,,,,,,OC[C@@H](S(=O)(=O)NCC1CCC(CC1)c1[nH]c(c(n1)c1cccc(c1C)O)C)c1cccnc1,
INSC-26,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C1N[C@@]2(CCN(C(=O)c3cc4cc(cc(C(=O)Nc5cc(O)ccc5Cl)c4[nH]3)C)C2)Oc2ccccc12,,,1,,,,,,Oc1ccc(c(c1)NC(=O)c1cc(C)cc2c1[nH]c(c2)C(=O)N1CC[C@]2(C1)NC(=O)c1c(O2)cccc1)Cl,
INSC-27,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,COc1cc2ccccc2n1CC(=O)OCC(=O)NC[C@@H]1[C@H](O)C[C@@H]1NC(=O)Nc1cccc(c1)F,,,1,,,,,,COc1cc2c(n1CC(=O)OCC(=O)NC[C@@H]1[C@H](O)C[C@@H]1NC(=O)Nc1cccc(c1)F)cccc2,
INSC-28,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1c(c(F)ccc1NC(=O)N1CCC2(CC1)c1cc([nH]c1C[C@@H](C(=O)N)[C@@H]2C(=O)Oc1c[nH]ccc1=O)C)C,,,1,,,,,,O=C([C@H]1[C@@H](Cc2c(C31CCN(CC3)C(=O)Nc1ccc(c(c1)C)F)cc([nH]2)C)C(=O)N)Oc1c[nH]ccc1=O,
INSC-29,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1ccc(O)c(CNC(=O)/C=C/[C@@]2(NC(=O)[C@@H](NC(=O)c3cc4c(c(C)ncc4cc3[C@@H](C)O)CN)C3CCC3)CCCOC2)c1,,,1,,,,,,NCc1c(C)ncc2c1cc(C(=O)N[C@H](C(=O)N[C@@]1(CCCOC1)/C=C/C(=O)NCc1ccccc1O)C1CCC1)c(c2)[C@H](O)C,
INSC-30,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1(nc2c(c(c1CO)C(=O)N[C@H](C(=O)N[C@H](/C=C/C(=O)NCc1cccc(c1)F)c1ccc(cc1)O)CC(C)C)cccc2)CCN,,,1,,,,,,NCCc1nc2ccccc2c(c1CO)C(=O)N[C@H](C(=O)N[C@@H](c1ccc(cc1)O)/C=C/C(=O)NCc1cccc(c1)F)CC(C)C,
INSC-31,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1cccc(CNC(=O)/C=C/[C@@H](NC(=O)[C@@H](NC(=O)c2cc(C)n3ncc(c3c2CO)CN)[C@H]2CC2(C)C)c2ccc(O)cc2)c1,,,1,,,,,,NCc1cnn2c1c(CO)c(cc2C)C(=O)N[C@@H]([C@H]1CC1(C)C)C(=O)N[C@@H](c1ccc(cc1)O)/C=C/C(=O)NCc1ccccc1,
INSC-32,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,COc1ccc(S(=O)(=O)N[C@@](C(=O)N[C@]2(C(=O)NC/C=C/C(=O)NCc3ccc(Cl)cc3)C[C@@H](C2)C(F)(F)F)(c2ccncc2F)C)c(c1)F,,,1,,,,,,COc1ccc(c(c1)F)S(=O)(=O)N[C@](c1ccncc1F)(C(=O)N[C@@]1(C[C@@H](C1)C(F)(F)F)C(=O)NC/C=C/C(=O)NCc1ccc(cc1)Cl)C,
INSC-33,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1ccc(F)cc1CNC(=O)/C=C/[C@@H](NC(=O)C1(NC(=O)c2c(C)cc3n(C)cc(c3c2)N)CC(C)(C1)C)c1ccc(O)cc1,,,1,,,,,,O=C(/C=C/[C@H](c1ccc(cc1)O)NC(=O)C1(NC(=O)c2cc3c(N)cn(c3cc2C)C)CC(C1)(C)C)NCc1cccc(c1)F,
INSC-34,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1cccc(CNC(=O)/C=C/[C@@H](NC(=O)C2(NC(=O)c3c(C)cc4CCNCc4c3)CC2)[C@H]2CCOC2)c1,,,1,,,,,,O=C(NCc1ccccc1)/C=C/[C@H]([C@H]1CCOC1)NC(=O)C1(CC1)NC(=O)c1cc2CNCCc2cc1C,
INSC-35,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1cc(ccc1CNC(=O)/C=C/[C@@H](NC(=O)[C@]1(NC(=O)c2c(C)cc3cnc(n3c2)N)C[C@H](C1)C)c1ccnnc1)O,,,1,,,,,,C[C@@H]1C[C@@](C1)(NC(=O)c1cn2c(N)ncc2cc1C)C(=O)N[C@@H](c1ccnnc1)/C=C/C(=O)NCc1ccc(cc1)O,
INSC-36,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C(NC(=O)NC1(C(=O)N[C@H](/C=C/C(=O)OCc2ccccc2)c2ccncn2)CCOCC1)c1ccc2c(c1)OCCN2,,,1,,,,,,O=C(NC1(CCOCC1)C(=O)N[C@@H](c1ccncn1)/C=C/C(=O)OCc1ccccc1)NCc1ccc2c(c1)OCCN2,
INSC-37,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,Cc1[nH]ncc1C[C@H](C)NC(=O)NC1(C(=O)N[C@@H](/C=C/C(=O)Oc2ccccc2)c2cc[nH]c2)CCCCC1,,,1,,,,,,C[C@@H](Cc1cn[nH]c1C)NC(=O)NC1(CCCCC1)C(=O)N[C@H](c1c[nH]cc1)/C=C/C(=O)Oc1ccccc1,
INSC-38,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC1CCN(C(=O)c2ccc(NC(=O)CNC(=O)c3csc(NC(=O)C4(c5cnccc5)CCC4)n3)cc2)CC1,,,1,,,,,,CC1CCN(CC1)C(=O)c1ccc(cc1)NC(=O)CNC(=O)c1csc(n1)NC(=O)C1(CCC1)c1cccnc1,
INSC-39,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C(Nc1cc(c(c2nc(OCC3(O)CCN(C4CCC4)CC3)cnc2OCC2CC2)c(c1)F)C)Nc1ccc(cc1)F,,,1,,,,,,O=C(Nc1ccc(cc1)F)Nc1cc(C)c(c(c1)F)c1nc(cnc1OCC1CC1)OCC1(O)CCN(CC1)C1CCC1,
INSC-40,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C[C@](CO)(NC(=O)N[C@H]1C[C@@H](O)c2cc(cc(C(=O)Cc3ccccc3OC)c12)F)c1cccc(OC)c1,,,1,,,,,,COc1cccc(c1)[C@](NC(=O)N[C@H]1C[C@H](c2c1c(cc(c2)F)C(=O)Cc1ccccc1OC)O)(CO)C,
INSC-41,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,COc1cc(OCC(=O)N)cc([C@H](NC(=O)[C@H](C(=O)NCC(=O)O)C(F)(F)F)c2cc(c(OC)cc2)C)c1,,,1,,,,,,COc1cc(OCC(=O)N)cc(c1)[C@@H](c1ccc(c(c1)C)OC)NC(=O)[C@@H](C(F)(F)F)C(=O)NCC(=O)O,
INSC-42,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(C)CNC(=O)c1ccc(c2nc(CC(=O)N[C@H](C[C@@H](CO)C)C(=O)Nc3ccc(O)c(c3)F)no2)cc1,,,1,,,,,,OC[C@H](C[C@H](C(=O)Nc1ccc(c(c1)F)O)NC(=O)Cc1noc(n1)c1ccc(cc1)C(=O)NCC(C)C)C,
INSC-43,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,N[C@H]1CC[C@@H](S(=O)(=O)c2cc(cc(c3cn4ccc(Cc5cccc6[nH]c(nc56)C)c4c(=O)[nH]3)c2)F)[C@@H]1C,,,1,,,,,,Fc1cc(cc(c1)S(=O)(=O)[C@@H]1CC[C@@H]([C@H]1C)N)c1[nH]c(=O)c2n(c1)ccc2Cc1cccc2c1nc([nH]2)C,
INSC-44,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,Cc1ccc(C(=O)N2CCOCC2)cc1c1nc(CN2CCC(CO)(CCc3cc(c(O)cc3)F)CC2)no1,,,1,,,,,,OCC1(CCN(CC1)Cc1noc(n1)c1cc(ccc1C)C(=O)N1CCOCC1)CCc1ccc(c(c1)F)O,
INSC-45,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C(N[C@@H]1CCC[C@]2(CC[C@@H](N3CCN(c4ccccc4Cl)CC3)S(=O)(=O)N2)C1)c1cc(O)c(O)c(F)c1,,,1,,,,,,O=C(c1cc(O)c(c(c1)F)O)N[C@@H]1CCC[C@@]2(C1)CC[C@H](S(=O)(=O)N2)N1CCN(CC1)c1ccccc1Cl,
INSC-46,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C(C(=O)N[C@H](Cc1ccc(C)cc1F)C(=O)Nc1cc(C2=NNS(=O)(=O)C3=C2CCC(=O)N3c2ccc(F)cc2)ccc1C)C,,,1,,,,,,CCC(=O)N[C@@H](C(=O)Nc1cc(ccc1C)C1=NNS(=O)(=O)C2=C1CCC(=O)N2c1ccc(cc1)F)Cc1ccc(cc1F)C,
INSC-47,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1ccc(C(F)(F)OC)c2sc(N(C(=O)c3cc(C)n(C(=O)CC)n3)[C@@H]3CC[C@@H](CO)CC3)nc12,,,1,,,,,,OC[C@@H]1CC[C@H](CC1)N(C(=O)c1nn(c(c1)C)C(=O)CC)c1nc2c(s1)c(ccc2)C(OC)(F)F,
INSC-48,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C(C(=O)Nc1ccc(C(=O)N[C@@]2(C(=O)Nc3ccc(C(=O)NCc4ccc(cn4)F)cc3)CC[C@@H](O)CC2)cc1)C,,,1,,,,,,CCC(=O)Nc1ccc(cc1)C(=O)N[C@@]1(CC[C@@H](CC1)O)C(=O)Nc1ccc(cc1)C(=O)NCc1ccc(cn1)F,
INSC-49,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,Cc1nnc(c2ccc(NC(=O)[C@]3(O)CN(C(=O)CC)C[C@H]3C(=O)Nc3ccc(NC)cc3)cc2)o1,,,1,,,,,,CCC(=O)N1C[C@H]([C@](C1)(O)C(=O)Nc1ccc(cc1)c1nnc(o1)C)C(=O)Nc1ccc(cc1)NC,
INSC-50,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(C)(NCc1cc2cc(ccc2[nH]1)F)C(=O)Nc1ccc(C(=O)Nc2ccccc2N2CCN(CCO)CC2)cc1,,,1,,,,,,OCCN1CCN(CC1)c1ccccc1NC(=O)c1ccc(cc1)NC(=O)C(NCc1[nH]c2c(c1)cc(cc2)F)(C)C,
INSC-51,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC[C@H](CC(=O)N(CCN1CC[C@@]21C[C@H]2N)c1nc2c(OC)ccc(O)c2s1)c1ccc(Cl)cc1,,,1,,,,,,CC[C@@H](c1ccc(cc1)Cl)CC(=O)N(c1sc2c(n1)c(OC)ccc2O)CCN1CC[C@@]21C[C@H]2N,
INSC-52,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,c1c(c(CNC(=O)NCC2(N)CC2)c(cc1C(=O)N[C@H](c1c(cccc1C(F)(F)F)Cl)[C@@H]1CCCO1)F)C,,,1,,,,,,O=C(NCC1(N)CC1)NCc1c(C)cc(cc1F)C(=O)N[C@H](c1c(Cl)cccc1C(F)(F)F)[C@@H]1CCCO1,
INSC-53,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(C)CNC(=O)[C@@H](c1ccc(O)cc1)N1C(=O)N[C@@](Cc2ccc(F)cc2)(C(=O)NCC2(O)CCC(CC2)(F)F)c2ccc(C(=O)N3CCCC3)cc12,,,1,,,,,,CC(CNC(=O)[C@H](N1C(=O)N[C@@](c2c1cc(cc2)C(=O)N1CCCC1)(Cc1ccc(cc1)F)C(=O)NCC1(O)CCC(CC1)(F)F)c1ccc(cc1)O)C,
INSC-54,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(C)(C(=O)Nc1c2c(c(NC(=O)Nc3ccc(cc3)F)cc1)CCC2)C(=O)N1CCC[C@H]1C(=O)c1ccc(O)cc1Cl,,,1,,,,,,O=C(Nc1ccc(c2c1CCC2)NC(=O)C(C(=O)N1CCC[C@H]1C(=O)c1ccc(cc1Cl)O)(C)C)Nc1ccc(cc1)F,
INSC-55,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,N(c1ccc(F)c(OC[C@@H](O)[C@@H]2C[C@@H](CC(=O)n3nnc4c(OC(F)(F)c5ccc(OC)cc5)c(O)ccc34)C2)c1)C,,,1,,,,,,CNc1ccc(c(c1)OC[C@H]([C@@H]1C[C@H](C1)CC(=O)n1nnc2c1ccc(c2OC(c1ccc(cc1)OC)(F)F)O)O)F,
INSC-56,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CCOC(=O)c1noc([C@@H](N[C@H](C)CCc2ncc(C)[nH]2)c2cc(O)ccc2OC2(C3CC3)CCCC2)n1,,,1,,,,,,CCOC(=O)c1noc(n1)[C@H](c1cc(O)ccc1OC1(CCCC1)C1CC1)N[C@@H](CCc1ncc([nH]1)C)C,
INSC-57,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C[C@H](N)CCc1cc(O)cc(c2nc(=O)n(C)c3c2C(=O)N(C)[C@H]3N(C)Cc2ccccc2F)c1Cl,,,1,,,,,,C[C@@H](CCc1cc(O)cc(c1Cl)c1nc(=O)n(c2c1C(=O)N([C@H]2N(Cc1ccccc1F)C)C)C)N,
INSC-58,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,Cc1c(CC[C@](C)(N)CCc2ccc(O)c(F)c2)cc(O)cc1c1ncc(=O)n2c1C(=O)C[C@]12OCCOC1,,,1,,,,,,Oc1cc(CC[C@@](CCc2ccc(c(c2)F)O)(N)C)c(c(c1)c1ncc(=O)n2c1C(=O)C[C@@]12COCCO1)C,
INSC-59,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C1c2cc(S(=O)(=O)NCCN)ccc2[C@@](C)(C(=O)c2cnc3cc(O)ccn23)CN1Cc1ccc(s1)C,,,1,,,,,,NCCNS(=O)(=O)c1ccc2c(c1)CN(C[C@]2(C)C(=O)c1cnc2n1ccc(c2)O)Cc1ccc(s1)C,
INSC-60,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC[C@@H](Oc1ccc([C@](C)(O)c2ccc(C(=O)Nc3cc(C(=O)NCC)ccc3C)cc2)c(c1)F)C(=O)N[C@H]1CCS(=O)(=O)C1,,,1,,,,,,CCNC(=O)c1ccc(c(c1)NC(=O)c1ccc(cc1)[C@](c1ccc(cc1F)O[C@@H](C(=O)N[C@H]1CCS(=O)(=O)C1)CC)(O)C)C,
INSC-61,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C[C@]1(O)CN(C(=O)c2nc3ccccc3c(CN3CCCC3)c2[C@@H](O)c2ccc(NC(=O)N)cc2)CC[C@H]1Cc1ccc(cc1)F,,,1,,,,,,NC(=O)Nc1ccc(cc1)[C@@H](c1c(nc2c(c1CN1CCCC1)cccc2)C(=O)N1CC[C@H]([C@@](C1)(C)O)Cc1ccc(cc1)F)O,
INSC-62,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CN1CCC(Cc2cc(c3c(cc(cc3)F)F)no2)([C@@H](N[C@H]2CC[C@H](O)C2)C(=O)Nc2cc(O)n(C)c2)CC1,,,1,,,,,,O[C@H]1CC[C@@H](C1)N[C@H](C1(CCN(CC1)C)Cc1onc(c1)c1ccc(cc1F)F)C(=O)Nc1cc(n(c1)C)O,
INSC-63,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,COc1ccc(O)cc1C[C@]1(CNC(=O)c2nc(C(=O)OCCNc3cnc(cc3)C)cs2)CCOC1,,,1,,,,,,COc1ccc(cc1C[C@]1(COCC1)CNC(=O)c1scc(n1)C(=O)OCCNc1ccc(nc1)C)O,
INSC-64,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,Fc1ccc2c(c1)NC(=O)[C@H]2CC(=O)N1CCC(O)(c2ccc3[nH]c(c4ccc(cc4O)F)nc3c2)CC1,,,1,,,,,,Fc1ccc2c(c1)NC(=O)[C@H]2CC(=O)N1CCC(CC1)(O)c1ccc2c(c1)nc([nH]2)c1ccc(cc1O)F,
INSC-65,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C[C@@H](C(=O)N[C@@H]1CC[C@@H](O)CC1)S(=O)(=O)c1cc(c(NC(=O)NCc2ccc(C(F)(F)F)cc2)cc1)C,,,1,,,,,,O[C@@H]1CC[C@H](CC1)NC(=O)[C@@H](S(=O)(=O)c1ccc(c(c1)C)NC(=O)NCc1ccc(cc1)C(F)(F)F)C,
INSC-66,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C1C(CC(=O)Nc2ccc(N3C(=O)N[C@@](C)(c4ccc(cc4)F)C3=O)cc2C(=O)NCc2ccc(O)cc2OC)C1,,,1,,,,,,COc1cc(O)ccc1CNC(=O)c1cc(ccc1NC(=O)CC1CC1)N1C(=O)N[C@@](C1=O)(C)c1ccc(cc1)F,
INSC-67,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C[C@H](C(=O)Nc1ccc(C2(C)CCOCC2)c(F)c1)N1CC[C@@H](Oc2cccnc2S(=O)(=O)c2cnccc2CC2=CCN(CC2)C)C1,,,1,,,,,,CN1CCC(=CC1)Cc1ccncc1S(=O)(=O)c1ncccc1O[C@@H]1CCN(C1)[C@@H](C(=O)Nc1ccc(c(c1)F)C1(C)CCOCC1)C,
INSC-68,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C(N[C@@H]1CCOC1)c1c(CO)nsc1N[C@H]1CCCC[C@H]1C(=O)Nc1c(sc2ccccc12)C,,,1,,,,,,OCc1nsc(c1C(=O)N[C@H]1COCC1)N[C@H]1CCCC[C@H]1C(=O)Nc1c(C)sc2c1cccc2,
INSC-69,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,COCC(=O)N[C@]1(C(=O)Nc2ccc(CNc3cc(c4ccc(F)cc4)[nH]c3C)cc2OC)CC[C@@H](O)C1,,,1,,,,,,COCC(=O)N[C@@]1(CC[C@H](C1)O)C(=O)Nc1ccc(cc1OC)CNc1cc([nH]c1C)c1ccc(cc1)F,
INSC-70,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,NC[C@H]1CCN(C(=O)c2cc(C(=O)NCc3ccc(C(F)(F)F)cc3)ccc2NC(=O)N2CCCC2)C1,,,1,,,,,,NC[C@H]1CCN(C1)C(=O)c1cc(ccc1NC(=O)N1CCCC1)C(=O)NCc1ccc(cc1)C(F)(F)F,
INSC-71,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CNCc1cccn1c1ccc(NC(=O)[C@@H]2C[C@H](O)CN2c2cccc(NC(=O)Nc3ccc4c(c3)OCCO4)c2)c(F)c1,,,1,,,,,,CNCc1cccn1c1ccc(c(c1)F)NC(=O)[C@@H]1C[C@@H](CN1c1cccc(c1)NC(=O)Nc1ccc2c(c1)OCCO2)O,
INSC-72,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(=O)N1CCC(Cc2cc(c3c(cc(cc3)F)F)no2)([C@@H](N[C@H]2CC[C@H](O)C2)C(=O)Nc2cc(NC)c3n2ccnc3)CC1,,,1,,,,,,CNc1cc(n2c1cncc2)NC(=O)[C@@H](C1(CCN(CC1)C(=O)C)Cc1onc(c1)c1ccc(cc1F)F)N[C@H]1CC[C@@H](C1)O,
INSC-73,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,Cc1c(CCC2(N)COC2)cncc1c1cc(F)cc2c1C(=O)NC12CCCCC1,,,1,,,,,,Fc1cc2c(c(c1)c1cncc(c1C)CCC1(N)COC1)C(=O)NC12CCCCC1,
INSC-74,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,Cc1c(CC[C@]2(N)[C@H](C2)c2ccc(OC)cc2)cc(O)cc1c1nc2c(c(=O)[nH]1)[C@@H](C(F)(F)F)CC(=O)N2C,,,1,,,,,,COc1ccc(cc1)[C@H]1C[C@]1(N)CCc1cc(O)cc(c1C)c1nc2N(C)C(=O)C[C@@H](c2c(=O)[nH]1)C(F)(F)F,
INSC-75,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C([C@H](N[C@H](C)[C@H]1Cc2c(C1)c(ccc2)NC(=O)N1CC(O)C1)c1cncc(C2(N)CC2)c1)NC,,,1,,,,,,CNC(=O)[C@@H](c1cncc(c1)C1(N)CC1)N[C@@H]([C@@H]1Cc2c(C1)cccc2NC(=O)N1CC(C1)O)C,
INSC-76,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,N(C(=O)[C@H]1CC2(C[C@H](CC(=O)n3cnc4c(C#Cc5ccncc5)cccc34)C2)[C@H]1O)(C)C1CC1,,,1,,,,,,O[C@H]1[C@H](CC21C[C@H](C2)CC(=O)n1cnc2c1cccc2C#Cc1ccncc1)C(=O)N(C1CC1)C,
INSC-77,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C(N[C@@H]1CCC[C@@]2(C1)C[C@H](N1CCN(c3cnccc3)CC1)S(=O)(=O)N2)C1CCC1,,,1,,,,,,O=C(C1CCC1)N[C@@H]1CCC[C@@]2(C1)C[C@@H](S(=O)(=O)N2)N1CCN(CC1)c1cccnc1,
INSC-78,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C(C1(N)CC1)Nc1cccc(NC(=O)c2cc(c3ccc(cc3C)F)cc(F)c2)c1,,,1,,,,,,Fc1cc(cc(c1)c1ccc(cc1C)F)C(=O)Nc1cccc(c1)NC(=O)C1(N)CC1,
INSC-79,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(C)NC[C@@H](C(=O)NCC(=O)N1CC[C@@H](c2ccc3[nH]c(c4c(cc(cc4)F)C)nc3c2)C1)c1ccc(F)cc1OC,,,1,,,,,,COc1cc(F)ccc1[C@H](C(=O)NCC(=O)N1CC[C@H](C1)c1ccc2c(c1)nc([nH]2)c1ccc(cc1C)F)CNC(C)C,
INSC-80,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C(=O)(N[C@@H](Cc1ccc(cc1)F)[C@H](O)CN1C(=O)N[C@@H](Nc2ccc(CN)cc2)C21CCC2)C1CC1,,,1,,,,,,NCc1ccc(cc1)N[C@@H]1NC(=O)N(C21CCC2)C[C@H]([C@H](Cc1ccc(cc1)F)NC(=O)C1CC1)O,
INSC-81,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,COc1cc(O)ccc1NC(=O)N(CCN1CCOCC1)CC(=O)N(C1(C)CC1)Cc1cc(ccn1)C,,,1,,,,,,COc1cc(O)ccc1NC(=O)N(CC(=O)N(C1(C)CC1)Cc1nccc(c1)C)CCN1CCOCC1,
INSC-82,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C(CCCc1ccc2c(c1)S(=O)(=O)CCN2C(=O)Cc1ccc(cc1)O)c1c(c2ccc(cc2)F)ccnc1C1CCN(CC1)C,,,1,,,,,,CN1CCC(CC1)c1nccc(c1C(=O)CCCc1ccc2c(c1)S(=O)(=O)CCN2C(=O)Cc1ccc(cc1)O)c1ccc(cc1)F,
INSC-83,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,NC1(CC[C@@H](NC(=O)N2Cc3c(cccc3C(c3nc4ccc(F)cc4[nH]3)CO)C3(C2)CN(C3)C)[C@H]2CCOC2)CC1,,,1,,,,,,OCC(c1cccc2c1CN(CC12CN(C1)C)C(=O)N[C@@H]([C@H]1CCOC1)CCC1(N)CC1)c1[nH]c2c(n1)ccc(c2)F,
INSC-84,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C(C(=O)c1c(cccc1N(C(=O)Nc1ccc2c(c1)[C@@H](C(=O)c1ccc3c(c1)CCN3)CC2)C)F)N,,,1,,,,,,NCC(=O)c1c(F)cccc1N(C(=O)Nc1ccc2c(c1)[C@H](CC2)C(=O)c1ccc2c(c1)CCN2)C,
INSC-85,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C(Nc1ccc2c(c1)[C@@H](C(=O)c1c(cncc1C1CCNCC1)Nc1ccc(F)cc1F)OC2)Nc1c(c(O)ccc1O)C,,,1,,,,,,O=C(Nc1c(O)ccc(c1C)O)Nc1ccc2c(c1)[C@H](OC2)C(=O)c1c(cncc1C1CCNCC1)Nc1ccc(cc1F)F,
INSC-86,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C(C(=O)N[C@@H](Cc1ccc(cc1)F)[C@H](O)C[C@H]1CCC2=C1S(=O)(=O)N=C(c1cc(ccc1)Cc1cc(c(c(c1)F)N1CCN(C)CC1)F)N2)C,,,1,,,,,,CCC(=O)N[C@H]([C@@H](C[C@H]1CCC2=C1S(=O)(=O)N=C(N2)c1cccc(c1)Cc1cc(F)c(c(c1)F)N1CCN(CC1)C)O)Cc1ccc(cc1)F,
INSC-87,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C[C@@H](Cc1cc(F)ccc1)NC[C@@H]1COCC[C@@]21NC(=O)N(c1ccc(CNC(=O)C3CC3)cc1Cl)C2=O,,,1,,,,,,C[C@@H](Cc1cccc(c1)F)NC[C@@H]1COCC[C@@]21NC(=O)N(C2=O)c1ccc(cc1Cl)CNC(=O)C1CC1,
INSC-88,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,O=C(c1c(c2cccc(F)c2C)cncc1C1CCN(CC1)C)[C@H]1CCc2ccc3c(c12)CCN3S(=O)(=O)CC,,,1,,,,,,CCS(=O)(=O)N1CCc2c1ccc1c2[C@H](CC1)C(=O)c1c(cncc1c1cccc(c1C)F)C1CCN(CC1)C,
INSC-89,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,N[C@@H](Cc1ccc([nH]1)C)CCNC1=CC=C(c2cc(c(C)cc2Cl)NC(=O)C2CC2)S(=O)(=O)N1C,,,1,,,,,,N[C@@H](Cc1ccc([nH]1)C)CCNC1=CC=C(S(=O)(=O)N1C)c1cc(NC(=O)C2CC2)c(cc1Cl)C,
INSC-90,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(C)C[C@H]1C(=O)N[C@@H](Cn2c(=O)[nH]cc2COCC[C@@H](C(=O)N1)NC(=O)[C@H](C(F)(F)F)N)/C=C/C(=O)OCc1ccccc1,,,1,,,,,,CC(C[C@@H]1NC(=O)[C@H](CCOCc2n(C[C@H](NC1=O)/C=C/C(=O)OCc1ccccc1)c(=O)[nH]c2)NC(=O)[C@H](C(F)(F)F)N)C,
INSC-91,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(C)C[C@H]1C(=O)N[C@@H](CN2C(=O)NC[C@H](C2)CCC[C@@H](C(=O)N1)NC(=O)[C@H](C)Nc1ccccc1)/C=C/C(=O)OCc1ccccc1,,,1,,,,,,O=C(/C=C/[C@@H]1CN2C[C@H](CCC[C@@H](C(=O)N[C@H](C(=O)N1)CC(C)C)NC(=O)[C@@H](Nc1ccccc1)C)CNC2=O)OCc1ccccc1,
INSC-92,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,CC(C)(C[C@H]1C(=O)N[C@@H](CN2C(=O)NC[C@H](C2)CCC[C@@H](C(=O)N1)NC(=O)[C@H](C(F)(F)F)Nc1ccccc1)/C=C/C(=O)c1[nH]nnc1)F,,,1,,,,,,O=C([C@H](C(F)(F)F)Nc1ccccc1)N[C@H]1CCC[C@@H]2CNC(=O)N(C2)C[C@H](NC(=O)[C@@H](NC1=O)CC(F)(C)C)/C=C/C(=O)c1cnn[nH]1,
INSC-93,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,N(c1c2c(nc(c3[nH]c([C@@H](NC(=O)c4sccn4)CC)cc3)n1)O[C@]1(CCNC1=O)CC(=C)C2=O)[C@@H](C)CC,,,1,,,,,,CC[C@@H](Nc1nc(nc2c1C(=O)C(=C)C[C@]1(O2)CCNC1=O)c1ccc([nH]1)[C@@H](NC(=O)c1nccs1)CC)C,
INSC-94,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,N(c1c2c(nc(C(=O)NC[C@@H](O)C(F)(F)F)n1)O[C@]1(CCNC1=O)C(=O)C(=C)C2=O)CC(C)C,,,1,,,,,,CC(CNc1nc(nc2c1C(=O)C(=C)C(=O)[C@]1(O2)CCNC1=O)C(=O)NC[C@H](C(F)(F)F)O)C,
INSC-95,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,N(c1c2c(nc(n1)n1c(cc3c1cccc3)C)O[C@]1(CCNC1=O)C(=O)C(=C)C2=O)CC(C)C,,,1,,,,,,CC(CNc1nc(nc2c1C(=O)C(=C)C(=O)[C@]1(O2)CCNC1=O)n1c(C)cc2c1cccc2)C,
INSC-96,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C1N2C[C@@](C1)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](/C=C/C(=O)OCc1ccccc1)C/C=C/CCC2)NC(=O)CN,,,1,,,,,,NCC(=O)N[C@@]12CCN(C1)CCC/C=C/C[C@H](NC(=O)[C@@H](NC2=O)CC(C)C)/C=C/C(=O)OCc1ccccc1,
INSC-97,SARS-CoV-2,10.1101/2020.03.03.972133,Simulation,C(=C\C(=O)OCc1ccccc1)/[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H]2[C@@H](C2)CC/C=C\C1)NC,,,1,,,,,,CN[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C/C=C\CC[C@H]2[C@@H]1C2)/C=C/C(=O)OCc1ccccc1,
Glycyrrhizin,SARS,10.1016/j.jcv.2004.03.003,Experimental,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C,14982,,1,Significant antiviral activity against SARS,,,,,OC1C(OC2OC(C(=O)O)C(C(C2O)O)O)C(OC(C1O)C(=O)O)OC1CCC2(C(C1(C)C)CCC1(C2C(=O)C=C2C1(C)CCC1(C2CC(C)(CC1)C(=O)O)C)C)C,
Ribavirin,SARS,10.1016/j.jcv.2004.03.003,Experimental,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,37542,,1,Detectable antiviral activity against SARS,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,
Lopinavir,SARS,10.1016/j.jcv.2004.03.003,Experimental,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,92727,,1,Detectable antiviral activity against SARS,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
Rimantadine,SARS,10.1016/j.jcv.2004.03.003,Experimental,CC(C12CC3CC(C1)CC(C3)C2)N,5071,,1,Detectable antiviral activity against SARS,,,,,CC(C12CC3CC(C2)CC(C1)C3)N,
Baicalin,SARS,10.1016/j.jcv.2004.03.003,Experimental,C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O,64982,,1,Detectable antiviral activity against SARS,,,,,OC(=O)C1OC(Oc2cc3oc(cc(=O)c3c(c2O)O)c2ccccc2)C(C(C1O)O)O,
Dihydrotanshinone,MERS,10.1016/j.ijantimicag.2018.05.003,Experimental,CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C(C=CC=C43)C,5316743,,1,Compound may have dual inhibitory effects blocks virus entry and replication,,,,,CC1COC2=C1C(=O)C(=O)c1c2ccc2c1cccc2C,
Ribavirin,SARS,10.1371/journal.pmed.0030343,Experimental,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,37542,,1,Review of 30 reports no conclusive evidence of recovery. Used with Corticosteroid and Lopinavir show a lower death rate.,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,
Lopinavir,SARS,10.1371/journal.pmed.0030343,Experimental,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,92727,,1,Used with Ribavirin and Lopinavir showed lower death rate.,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
Ribavirin,MERS,nrd.2015.37,Experimental,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,37542,,1,lower 21‐day ARDS and death rates,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,
Lopinavir,MERS,nrd.2015.37,Experimental,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,92727,,1,lower 21‐day ARDS and death rates,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
ritonavir,MERS,nrd.2015.37,Experimental,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,392622,,1,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,
hydrocortisone,MERS,nrd.2015.37,Experimental,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,5754,,1,,,,,,OCC(=O)C1(O)CCC2C1(C)CC(O)C1C2CCC2=CC(=O)CCC12C,
methylprednisolone,MERS,nrd.2015.37,Experimental,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,6741,,1,might prolong viraemia,,,,,OCC(=O)C1(O)CCC2C1(C)CC(O)C1C2CC(C2=CC(=O)C=CC12C)C,
Nitazoxanide A,MERS,nrd.2015.37,Experimental,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,,,1,induces the host innate immune response,,,,,CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+](=O)[O-],
Chlorpromazine,MERS,nrd.2015.37,Experimental,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,2726,,1,,,,,,CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C,
Ouabain,MERS,nrd.2015.37,Experimental,CC1C(C(C(C(O1)OC2CC(C3(C4C(CCC3(C2)O)C5(CCC(C5(CC4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O,439501,,1,,,,,,OCC12C(O)CC(CC2(O)CCC2C1C(O)CC1(C2(O)CCC1C1=CC(=O)OC1)C)OC1OC(C)C(C(C1O)O)O,
Bufalin,MERS,nrd.2015.37,Experimental,CC12CCC(CC1CCC3C2CCC4(C3(CCC4C5=COC(=O)C=C5)O)C)O,9547215,,1,,,,,,OC1CCC2(C(C1)CCC1C2CCC2(C1(O)CCC2c1ccc(=O)oc1)C)C,
Chloroquine,MERS,nrd.2015.37,Experimental,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,2719,,1,,,,,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,
Camostat mesylate,MERS,nrd.2015.37,Experimental,CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N.CS(=O)(=O)O,5284360,,1,,,,,,CS(=O)(=O)O.CN(C(=O)COC(=O)Cc1ccc(cc1)OC(=O)c1ccc(cc1)N=C(N)N)C,
Trametinib,MERS,nrd.2015.37,Experimental,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,11707110,,1,May be associated with immunopathology,,,,,CC(=O)Nc1cccc(c1)n1c(=O)n(C2CC2)c(=O)c2c1c(C)c(=O)n(c2Nc1ccc(cc1F)I)C,
Selumetinib,MERS,nrd.2015.37,Experimental,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO,10127622,,1,May be associated with immunopathology,,,,,OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1Cl)Br)F,
Everolimus,MERS,nrd.2015.37,Experimental,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,6442177,,1,May be associated with immunopathology,,,,,OCCOC1CCC(CC1OC)CC(C1OC(=O)C2CCCCN2C(=O)C(=O)C2(O)OC(CCC2C)CC(OC)C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)C1)C)C)O)OC)C)C)C)C,
Rapamycin,MERS,nrd.2015.37,Experimental,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,5284616,,1,May be associated with immunopathology,,,,,COC1CC(CCC1O)CC(C1OC(=O)C2CCCCN2C(=O)C(=O)C2(O)OC(CCC2C)CC(OC)C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)C1)C)C)O)OC)C)C)C)C,
Dasatinib,MERS,nrd.2015.37,Experimental,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,3062316,,1,May be associated with immunopathology,,,,,OCCN1CCN(CC1)c1cc(nc(n1)C)Nc1ncc(s1)C(=O)Nc1c(C)cccc1Cl,
Imatinib,MERS,nrd.2015.37,Experimental,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,5291,,1,May be associated with immunopathology,,,,,CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1nccc(n1)c1cccnc1)C,
Ribavirin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,37542,,1,Potential PLpro inhibitors from ZINC,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,Anti-virus
Valganciclovir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N,135413535,,1,Potential PLpro inhibitors from ZINC,,,,,OCC(OCn1cnc2c1nc(N)[nH]c2=O)COC(=O)C(C(C)C)N,Anti-virus
β-Thymidine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O,,,1,Potential PLpro inhibitors from ZINC,,,,,OCC1OC(CC1O)n1cc(C)c(=O)[nH]c1=O,Anti-virus
Aspartame,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,COC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(=O)O)N,134601,,1,Potential PLpro inhibitors from ZINC,,,,,COC(=O)C(NC(=O)C(CC(=O)O)N)Cc1ccccc1,Non-carbohydrate sweetener
Oxprenolol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)NCC(COC1=CC=CC=C1OCC=C)O,4631,,1,Potential PLpro inhibitors from ZINC,,,,,C=CCOc1ccccc1OCC(CNC(C)C)O,"Anti-hypertensive,"
Doxycycline,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,54671203,,1,Potential PLpro inhibitors from ZINC,,,,,CN(C1C(=O)C(=C(C2(C1C(O)C1C(C)c3cccc(c3C(=C1C2=O)O)O)O)O)C(=O)N)C,Anti-bacterial effect
Acetophenazine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO,17676,,1,Potential PLpro inhibitors from ZINC,,,,,OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(=O)C,Anti-psychotic effect
Iopromide,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)NC(=O)COC)I,3736,,1,Potential PLpro inhibitors from ZINC,,,,,COCC(=O)Nc1c(I)c(C(=O)NCC(CO)O)c(c(c1I)C(=O)N(CC(CO)O)C)I,"Low osmolar, non-ionic contrast agent"
Riboflavin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(CO)O)O)O,493570,,1,Potential PLpro inhibitors from ZINC,,,,,OCC(C(C(Cn1c2cc(C)c(cc2nc2c1nc(=O)[nH]c2=O)C)O)O)O,Treatment of vitamin B2 deficiency
Reproterol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCCNCC(C3=CC(=CC(=C3)O)O)O,25654,,1,Potential PLpro inhibitors from ZINC,,,,,Oc1cc(O)cc(c1)C(CNCCCn1cnc2c1c(=O)n(C)c(=O)n2C)O,Treatment of bronchial asthma
"2,2′-Cyclocytidine",SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CN2C3C(C(C(O3)CO)O)OC2=NC1=N,,,1,Potential PLpro inhibitors from ZINC,,,,,OCC1OC2C(C1O)Oc1n2ccc(=N)n1,Anti-tumor
Chloramphenicol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC(=CC=C1C(C(CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],5959,,1,Potential PLpro inhibitors from ZINC,,,,,OCC(C(c1ccc(cc1)[N+](=O)[O-])O)NC(=O)C(Cl)Cl,Anti-bacterial effect
Chlorphenesin carbamate,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC(=CC=C1OCC(COC(=O)N)O)Cl,2724,,1,Potential PLpro inhibitors from ZINC,,,,,OC(COC(=O)N)COc1ccc(cc1)Cl,Muscle relaxant effect
Levodropropizine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1CN(CCN1CC(CO)O)C2=CC=CC=C2,65859,,1,Potential PLpro inhibitors from ZINC,,,,,OCC(CN1CCN(CC1)c1ccccc1)O,Anti-tussive effect
Cefamandole,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)NC(=O)C(C4=CC=CC=C4)O)SC2)C(=O)O,456255,,1,Potential PLpro inhibitors from ZINC,,,,,OC(C(=O)NC1C(=O)N2C1SCC(=C2C(=O)O)CSc1nnnn1C)c1ccccc1,Anti-bacterial effect
Floxuridine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1C(C(OC1N2C=C(C(=O)NC2=O)F)CO)O,5790,,1,Potential PLpro inhibitors from ZINC,,,,,OCC1OC(CC1O)n1cc(F)c(=O)[nH]c1=O,
Tigecycline,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)(C)NCC(=O)NC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C,54686904,,1,Potential PLpro inhibitors from ZINC,,,,,O=C(Nc1cc(N(C)C)c2c(c1O)C(=C1C(C2)CC2C(C1=O)(O)C(=C(C(=O)C2N(C)C)C(=O)N)O)O)CNC(C)(C)C,
Pemetrexed,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,135410875,,1,Potential PLpro inhibitors from ZINC,,,,,OC(=O)CCC(C(=O)O)NC(=O)c1ccc(cc1)CCc1c[nH]c2c1c(=O)[nH]c(n2)N,
L(+)-Ascorbic acid,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C(C(C1C(=C(C(=O)O1)O)O)O)O,54670067,,1,Potential PLpro inhibitors from ZINC,,,,,OCC(C1OC(=O)C(=C1O)O)O,
Glutathione,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C(CC(=O)NC(CS)C(=O)NCC(=O)O)C(C(=O)O)N,124886,,1,Potential PLpro inhibitors from ZINC,,,,,SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N,
Hesperetin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,COC1=C(C=C(C=C1)C2CC(=O)C3=C(C=C(C=C3O2)O)O)O,72281,,1,Potential PLpro inhibitors from ZINC,,,,,COc1ccc(cc1O)C1CC(=O)c2c(O1)cc(cc2O)O,
Ademetionine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C[S+](CCC(C(=O)[O-])N)CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O,34755,,1,Potential PLpro inhibitors from ZINC,,,,,C[S+](CC1OC(C(C1O)O)n1cnc2c1ncnc2N)CCC(C(=O)[O-])N,
Masoprocol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(CC1=CC(=C(C=C1)O)O)C(C)CC2=CC(=C(C=C2)O)O,71398,,1,Potential PLpro inhibitors from ZINC,,,,,CC(C(Cc1ccc(c(c1)O)O)C)Cc1ccc(c(c1)O)O,
Isotretinoin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,5282379,,1,Potential PLpro inhibitors from ZINC,,,,,CC(=CC=CC(=CC(=O)O)C)C=CC1=C(C)CCCC1(C)C,
Dantrolene,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1C(=O)NC(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-],6914273,,1,Potential PLpro inhibitors from ZINC,,,,,O=C1CN(C(=O)N1)N=Cc1ccc(o1)c1ccc(cc1)[N+](=O)[O-],
Sulfasalazine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,5339,,1,Potential PLpro inhibitors from ZINC,,,,,OC(=O)c1cc(N=Nc2ccc(cc2)S(=O)(=O)Nc2ccccn2)ccc1O,
Silybin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O,31553,,1,Potential PLpro inhibitors from ZINC,,,,,OCC1Oc2ccc(cc2OC1c1ccc(c(c1)OC)O)C1Oc2cc(O)cc(c2C(=O)C1O)O,
Nicardipine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,4474,,1,Potential PLpro inhibitors from ZINC,,,,,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCN(Cc1ccccc1)C)C,
Sildenafil,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,135398744,,1,Potential PLpro inhibitors from ZINC,,,,,CCCc1nn(c2c1nc([nH]c2=O)c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC1)C)C,
Platycodin D,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1C(C(C(C(O1)OC2C(C(COC2OC(=O)C34CCC(CC3C5=CCC6C(C5(CC4O)C)(CCC7C6(CC(C(C7(CO)CO)OC8C(C(C(C(O8)CO)O)O)O)O)C)C)(C)C)O)O)O)O)OC9C(C(C(CO9)O)OC1C(C(CO1)(CO)O)O)O,162859,,1,Potential PLpro inhibitors from in-house natural product database.,,,,,OCC1(CO)C(OC2OC(CO)C(C(C2O)O)O)C(O)CC2(C1CCC1(C2CC=C2C1(C)CC(O)C1(C2CC(CC1)(C)C)C(=O)OC1OCC(C(C1OC1OC(C)C(C(C1O)O)OC1OCC(C(C1O)OC1OCC(C1O)(O)CO)O)O)O)C)C,
Chrysin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O,5281607,,1,Potential PLpro inhibitors from in-house natural product database.,,,,,Oc1cc(O)c2c(c1)oc(cc2=O)c1ccccc1,
Neohesperidin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC(=C(C=C5)OC)O)O)CO)O)O)O)O)O,442439,,1,Potential PLpro inhibitors from in-house natural product database.,,,,,OCC1OC(Oc2cc3OC(CC(=O)c3c(c2)O)c2ccc(c(c2)O)OC)C(C(C1O)O)OC1OC(C)C(C(C1O)O)O,
Baicalin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O,64982,,1,Potential PLpro inhibitors from in-house natural product database.,,,,,OC(=O)C1OC(Oc2cc3oc(cc(=O)c3c(c2O)O)c2ccccc2)C(C(C1O)O)O,
(–)-Epigallocatechin gallate,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1C23C(C4=CC=CC=C4N2C(=O)C5=CC=CC=C5N3)C(=O)O1,,,1,Potential PLpro inhibitors from in-house natural product database.,,,,,O=C1OCC23C1c1ccccc1N3C(=O)c1c(N2)cccc1,
Phaitanthrin D,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1C23C(C4=CC=CC=C4N2C(=O)C5=CC=CC=C5N3)C(=O)O1,24970703,,1,Potential PLpro inhibitors from in-house natural product database.,,,,,O=C1OCC23C1c1ccccc1N3C(=O)c1c(N2)cccc1,
Piceatannol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC(=C(C=C1C=CC2=CC(=CC(=C2)O)O)O)O,667639,,1,Potential PLpro inhibitors from in-house natural product database.,,,,,Oc1cc(C=Cc2ccc(c(c2)O)O)cc(c1)O,
Rosmarinic acid,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O,5281792,,1,Potential PLpro inhibitors from in-house natural product database.,,,,,O=C(OC(C(=O)O)Cc1ccc(c(c1)O)O)C=Cc1ccc(c(c1)O)O,
Magnolol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C=CCC1=CC(=C(C=C1)O)C2=C(C=CC(=C2)CC=C)O,72300,,1,Potential PLpro inhibitors from in-house natural product database.,,,,,C=CCc1ccc(c(c1)c1cc(CC=C)ccc1O)O,
Lymecycline,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1(C2CC3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)NCNCCCCC(C(=O)O)N)N(C)C)O,54707177,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,NC(C(=O)O)CCCCNCNC(=O)C1=C(O)C2(C(C(C1=O)N(C)C)CC1C(=C(O)c3c(C1(C)O)cccc3O)C2=O)O,
Chlorhexidine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl,9552079,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,NC(=NCCCCCCN=C(N=C(Nc1ccc(cc1)Cl)N)N)N=C(Nc1ccc(cc1)Cl)N,
Alfuzosin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC,2092,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,COc1cc2nc(nc(c2cc1OC)N)N(CCCNC(=O)C1CCCO1)C,
Cilastatin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1(CC1C(=O)NC(=CCCCCSCC(C(=O)O)N)C(=O)O)C,6435415,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,OC(=O)C(CSCCCCC=C(C(=O)O)NC(=O)C1CC1(C)C)N,
Famotidine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N,5702160,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,NC(=Nc1scc(n1)CSCCC(=NS(=O)(=O)N)N)N,
Almitrine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C,33887,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,C=CCNc1nc(nc(n1)NCC=C)N1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F,
Progabide,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC(=CC=C1C(=NCCCC(=O)N)C2=C(C=CC(=C2)F)O)Cl,44115,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,NC(=O)CCCN=C(c1cc(F)ccc1O)c1ccc(cc1)Cl,
Nepafenac,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N,151075,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,NC(=O)Cc1cccc(c1N)C(=O)c1ccccc1,
Carvedilol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,2585,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O,
Amprenavir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,65016,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1CCOC1)O)C,
Tigecycline,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)(C)NCC(=O)NC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C,54686904,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,O=C(Nc1cc(N(C)C)c2c(c1O)C(=C1C(C2)CC2C(C1=O)(O)C(=C(C(=O)C2N(C)C)C(=O)N)O)O)CNC(C)(C)C,
Demeclocycline,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CN(C)C1C2CC3C(C4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O,54680690,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,CN(C1C(=O)C(=C(C2(C1CC1C(=C(O)c3c(C1O)c(Cl)ccc3O)C2=O)O)O)C(=O)N)C,
Montelukast,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,5281040,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,OC(=O)CC1(CSC(c2cccc(c2)C=Cc2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1,
Carminic acid,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=C2C(=CC(=C1C(=O)O)O)C(=O)C3=C(C2=O)C(=C(C(=C3O)O)C4C(C(C(C(O4)CO)O)O)O)O,10255083,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,OCC1OC(C(C(C1O)O)O)c1c(O)c2c(c(c1O)O)C(=O)c1c(C2=O)c(C)c(c(c1)O)C(=O)O,
Mimosine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CN(C=C(C1=O)O)CC(C(=O)O)N,3862,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,OC(=O)C(Cn1ccc(=O)c(c1)O)N,
Flavin mononucleotide,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)O)O)O)O,,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,O=c1[nH]c(=O)c2c(n1)n(CC(C(C(COP(=O)(O)O)O)O)O)c1c(n2)cc(c(c1)C)C,
Lutein,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=C(C(CC(C1)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2C(=CC(CC2(C)C)O)C)C)C,,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,CC(=CC=CC=C(C=CC=C(C=CC1=C(C)CC(CC1(C)C)O)C)C)C=CC=C(C=CC1C(=CC(CC1(C)C)O)C)C,
Cefpiramide,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=CC(=O)C(=CN1)C(=O)NC(C2=CC=C(C=C2)O)C(=O)NC3C4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O,5281243,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,Oc1ccc(cc1)C(C(=O)NC1C(=O)N2C1SCC(=C2C(=O)O)CSc1nnnn1C)NC(=O)c1c[nH]c(cc1=O)C,
Phenethicillin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C(=O)NC1C2N(C1=O)C(C(S2)(C)C)C(=O)O)OC3=CC=CC=C3,636405,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,CC(C(=O)NC1C(=O)N2C1SC(C2C(=O)O)(C)C)Oc1ccccc1,
Candoxatril,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,COCCOCC(CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)OC3=CC4=C(CCC4)C=C3,272833,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,COCCOCC(C(=O)Oc1ccc2c(c1)CCC2)CC1(CCCC1)C(=O)NC1CCC(CC1)C(=O)O,
Nicardipine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,5362417,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCN(Cc1ccccc1)C)C,
Estradiol valerate,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCCCC(=O)OC1CCC2C1(CCC3C2CCC4=C3C=CC(=C4)O)C,4474,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,CCCCC(=O)OC1CCC2C1(C)CCC1C2CCc2c1ccc(c2)O,
Pioglitazone,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,13791,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,CCc1ccc(nc1)CCOc1ccc(cc1)CC1SC(=O)NC1=O,
Conivaptan,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6,4829,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,Cc1[nH]c2c(n1)c1ccccc1N(CC2)C(=O)c1ccc(cc1)NC(=O)c1ccccc1c1ccccc1,
Telmisartan,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,151171,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2,
Doxycycline,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,65999,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,CN(C1C(=O)C(=C(C2(C1C(O)C1C(C)c3cccc(c3C(=C1C2=O)O)O)O)O)C(=O)N)C,
Oxytetracycline,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1(C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O,54671203,,1,Potential 3CLpro inhibitors from ZINC drug database,,,,,CN(C1C(=O)C(=C(C2(C1C(O)C1C(=C(O)c3c(C1(C)O)cccc3O)C2=O)O)O)C(=O)N)C,
Valganciclovir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N,54675779,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,OCC(OCn1cnc2c1nc(N)[nH]c2=O)COC(=O)C(C(C)C)N,
Chlorhexidine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl,135413535,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,NC(=NCCCCCCN=C(N=C(Nc1ccc(cc1)Cl)N)N)N=C(Nc1ccc(cc1)Cl)N,
Ceftibuten,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1C=C(N2C(S1)C(C2=O)NC(=O)C(=CCC(=O)O)C3=CSC(=N3)N)C(=O)O,9552079,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,OC(=O)CC=C(C(=O)NC1C(=O)N2C1SCC=C2C(=O)O)c1csc(n1)N,
Fenoterol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(CC1=CC=C(C=C1)O)NCC(C2=CC(=CC(=C2)O)O)O,5282242,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,CC(Cc1ccc(cc1)O)NCC(c1cc(O)cc(c1)O)O,
Fludarabine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N,3343,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,OCC1OC(C(C1O)O)n1cnc2c1nc(F)nc2N,
Itraconazole,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,657237,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,CCC(n1ncn(c1=O)c1ccc(cc1)N1CCN(CC1)c1ccc(cc1)OCC1COC(O1)(Cn1cncn1)c1ccc(cc1Cl)Cl)C,
Cefuroxime,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O,3793,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,CON=C(C(=O)NC1C(=O)N2C1SCC(=C2C(=O)O)COC(=O)N)c1ccco1,
Atovaquone,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O,5479529,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,Clc1ccc(cc1)C1CCC(CC1)C1=C(O)c2c(C(=O)C1=O)cccc2,
Chenodeoxycholic acid,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C,74989,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,OC1CCC2(C(C1)CC(C1C2CCC2(C1CCC2C(CCC(=O)O)C)C)O)C,
Cromolyn,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,10133,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,OC(COc1cccc2c1c(=O)cc(o2)C(=O)O)COc1cccc2c1c(=O)cc(o2)C(=O)O,
Pancuronium bromide,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(=O)OC1CC2CCC3C(C2(CC1[N+]4(CCCCC4)C)C)CCC5(C3CC(C5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-].[Br-],2882,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,CC(=O)OC1CC2CCC3C(C2(CC1[N+]1(C)CCCCC1)C)CCC1(C3CC(C1OC(=O)C)[N+]1(C)CCCCC1)C.[Br-].[Br-],
Cortisone,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC12CCC(=O)C=C1CCC3C2C(=O)CC4(C3CCC4(C(=O)CO)O)C,27350,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,OCC(=O)C1(O)CCC2C1(C)CC(=O)C1C2CCC2=CC(=O)CCC12C,
Tibolone,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1CC2=C(CCC(=O)C2)C3C1C4CCC(C4(CC3)C)(C#C)O,222786,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,C#CC1(O)CCC2C1(C)CCC1C2C(C)CC2=C1CCC(=O)C2,
Novobiocin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=C(C=CC2=C1OC(=O)C(=C2O)NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)OC4C(C(C(C(O4)(C)C)OC)OC(=O)N)O,444008,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,COC1C(OC(=O)N)C(O)C(OC1(C)C)Oc1ccc2c(c1C)oc(=O)c(c2O)NC(=O)c1ccc(c(c1)CC=C(C)C)O,
Silybin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O,54675769,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,OCC1Oc2ccc(cc2OC1c1ccc(c(c1)OC)O)C1Oc2cc(O)cc(c2C(=O)C1O)O,
Idarubicin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,31553,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,OC1C(N)CC(OC1C)OC1CC(O)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2)C(=O)C,
Bromocriptine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,42890,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,CC(CC1C(=O)N2CCCC2C2(N1C(=O)C(O2)(NC(=O)C1CN(C)C2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C,
Diphenoxylate,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCOC(=O)C1(CCN(CC1)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,31101,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,CCOC(=O)C1(CCN(CC1)CCC(c1ccccc1)(c1ccccc1)C#N)c1ccccc1,
Benzylpenicilloyl G,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1(C(NC(S1)C(C(=O)NCCCCCC(=O)O)NC(=O)CC2=CC=CC=C2)C(=O)O)C,13505,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,O=C(NC(C1NC(C(S1)(C)C)C(=O)O)C(=O)NCCCCCC(=O)O)Cc1ccccc1,
Dabigatran etexilate,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCCCCCOC(=O)N=C(N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,119212,,1,Potential RdRp inhibitors from ZINC drug database.,,,,,CCCCCCOC(=O)N=C(c1ccc(cc1)NCc1nc2c(n1C)ccc(c2)C(=O)N(c1ccccn1)CCC(=O)OCC)N,
Betulonal,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(=C)C1CCC2(C1C3CCC4C5(CCC(=O)C(C5CCC4(C3(CC2)C)C)(C)C)C)C=O,,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,O=CC12CCC(C2C2C(CC1)(C)C1(C)CCC3C(C1CC2)(C)CCC(=O)C3(C)C)C(=C)C,
Andrographiside,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC12CCC(C(C1CCC(=C)C2CC=C3C(COC3=O)O)(C)COC4C(C(C(C(O4)CO)O)O)O)O,,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,OCC1OC(OCC2(C)C(O)CCC3(C2CCC(=C)C3CC=C2C(O)COC2=O)C)C(C(C1O)O)O,
Cerevisterol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2=CC(C4(C3(CCC(C4)O)C)O)O)C,,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,OC1CCC2(C(C1)(O)C(O)C=C1C2CCC2(C1CCC2C(C=CC(C(C)C)C)C)C)C,
Hesperidin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O,10181133,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,COc1ccc(cc1O)C1CC(=O)c2c(O1)cc(cc2O)OC1OC(COC2OC(C)C(C(C2O)O)O)C(C(C1O)O)O,
Neohesperidin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC(=C(C=C5)OC)O)O)CO)O)O)O)O)O,10621,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,OCC1OC(Oc2cc3OC(CC(=O)c3c(c2)O)c2ccc(c(c2)O)OC)C(C(C1O)O)OC1OC(C)C(C(C1O)O)O,
Andrograpanin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1(CCCC2(C1CCC(=C)C2CCC3=CCOC3=O)C)CO,442439,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,OCC1(C)CCCC2(C1CCC(=C)C2CCC1=CCOC1=O)C,
Cosmosiin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)OC4C(C(C(C(O4)CO)O)O)O)O)O,,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,OCC1OC(Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)C(C(C1O)O)O,
Biorobin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)O)O)O)O)O)O,,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,Oc1ccc(cc1)c1oc2cc(O)cc(c2c(=O)c1OC1OC(COC2OC(C)C(C(C2O)O)O)C(C(C1O)O)O)O,
Gnidicin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1C(C2(C3C4C1(C5C=C(C(=O)C5(C(C6(C4O6)CO)O)O)C)OC(O3)(O2)C7=CC=CC=C7)C(=C)C)OC(=O)C=CC8=CC=CC=C8,12313332,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,OCC12OC1C1C3OC4(OC1(C1C(C2O)(O)C(=O)C(=C1)C)C(C(C3(O4)C(=C)C)OC(=O)C=Cc1ccccc1)C)c1ccccc1,
Rosmarinic acid,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O,,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,O=C(OC(C(=O)O)Cc1ccc(c(c1)O)O)C=Cc1ccc(c(c1)O)O,
Oleanolic acid,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)C(=O)O)C,,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,OC1CCC2(C(C1(C)C)CCC1(C2CC=C2C1(C)CCC1(C2CC(C)(C)CC1)C(=O)O)C)C,
Stigmast-5-en-3-ol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C,10494,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,CCC(C(C)C)CCC(C1CCC2C1(C)CCC1C2CC=C2C1(C)CCC(C2)O)C,
Berchemol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,COC1=C(C=CC(=C1)CC2COC(C2(CO)O)C3=CC(=C(C=C3)O)OC)O,,,1,Potential 3CLpro inhibitors from in-house natural product database.,,,,,COc1cc(ccc1O)CC1COC(C1(O)CO)c1ccc(c(c1)OC)O,
Betulonal,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(=C)C1CCC2(C1C3CCC4C5(CCC(=O)C(C5CCC4(C3(CC2)C)C)(C)C)C)C=O,14521044,,1,Potential RdRp inhibitors from in-house natural product database.,,,,,O=CC12CCC(C2C2C(CC1)(C)C1(C)CCC3C(C1CC2)(C)CCC(=O)C3(C)C)C(=C)C,
Gnidicin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1C(C2(C3C4C1(C5C=C(C(=O)C5(C(C6(C4O6)CO)O)O)C)OC(O3)(O2)C7=CC=CC=C7)C(=C)C)OC(=O)C=CC8=CC=CC=C8,473111,,1,Potential RdRp inhibitors from in-house natural product database.,,,,,OCC12OC1C1C3OC4(OC1(C1C(C2O)(O)C(=O)C(=C1)C)C(C(C3(O4)C(=C)C)OC(=O)C=Cc1ccccc1)C)c1ccccc1,
Gniditrin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCCC=CC=CC=CC(=O)OC1C(C23C4C=C(C(=O)C4(C(C5(C(C2C6C1(OC(O6)(O3)C7=CC=CC=C7)C(=C)C)O5)CO)O)O)C)C,,,1,Potential RdRp inhibitors from in-house natural product database.,,,,,CCCC=CC=CC=CC(=O)OC1C(C)C23OC4(OC1(C(=C)C)C(C2C1OC1(C(C1(C3C=C(C1=O)C)O)O)CO)O4)c1ccccc1,
"Theaflavin 3,3′-di-O-gallate",SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC4=C(C(=C(C=C4C5C(CC6=C(C=C(C=C6O5)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)C(=O)C(=C3)O)OC(=O)C8=CC(=C(C(=C8)O)O)O,,,1,Potential RdRp inhibitors from in-house natural product database.,,,,,Oc1cc2OC(C(Cc2c(c1)O)OC(=O)c1cc(O)c(c(c1)O)O)c1cc(O)c(=O)c2c(c1)c(cc(c2O)O)C1Oc2cc(O)cc(c2CC1OC(=O)c1cc(O)c(c(c1)O)O)O,
Phyllaemblicin B,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1COC2(CC1OC(=O)C3=CC=CC=C3)C(=O)C4(C(CC(CC4O2)C(=O)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)O)O,,,1,Potential RdRp inhibitors from in-house natural product database.,,,,,OCC1OC(OC(=O)C2CC(O)C3(C(C2)OC2(C3=O)OCC(C(C2)OC(=O)c2ccccc2)C)O)C(C(C1O)O)OC1OC(CO)C(C(C1O)O)O,
Andrographiside,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC12CCC(C(C1CCC(=C)C2CC=C3C(COC3=O)O)(C)COC4C(C(C(C(O4)CO)O)O)O)O,,,1,Potential RdRp inhibitors from in-house natural product database.,,,,,OCC1OC(OCC2(C)C(O)CCC3(C2CCC(=C)C3CC=C2C(O)COC2=O)C)C(C(C1O)O)O,
Baicalin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O,44593583,,1,Potential RdRp inhibitors from in-house natural product database.,,,,,OC(=O)C1OC(Oc2cc3oc(cc(=O)c3c(c2O)O)c2ccccc2)C(C(C1O)O)O,
"1,7-Dihydroxy-3-methoxyxanthone",SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,COC1=CC(=C2C(=C1)OC3=C(C2=O)C=C(C=C3)O)O,,,1,Potential RdRp inhibitors from in-house natural product database.,,,,,COc1cc(O)c2c(c1)oc1c(c2=O)cc(cc1)O,
Emtricitabine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,,,1,known antiviral,,,,,Nc1nc(=O)n(cc1F)C1CSC(O1)CO,
Tenofovir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,,,1,known antiviral,,,,,CC(Cn1cnc2c1ncnc2N)OCP(=O)(O)O,
Efavirenz,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,,,1,known antiviral,,,,,FC(C1(C#CC2CC2)OC(=O)Nc2c1cc(Cl)cc2)(F)F,
Nevirapine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,60877,,1,known antiviral,,,,,Cc1ccnc2c1[nH]c(=O)c1c(n2C2CC2)nccc1,
Saquinavir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,464205,,1,known antiviral,,,,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,
Indinavir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,64139,,1,known antiviral,,,,,OC(CN1CCN(CC1C(=O)NC(C)(C)C)Cc1cccnc1)CC(C(=O)NC1C(O)Cc2c1cccc2)Cc1ccccc1,
Nelfinavir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,4463,,1,known antiviral,,,,,OC(C(NC(=O)c1cccc(c1C)O)CSc1ccccc1)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C,
Atazanavir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,441243,,1,known antiviral,,,,,COC(=O)NC(C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)CC(C(Cc1ccccc1)NC(=O)C(C(C)(C)C)NC(=O)OC)O,
Tipranavir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4,5362440,,1,known antiviral,,,,,CCCC1(CCc2ccccc2)CC(=C(C(=O)O1)C(c1cccc(c1)NS(=O)(=O)c1ccc(cn1)C(F)(F)F)CC)O,
Abacavir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO,64143,,1,known antiviral,,,,,OCC1C=CC(C1)n1cnc2c1nc(N)nc2NC1CC1,
Doravirine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F,148192,,1,known antiviral,,,,,N#Cc1cc(cc(c1)Cl)Oc1c(=O)n(ccc1C(F)(F)F)Cc1n[nH]c(=O)n1C,
Etravirine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N,54682461,,1,known antiviral,,,,,N#Cc1ccc(cc1)Nc1nc(N)c(c(n1)Oc1c(C)cc(cc1C)C#N)Br,
Rilpivirine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)C=CC#N,441300,,1,known antiviral,,,,,N#CC=Cc1cc(C)c(c(c1)C)Nc1ccnc(n1)Nc1ccc(cc1)C#N,
Dolutegravir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,58460047,,1,known antiviral,,,,,Fc1ccc(c(c1)F)CNC(=O)c1cn2CC3OCCC(N3C(=O)c2c(c1=O)O)C,
Raltegravir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F,193962,,1,known antiviral,,,,,Fc1ccc(cc1)CNC(=O)c1nc(n(c(=O)c1O)C)C(NC(=O)c1nnc(o1)C)(C)C,
Penciclovir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,6451164,,1,known antiviral,,,,,OCC(CCn1cnc2c1nc(N)[nH]c2=O)CO,
Cytarabine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,54726191,,1,known antiviral,,,,,OCC1OC(C(C1O)O)n1ccc(nc1=O)N,
Cidofovir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O,54671008,,1,known antiviral,,,,,OCC(Cn1ccc(nc1=O)N)OCP(=O)(O)O,
Tromantadine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CN(C)CCOCC(=O)NC12CC3CC(C1)CC(C3)C2,135398748,,1,known antiviral,,,,,CN(CCOCC(=O)NC12CC3CC(C2)CC(C1)C3)C,
Imiquimod,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,6253,,1,known antiviral,,,,,CC(Cn1cnc2c1c1ccccc1nc2N)C,
Podophyllotoxin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,COC1=CC(=CC(=C1OC)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O,60613,,1,known antiviral,,,,,COc1cc(cc(c1OC)OC)C1C2C(=O)OCC2C(c2c1cc1OCOc1c2)O,
Adefovir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=NC(=C2C(=N1)N(C=N2)CCOCP(=O)(O)O)N,64377,,1,known antiviral,,,,,Nc1ncnc2c1ncn2CCOCP(=O)(O)O,
Clevudine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)F,57469,,1,known antiviral,,,,,OCC1OC(C(C1O)F)n1cc(C)c(=O)[nH]c1=O,
Telbivudine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O,10607,,1,known antiviral,,,,,OCC1OC(CC1O)n1cc(C)c(=O)[nH]c1=O,
Ribavirin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,60172,,1,known antiviral,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,
Boceprevir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,73115,,1,known antiviral,,,,,O=C(NC(C)(C)C)NC(C(C)(C)C)C(=O)N1CC2C(C1C(=O)NC(C(=O)C(=O)N)CC1CCC1)C2(C)C,
Telaprevir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5,159269,,1,known antiviral,,,,,CCCC(C(=O)C(=O)NC1CC1)NC(=O)C1C2CCCC2CN1C(=O)C(C(C)(C)C)NC(=O)C(C1CCCCC1)NC(=O)c1nccnc1,
Arbidol,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3,37542,,1,known antiviral,,,,,CCOC(=O)c1c(CSc2ccccc2)n(c2c1c(CN(C)C)c(O)c(c2)Br)C,
Inosine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)CO)O)O,10324367,,1,known antiviral,,,,,OCC1OC(C(C1O)O)n1cnc2c1nc[nH]c2=O,
Rimantadine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C12CC3CC(C1)CC(C3)C2)N,3010818,,1,known antiviral,,,,,CC(C12CC3CC(C2)CC(C1)C3)N,
Amantadine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1C2CC3CC1CC(C2)(C3)N,131411,,1,known antiviral,,,,,NC12CC3CC(C2)CC(C1)C3,
Maraviroc,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,135398641,,1,known antiviral,,,,,O=C(C1CCC(CC1)(F)F)NC(c1ccccc1)CCN1C2CCC1CC(C2)n1c(C)nnc1C(C)C,
Zanamivir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N,5071,,1,known antiviral,,,,,OCC(C(C1OC(=CC(C1NC(=O)C)N=C(N)N)C(=O)O)O)O,
Acyclovir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=NC2=C(N1COCCO)N=C(NC2=O)N,2130,,1,known antiviral,,,,,OCCOCn1cnc2c1nc(N)[nH]c2=O,
Ganciclovir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,3002977,,1,known antiviral,,,,,OCC(OCn1cnc2c1nc(N)[nH]c2=O)CO,
Valganciclovir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N,60855,,1,known antiviral,,,,,OCC(OCn1cnc2c1nc(N)[nH]c2=O)COC(=O)C(C(C)C)N,
Valaciclovir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,135398513,,1,known antiviral,,,,,CC(C(C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O)N)C,
Suramin,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C,135398740,,1,known antiviral,,,,,O=C(Nc1cccc(c1)C(=O)Nc1cc(ccc1C)C(=O)Nc1ccc(c2c1c(cc(c2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)Nc1cccc(c1)C(=O)Nc1cc(ccc1C)C(=O)Nc1ccc(c2c1c(cc(c2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,
"DHPA (S)-9-(2,3-Dihydroxypropyl)adenine",SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=NC(=C2C(=N1)N(C=N2)CC(CO)O)N,135413535,,1,known antiviral,,,,,OCC(Cn1cnc2c1ncnc2N)O,
BVDU Brivudine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,O=c1nc(O)c(/C=C/Br)cn1[C@H]1C[C@H](O)[C@@H](CO)O1,135398742,,1,known antiviral,,,,,Br/C=C/c1cn([C@H]2C[C@@H]([C@H](O2)CO)O)c(=O)nc1O,
ACV triphosphate Acycloguanosine triphosphate,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=NC2=C(N1COCCOP(=O)(O)OP(=O)(O)OP(=O)(O)O)N=C(NC2=O)N,,,1,known antiviral,,,,,Nc1[nH]c(=O)c2c(n1)n(COCCOP(=O)(OP(=O)(OP(=O)(O)O)O)O)cn2,
(S)-HPMPA (S)-9-(3-hydroxy-2-phosphonomethoxypropyl)adenine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=NC(=C2C(=N1)N(C=N2)CC(CO)OCP(=O)(O)O)N,,,1,known antiviral,,,,,OCC(Cn1cnc2c1ncnc2N)OCP(=O)(O)O,
STAVUDINE,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO,,,1,known antiviral,,,,,Cc1cn(C2OC(C=C2)CO)c(=O)[nH]c1=O,
Didanosine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1CC(OC1CO)N2C=NC3=C2N=CNC3=O,,,1,known antiviral,,,,,OCC1CCC(O1)n1cnc2c1nc[nH]c2=O,
Zalcitabine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1CC(OC1CO)N2C=CC(=NC2=O)N,,,1,known antiviral,,,,,Nc1ccn(c(=O)n1)C1CCC(O1)CO,
Pyrimidinedione,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=CNC(=O)NC1=O,,,1,known antiviral,,,,,O=c1cc[nH]c(=O)[nH]1,
Emivirine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCOCN1C(=C(C(=O)NC1=O)C(C)C)CC2=CC=CC=C2,,,1,known antiviral,,,,,CCOCn1c(=O)[nH]c(=O)c(c1Cc1ccccc1)C(C)C,
Delavirdine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,,,1,known antiviral,,,,,CC(Nc1cccnc1N1CCN(CC1)C(=O)c1cc2c([nH]1)ccc(c2)NS(=O)(=O)C)C,
Dapivirine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=CC(=C(C(=C1)C)NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C,,,1,known antiviral,,,,,N#Cc1ccc(cc1)Nc1nccc(n1)Nc1c(C)cc(cc1C)C,
TIBO,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1CN2C3=C(CN1CC=C(C)C)C=CC=C3NC2=S,,,1,known antiviral,,,,,CC(=CCN1Cc2cccc3c2n(CC1C)c(=S)[nH]3)C,
Tivirapine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1CN2C3=C(C=CC(=C3CN1CC=C(C)C)Cl)NC2=S,,,1,known antiviral,,,,,CC(=CCN1Cc2c(Cl)ccc3c2n(CC1C)c(=S)[nH]3)C,
Elvitegravir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)C(CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O,,,1,known antiviral,,,,,OCC(n1cc(C(=O)O)c(=O)c2c1cc(OC)c(c2)Cc1cccc(c1F)Cl)C(C)C,
Cobicistat,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,18283,,1,known antiviral,,,,,O=C(NC(Cc1ccccc1)CCC(Cc1ccccc1)NC(=O)C(NC(=O)N(Cc1csc(n1)C(C)C)C)CCN1CCOCC1)OCc1cncs1,
Plerixafor,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3,135398739,,1,known antiviral,,,,,C1CNCCN(CCCNCCNC1)Cc1ccc(cc1)CN1CCNCCCNCCNCCC1,
Bictegravir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F,24066,,1,known antiviral,,,,,Fc1cc(F)c(c(c1)F)CNC(=O)c1cn2CC3OC4CCC(N3C(=O)c2c(c1=O)O)C4,
Rabacfosadine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCOC(=O)C(C)NP(=O)(COCCN1C=NC2=C(N=C(N=C21)N)NC3CC3)NC(C)C(=O)OCC,,,1,known antiviral,,,,,CCOC(=O)C(NP(=O)(NC(C(=O)OCC)C)COCCn1cnc2c1nc(N)nc2NC1CC1)C,
FV 100 Valnivudine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)C4CC(C(O4)COC(=O)C(C(C)C)N)O,65013,,1,known antiviral,,,,,CCCCCc1ccc(cc1)c1oc2c(c1)cn(c(=O)n2)C1CC(C(O1)COC(=O)C(C(C)C)N)O,
GS 9191,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)COC(=O)C(CC1=CC=CC=C1)NP(=O)(COCCN2C=NC3=C(N=C(N=C32)N)NC4CC4)NC(CC5=CC=CC=C5)C(=O)OCC(C)C,5625,,1,known antiviral,,,,,CC(COC(=O)C(NP(=O)(NC(C(=O)OCC(C)C)Cc1ccccc1)COCCn1cnc2c1nc(N)nc2NC1CC1)Cc1ccccc1)C,
PMEO-DAPy,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=C(N=C(N=C1OCCOCP(=O)(O)O)N)N,3000236,,1,known antiviral,,,,,Nc1cc(OCCOCP(=O)(O)O)nc(n1)N,
Ritonavir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,5277135,,1,known antiviral,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,
Lopinavir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,25151504,,1,known antiviral,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
Darunavir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,65015,,1,known antiviral,,,,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1COC2C1CCO2)O)C,
Favipiravir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1=C(N=C(C(=O)N1)C(=O)N)F,90311989,,1,known antiviral,,,,,Fc1c[nH]c(=O)c(n1)C(=O)N,
Famciclovir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,16047979,,1,known antiviral,,,,,CC(=O)OCC(CCn1cnc2c1nc(N)nc2)COC(=O)C,
Foscarnet,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C(=O)(O)P(=O)(O)O,,,1,known antiviral,,,,,OC(=O)P(=O)(O)O,
Lamivudine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C1C(OC(S1)CO)N2C=CC(=NC2=O)N,,,1,known antiviral,,,,,Nc1ccn(c(=O)n1)C1CSC(O1)CO,
Emtricitabine,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,N=c1nc(O)n([C@@H]2CS[C@H](CO)O2)cc1FC1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,,,1,known antiviral,,,,,OCC1SC(C(O1)n1cc(F)c(nc1=O)N)[F]c1cn([C@@H]2CS[C@@H](O2)CO)c(nc1=N)O,
Entecavir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N,,,1,known antiviral,,,,,OCC1C(O)CC(C1=C)n1cnc2c1nc(N)[nH]c2=O,
Beclabuvir,SARS-CoV-2,10.1016/j.apsb.2020.02.008,Simulation,CN1CC2CCC(C1)N2C(=O)C34CC3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8,,,1,known antiviral,,,,,COc1ccc2c(c1)C1CC1(Cn1c2c(C2CCCCC2)c2c1cc(cc2)C(=O)NS(=O)(=O)N(C)C)C(=O)N1C2CCC1CN(C2)C,
dec-RVKR-CMK,MERS,nrd.2015.37,Experimental,CCCCCCCCCC(=O)NC(CCCN=C(N)N)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(CCCN=C(N)N)C(=O)CCl,,,1,,,,,,NCCCCC(C(=O)NC(C(=O)CCl)CCCN=C(N)N)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CCCCCCCCC)CCCN=C(N)N,
β-D-N4-hydroxycytidine,SARS-COV-2,10.1101/2020.03.19.997890,Experimental,C1=CN(C(=O)N=C1NO)C2C(C(C(O2)CO)O)O,,,1,,,,,First time I've seen this compound,OCC1OC(C(C1O)O)n1ccc(nc1=O)NO,
dichlorobenzyl alcohol,SARS-COV-2,10.1177/095632020501600205,Experimental,C1=C(C=C(C=C1Cl)Cl)CO,,,1,,,,,,OCc1cc(Cl)cc(c1)Cl,
Amylmetacresol,SARS-COV-2,10.1177/095632020501600205,Experimental,CCCCCC1=C(C=C(C=C1)C)O,,,1,,,,,,CCCCCc1ccc(cc1O)C,
oseltamivir,Mixed,Kaggle,Mixed,CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC,65028,,1,,,,,,CCOC(=O)C1=CC(C(C(C1)N)NC(=O)C)OC(CC)CC,
abacavir,Mixed,Kaggle,Mixed,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO,441300,,1,,,,,,OCC1C=CC(C1)n1cnc2c1nc(N)nc2NC1CC1,
acyclovir,Mixed,Kaggle,Mixed,C1=NC2=C(N1COCCO)N=C(NC2=O)N,135398513,,1,,,,,,OCCOCn1cnc2c1nc(N)[nH]c2=O,
adefovir,Mixed,Kaggle,Mixed,C1=NC(=C2C(=N1)N(C=N2)CCOCP(=O)(O)O)N,60172,,1,,,,,,Nc1ncnc2c1ncn2CCOCP(=O)(O)O,
alisporivir,Mixed,Kaggle,Mixed,CCC1C(=O)N(C(C(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C,11513676,,1,,,,,,CC=CCC(C(C1C(=O)NC(CC)C(=O)N(C)C(C)C(=O)N(CC)C(C(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)O)C,
amdoxovir,Mixed,Kaggle,Mixed,C1C(OC(O1)CO)N2C=NC3=C(N=C(N=C32)N)N,124088,,1,,,,,,OCC1OCC(O1)n1cnc2c1nc(N)nc2N,
amprenavir,Mixed,Kaggle,Mixed,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,65016,,1,,,,,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1CCOC1)O)C,
atazanavir,Mixed,Kaggle,Mixed,CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,148192,,1,,,,,,COC(=O)NC(C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)CC(C(Cc1ccccc1)NC(=O)C(C(C)(C)C)NC(=O)OC)O,
balapiravir,Mixed,Kaggle,Mixed,CC(C)C(=O)OCC1(C(C(C(O1)N2C=CC(=NC2=O)N)OC(=O)C(C)C)OC(=O)C(C)C)N=[N+]=[N-],11691726,,1,,,,,,[N-]=[N+]=NC1(COC(=O)C(C)C)OC(C(C1OC(=O)C(C)C)OC(=O)C(C)C)n1ccc(nc1=O)N,
baloxavir,Mixed,Kaggle,Mixed,C1COCC2N1C(=O)C3=C(C(=O)C=CN3N2C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F)O,124081876,,1,,,,,,Fc1c(F)ccc2c1CSc1c(C2N2C3COCCN3C(=O)c3n2ccc(=O)c3O)cccc1,
beclabuvir,Mixed,Kaggle,Mixed,CN1CC2CCC(C1)N2C(=O)C34CC3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8,49773361,,1,,,,,,COc1ccc2c(c1)C1CC1(Cn1c2c(C2CCCCC2)c2c1cc(cc2)C(=O)NS(=O)(=O)N(C)C)C(=O)N1C2CCC1CN(C2)C,
boceprevir,Mixed,Kaggle,Mixed,CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,10324367,,1,,,,,,O=C(NC(C)(C)C)NC(C(C)(C)C)C(=O)N1CC2C(C1C(=O)NC(C(=O)C(=O)N)CC1CCC1)C2(C)C,
brincidofovir,Mixed,Kaggle,Mixed,CCCCCCCCCCCCCCCCOCCCOP(=O)(COC(CN1C=CC(=NC1=O)N)CO)O,483477,,1,,,,,,CCCCCCCCCCCCCCCCOCCCOP(=O)(COC(Cn1ccc(nc1=O)N)CO)O,
carbovir,Mixed,Kaggle,Mixed,C1C(C=CC1N2C=NC3=C2N=C(NC3=O)N)CO,135403630,,1,,,,,,OCC1C=CC(C1)n1cnc2c1nc(N)[nH]c2=O,
celgosivir,Mixed,Kaggle,Mixed,CCCC(=O)OC1CN2CCC(C2C(C1O)O)O,60734,,1,,,,,,CCCC(=O)OC1CN2CCC(C2C(C1O)O)O,
cidofovir,Mixed,Kaggle,Mixed,C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O,60613,,1,,,,,,OCC(Cn1ccc(nc1=O)N)OCP(=O)(O)O,
combivir,Mixed,Kaggle,Mixed,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N=[N+]=[N-],72187,,1,,,,,,[N-]=[N+]=NC1CC(OC1COP(=O)(OP(=O)(OP(=O)(O)O)O)O)n1cc(C)c(=O)[nH]c1=O,
daclatasvir,Mixed,Kaggle,Mixed,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,25154714,,1,,,,,,COC(=O)NC(C(=O)N1CCCC1c1ncc([nH]1)c1ccc(cc1)c1ccc(cc1)c1cnc([nH]1)C1CCCN1C(=O)C(C(C)C)NC(=O)OC)C(C)C,
danoprevir,Mixed,Kaggle,Mixed,CC(C)(C)OC(=O)NC1CCCCCC=CC2CC2(NC(=O)C3CC(CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6,11285588,,1,,,,,,O=C(OC(C)(C)C)NC1CCCCCC=CC2C(NC(=O)C3N(C1=O)CC(C3)OC(=O)N1Cc3c(C1)cccc3F)(C2)C(=O)NS(=O)(=O)C1CC1,
darunavir,Mixed,Kaggle,Mixed,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,213039,,1,,,,,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1COC2C1CCO2)O)C,
dasabuvir,Mixed,Kaggle,Mixed,CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)NS(=O)(=O)C)N4C=CC(=O)NC4=O,56640146,,1,,,,,,COc1c(cc(cc1C(C)(C)C)n1ccc(=O)[nH]c1=O)c1ccc2c(c1)ccc(c2)NS(=O)(=O)C,
dolutegravir,Mixed,Kaggle,Mixed,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,54726191,,1,,,,,,Fc1ccc(c(c1)F)CNC(=O)c1cn2CC3OCCC(N3C(=O)c2c(c1=O)O)C,
elbasvir,Mixed,Kaggle,Mixed,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC,71661251,,1,,,,,,COC(=O)NC(C(=O)N1CCCC1c1ncc([nH]1)c1ccc2c(c1)OC(n1c2cc2c1ccc(c2)c1cnc([nH]1)C1CCCN1C(=O)C(C(C)C)NC(=O)OC)c1ccccc1)C(C)C,
elvitegravir,Mixed,Kaggle,Mixed,CC(C)C(CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O,5277135,,1,,,,,,OCC(n1cc(C(=O)O)c(=O)c2c1cc(OC)c(c2)Cc1cccc(c1F)Cl)C(C)C,
entecavir,Mixed,Kaggle,Mixed,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N,135398508,,1,,,,,,OCC1C(O)CC(C1=C)n1cnc2c1nc(N)[nH]c2=O,
famciclovir,Mixed,Kaggle,Mixed,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,3324,,1,,,,,,CC(=O)OCC(CCn1cnc2c1nc(N)nc2)COC(=O)C,
famvir,Mixed,Kaggle,Mixed,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,3324,,1,,,,,,CC(=O)OCC(CCn1cnc2c1nc(N)nc2)COC(=O)C,
favipiravir,Mixed,Kaggle,Mixed,C1=C(N=C(C(=O)N1)C(=O)N)F,492405,,1,,,,,,Fc1c[nH]c(=O)c(n1)C(=O)N,
fosamprenavir,Mixed,Kaggle,Mixed,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N,131536,,1,,,,,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1CCOC1)OP(=O)(O)O)C,
galidesivir,Mixed,Kaggle,Mixed,C1=C(C2=C(N1)C(=NC=N2)N)C3C(C(C(N3)CO)O)O,10445549,,1,,,,,,OCC1NC(C(C1O)O)c1c[nH]c2c1ncnc2N,
ganciclovir,Mixed,Kaggle,Mixed,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,135398740,,1,,,,,,OCC(OCn1cnc2c1nc(N)[nH]c2=O)CO,
glecaprevir,Mixed,Kaggle,Mixed,CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C,66828839,,1,,,,,,O=C1OC2CCCC2OCC=CC(F)(F)c2c(OC3CN(C(=O)C(N1)C(C)(C)C)C(C3)C(=O)NC1(CC1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)nc1c(n2)cccc1,
grazoprevir,Mixed,Kaggle,Mixed,CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1,44603531,,1,,,,,,C=CC1CC1(NC(=O)C1CC2CN1C(=O)C(NC(=O)OC1CC1CCCCCc1c(O2)nc2cc(OC)ccc2n1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,
laninamivir,Mixed,Kaggle,Mixed,CC(=O)NC1C(C=C(OC1C(C(CO)O)OC)C(=O)O)N=C(N)N,502272,,1,,,,,,OCC(C(C1OC(=CC(C1NC(=O)C)N=C(N)N)C(=O)O)OC)O,
ledipasvir,Mixed,Kaggle,Mixed,CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,67505836,,1,,,,,,COC(=O)NC(C(=O)N1CC2(CC1c1ncc([nH]1)c1ccc3c(c1)C(F)(F)c1c3ccc(c1)c1ccc3c(c1)[nH]c(n3)C1C3CCC(N1C(=O)C(C(C)C)NC(=O)OC)C3)CC2)C(C)C,
letermovir,Mixed,Kaggle,Mixed,COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O,45138674,,1,,,,,,COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2C(N1c1cc(ccc1OC)C(F)(F)F)CC(=O)O,
lobucavir,Mixed,Kaggle,Mixed,C1C(C(C1N2C=NC3=C2N=C(NC3=O)N)CO)CO,135413519,,1,,,,,,OCC1C(CO)CC1n1cnc2c1nc(N)[nH]c2=O,
lopinavir,Mixed,Kaggle,Mixed,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,92727,,1,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
maribavir,Mixed,Kaggle,Mixed,CC(C)NC1=NC2=CC(=C(C=C2N1C3C(C(C(O3)CO)O)O)Cl)Cl,471161,,1,,,,,,OCC1OC(C(C1O)O)n1c(NC(C)C)nc2c1cc(Cl)c(c2)Cl,
nelfinavir,Mixed,Kaggle,Mixed,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,64143,,1,,,,,,OC(C(NC(=O)c1cccc(c1C)O)CSc1ccccc1)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C,
ombitasvir,Mixed,Kaggle,Mixed,CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,54767916,,1,,,,,,COC(=O)NC(C(=O)N1CCCC1C(=O)Nc1ccc(cc1)C1CCC(N1c1ccc(cc1)C(C)(C)C)c1ccc(cc1)NC(=O)C1CCCN1C(=O)C(C(C)C)NC(=O)OC)C(C)C,
oseltamivir,Mixed,Kaggle,Mixed,CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC,65028,,1,,,,,,CCOC(=O)C1=CC(C(C(C1)N)NC(=O)C)OC(CC)CC,
paritaprevir,Mixed,Kaggle,Mixed,CC1=CN=C(C=N1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8,45110509,,1,,,,,,Cc1ncc(nc1)C(=O)NC1CCCCCC=CC2C(NC(=O)C3N(C1=O)CC(C3)Oc1nc3ccccc3c3c1cccc3)(C2)C(=O)NS(=O)(=O)C1CC1,
penciclovir,Mixed,Kaggle,Mixed,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,135398748,,1,,,,,,OCC(CCn1cnc2c1nc(N)[nH]c2=O)CO,
pencyclovir,Mixed,Kaggle,Mixed,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,135398748,,1,,,,,,OCC(CCn1cnc2c1nc(N)[nH]c2=O)CO,
peramivir,Mixed,Kaggle,Mixed,CCC(CC)C(C1C(CC(C1O)C(=O)O)N=C(N)N)NC(=O)C,154234,,1,,,,,,CCC(C(C1C(N=C(N)N)CC(C1O)C(=O)O)NC(=O)C)CC,
pibrentasvir,Mixed,Kaggle,Mixed,CC(C(C(=O)N1CCCC1C2=NC3=C(N2)C=C(C(=C3)F)C4CCC(N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)C1CCCN1C(=O)C(C(C)OC)NC(=O)OC)NC(=O)OC)OC,58031952,,1,,,,,,COC(=O)NC(C(=O)N1CCCC1c1[nH]c2c(n1)cc(c(c2)C1CCC(N1c1cc(F)c(c(c1)F)N1CCC(CC1)c1ccc(cc1)F)c1cc2[nH]c(nc2cc1F)C1CCCN1C(=O)C(C(OC)C)NC(=O)OC)F)C(OC)C,
pimodivir,Mixed,Kaggle,Mixed,C1CC2CCC1C(C2NC3=NC(=NC=C3F)C4=CNC5=C4C=C(C=N5)F)C(=O)O,67286591,,1,,,,,,OC(=O)C1C2CCC(C1Nc1nc(ncc1F)c1c[nH]c3c1cc(F)cn3)CC2,
pirodavir,Mixed,Kaggle,Mixed,CCOC(=O)C1=CC=C(C=C1)OCCC2CCN(CC2)C3=NN=C(C=C3)C,71345,,1,,,,,,CCOC(=O)c1ccc(cc1)OCCC1CCN(CC1)c1ccc(nn1)C,
pocapavir,Mixed,Kaggle,Mixed,COC1=CC(=C(C=C1)OCC2=CC=C(C=C2)COC3=C(C=CC=C3Cl)Cl)Cl,1455,,1,,,,,,COc1ccc(c(c1)Cl)OCc1ccc(cc1)COc1c(Cl)cccc1Cl,
presatovir,Mixed,Kaggle,Mixed,CC1=CN2C(=CC(=N2)C3CCCCN3C(=O)C4=C(C=CC(=C4)Cl)NS(=O)(=O)C)N=C1N5CCC(C5)N,58029842,,1,,,,,,NC1CCN(C1)c1nc2cc(nn2cc1C)C1CCCCN1C(=O)c1cc(Cl)ccc1NS(=O)(=O)C,
raltegravir,Mixed,Kaggle,Mixed,CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F,54671008,,1,,,,,,Fc1ccc(cc1)CNC(=O)c1nc(n(c(=O)c1O)C)C(NC(=O)c1nnc(o1)C)(C)C,
remdesivir,Mixed,Kaggle,Mixed,CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,121304016,,1,,,,,,CCC(COC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,
ritonavir,Mixed,Kaggle,Mixed,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,392622,,1,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,
rupintrivir,Mixed,Kaggle,Mixed,CCOC(=O)C=CC(CC1CCNC1=O)NC(=O)C(CC2=CC=C(C=C2)F)CC(=O)C(C(C)C)NC(=O)C3=NOC(=C3)C,6440352,,1,,,,,,CCOC(=O)C=CC(CC1CCNC1=O)NC(=O)C(Cc1ccc(cc1)F)CC(=O)C(C(C)C)NC(=O)c1noc(c1)C,
saquinavir,Mixed,Kaggle,Mixed,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,441243,,1,,,,,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,
simeprevir,Mixed,Kaggle,Mixed,CC1=C(C=CC2=C1N=C(C=C2OC3CC4C(C3)C(=O)N(CCCCC=CC5CC5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC,24873435,,1,,,,,,COc1ccc2c(c1C)nc(cc2OC1CC2C(C1)C(=O)N(C)CCCCC=CC1C(NC2=O)(C1)C(=O)NS(=O)(=O)C1CC1)c1scc(n1)C(C)C,
sofosbuvir,Mixed,Kaggle,Mixed,CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3,45375808,,1,,,,,,CC(OC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)(C)F)n1ccc(=O)[nH]c1=O)C)C,
telaprevir,Mixed,Kaggle,Mixed,CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5,3010818,,1,,,,,,CCCC(C(=O)C(=O)NC1CC1)NC(=O)C1C2CCCC2CN1C(=O)C(C(C)(C)C)NC(=O)C(C1CCCCC1)NC(=O)c1nccnc1,
tenofovir,Mixed,Kaggle,Mixed,CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,464205,,1,,,,,,CC(Cn1cnc2c1ncnc2N)OCP(=O)(O)O,
tipranavir,Mixed,Kaggle,Mixed,CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4,54682461,,1,,,,,,CCCC1(CCc2ccccc2)CC(=C(C(=O)O1)C(c1cccc(c1)NS(=O)(=O)c1ccc(cn1)C(F)(F)F)CC)O,
umifenovir,Mixed,Kaggle,Mixed,CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3,131411,,1,,,,,,CCOC(=O)c1c(CSc2ccccc2)n(c2c1c(CN(C)C)c(O)c(c2)Br)C,
valacyclovir,Mixed,Kaggle,Mixed,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,135398742,,1,,,,,,CC(C(C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O)N)C,
valganciclovir,Mixed,Kaggle,Mixed,CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N,135413535,,1,,,,,,OCC(OCn1cnc2c1nc(N)[nH]c2=O)COC(=O)C(C(C)C)N,
vapendavir,Mixed,Kaggle,Mixed,CCOC1=NOC2=C1C=CC(=C2)OCCC3CCN(CC3)C4=NN=C(C=C4)C,504457,,1,,,,,,CCOc1noc2c1ccc(c2)OCCC1CCN(CC1)c1ccc(nn1)C,
velpatasvir,Mixed,Kaggle,Mixed,CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC,67683363,,1,,,,,,COCC1CC(N(C1)C(=O)C(c1ccccc1)NC(=O)OC)c1ncc([nH]1)c1ccc2c(c1)COc1c2cc2ccc3c(c2c1)nc([nH]3)C1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C,
voxilaprevir,Mixed,Kaggle,Mixed,CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C,89921642,,1,,,,,,CCC1C2CN(C1C(=O)NC1(CC1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)C(NC(=O)OC1CC1CCCCC(c1c(O2)nc2cc(OC)ccc2n1)(F)F)C(C)(C)C,
zanamivir,Mixed,Kaggle,Mixed,CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N,60855,,1,,,,,,OCC(C(C1OC(=CC(C1NC(=O)C)N=C(N)N)C(=O)O)O)O,
zintevir,Mixed,Kaggle,Mixed,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=O)(O)OC4CC(OC4COP(=O)(O)OC5CC(OC5COP(=O)(O)OC6CC(OC6COP(=O)(O)OC7CC(OC7COP(=O)(O)OC8CC(OC8COP(=O)(O)OC9CC(OC9COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(OC1CC(OC1CO)N1C=NC2=C1N=C(NC2=O)N)S)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)O,16130283,,1,,,,,,OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=O)(OCC1OC(CC1OP(=S)(OCC1OC(CC1O)n1cc(C)c(=O)[nH]c1=O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1cc(C)c(=O)[nH]c1=O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1cc(C)c(=O)[nH]c1=O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1cc(C)c(=O)[nH]c1=O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1cc(C)c(=O)[nH]c1=O)S)n1cnc2c1nc(N)[nH]c2=O,
ziresovir,Mixed,Kaggle,Mixed,CC1=CC2=C(C=C1)N=C(N=C2NCC3(COC3)N)N4CCS(=O)(=O)C5=CC=CC=C5C4,71262247,,1,,,,,,Cc1ccc2c(c1)c(NCC1(N)COC1)nc(n2)N1CCS(=O)(=O)c2c(C1)cccc2,
prulifloxacin,SARS-COV-2,10.1101/2020.01.28.922922,Experimental,CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C,65947,viral main protease,1,,,,,,O=c1oc(c(o1)CN1CCN(CC1)c1cc2c(cc1F)c(=O)c(c1n2C(C)S1)C(=O)O)C,
tegobuvir,SARS-COV-2,10.1101/2020.01.28.922922,Experimental,C1=CC=C(C(=C1)C2=NC3=CN(C=CC3=N2)CC4=NN=C(C=C4)C5=C(C=C(C=C5)C(F)(F)F)C(F)(F)F)F,23649154,viral main protease,1,,,,,,Fc1ccccc1c1nc2c(n1)cn(cc2)Cc1ccc(nn1)c1ccc(cc1C(F)(F)F)C(F)(F)F,
bictegravir,SARS-COV-2,10.1101/2020.01.28.922922,Experimental,C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F,90311989,viral main protease,1,,,,,,Fc1cc(F)c(c(c1)F)CNC(=O)c1cn2CC3OC4CCC(N3C(=O)c2c(c1=O)O)C4,
nelfinavir,SARS-COV-2,10.1101/2020.01.28.922922,Experimental,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,64143,viral main protease,1,,,,,,OC(C(NC(=O)c1cccc(c1C)O)CSc1ccccc1)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C,
Lopinavir,SARS-COV-2,,Experimental,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,92727,3CLpro,1,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
ritonavir,SARS-COV-2,,Experimental,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,392622,3CLpro,1,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,
favipiravir,SARS-COV-2,,Experimental,C1=C(N=C(C(=O)N1)C(=O)N)F,492405,guanine analogues,1,,,,,,Fc1c[nH]c(=O)c(n1)C(=O)N,
ribavirin,SARS-COV-2,,Experimental,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,37542,guanine analogues,1,,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,
monophosphoramidate,SARS-COV-2,,Experimental,[Na+].Nc1ncnc2n(cnc12)[C@@H]3O[C@H](COP(N)([O-])=O)[C@@H](O)[C@H]3O,,guanine analogues,1,,,,,,O[C@@H]1[C@H](O)[C@H](O[C@H]1n1cnc2c1ncnc2N)COP(=O)(N)[O-].[Na+],
remdesivir,SARS-COV-2,,Experimental,CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,121304016,,1,,,,,,CCC(COC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,
ASC09 (TMC-310911),SARS-COV-2,,Experimental,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC5=C(C=C4)N=C(S5)NC6CCN(CC6)C7CCCC7,,,1,,,,,,CC(CN(S(=O)(=O)c1ccc2c(c1)sc(n2)NC1CCN(CC1)C1CCCC1)CC(C(Cc1ccccc1)NC(=O)OC1COC2C1CCO2)O)C,ChiCTR2000029603
arbidol,SARS-COV-2,,Experimental,CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3,131411,,1,,,,,,CCOC(=O)c1c(CSc2ccccc2)n(c2c1c(CN(C)C)c(O)c(c2)Br)C,
Chlorpromazine hydrochloride,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,6240,,1,,,,,,CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C.Cl,
ribavirin,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,37542,,1,,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,
mycophenolic acid,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O,446541,,1,,,,,,COc1c(CC=C(CCC(=O)O)C)c(O)c2c(c1C)COC2=O,
Disulfiram,SARS-COV-2,https://blogs.sciencemag.org/pipeline/archives/2020/03/27/known-drugs-against-the-coronovirus-runner-up-candidates,Experimental,CCN(CC)C(=S)SSC(=S)N(CC)CC,3117,,1,,,,,,CCN(C(=S)SSC(=S)N(CC)CC)CC,
Nitazoxonide,SARS-COV-2,https://blogs.sciencemag.org/pipeline/archives/2020/03/27/known-drugs-against-the-coronovirus-runner-up-candidates,Experimental,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,,,1,,,,,,CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+](=O)[O-],
Niclosamide,SARS-COV-2,https://blogs.sciencemag.org/pipeline/archives/2020/03/27/known-drugs-against-the-coronovirus-runner-up-candidates,Experimental,C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O,4477,,1,,,,,,Clc1ccc(c(c1)C(=O)Nc1ccc(cc1Cl)[N+](=O)[O-])O,
ciclesonide,SARS-COV-2,https://blogs.sciencemag.org/pipeline/archives/2020/03/27/known-drugs-against-the-coronovirus-runner-up-candidates,Experimental,CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6,6918155,,1,,,,,,O=C(C(C)C)OCC(=O)C12OC(OC1CC1C2(C)CC(O)C2C1CCC1=CC(=O)C=CC21C)C1CCCCC1,
quercetin,SARS-COV-2,https://blogs.sciencemag.org/pipeline/archives/2020/03/27/known-drugs-against-the-coronovirus-runner-up-candidates,Experimental,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,5280343,,1,,,,,,Oc1cc(O)c2c(c1)oc(c(c2=O)O)c1ccc(c(c1)O)O,
tetra-O-galloyl-D-glucose (TGG),SARS-COV-2,10.1128/JVI.78.20.11334–11339.2004,Experimental,C1=C(C=C(C(=C1O)O)O)C(=O)OCC2C(C(C(C(O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O,,,1,,,,,,OC1C(OC(C(C1OC(=O)c1cc(O)c(c(c1)O)O)OC(=O)c1cc(O)c(c(c1)O)O)COC(=O)c1cc(O)c(c(c1)O)O)OC(=O)c1cc(O)c(c(c1)O)O,might be wrong compound...
luteolin,SARS-COV-2,10.1128/JVI.78.20.11334–11339.2004,Experimental,C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O,5280445,,1,,,,,,Oc1cc(O)c2c(c1)oc(cc2=O)c1ccc(c(c1)O)O,
Scutellarein,SARS,10.7150/ijbs.45538,Experimental,C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O)O,5281697,,1,Inhibit nsP13 by affecting the ATPase activity,,,,,Oc1ccc(cc1)c1cc(=O)c2c(o1)cc(c(c2O)O)O,
Glycyrrhizin,SARS,10.7150/ijbs.45538,Experimental,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C,14982,,1,Inhibit nsP13 by affecting the ATPase activity,,,,,OC1C(OC2OC(C(=O)O)C(C(C2O)O)O)C(OC(C1O)C(=O)O)OC1CCC2(C(C1(C)C)CCC1(C2C(=O)C=C2C1(C)CCC1(C2CC(C)(CC1)C(=O)O)C)C)C,
Herbacetin,MERS,10.7150/ijbs.45538,Experimental,C1=CC(=CC=C1C2=C(C(=O)C3=C(O2)C(=C(C=C3O)O)O)O)O,5280544,,1,Inhibit cleavage activity of MERS-3CLpro enzyme,,,,,Oc1ccc(cc1)c1oc2c(O)c(O)cc(c2c(=O)c1O)O,
helichrysetin,MERS,10.7150/ijbs.45538,Experimental,COC1=CC(=CC(=C1C(=O)C=CC2=CC=C(C=C2)O)O)O,6253344,,1,Inhibit cleavage activity of MERS-3CLpro enzyme,,,,,COc1cc(O)cc(c1C(=O)C=Cc1ccc(cc1)O)O,
Tetrandrine,SARS,10.7150/ijbs.45538,Experimental,CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC,73078,,1,Inhibit the expression of HCoV- OC43 spike and nucleocapsid protein.,,,,,COc1c(OC)cc2c3c1Oc1cc4c(cc1OC)CCN(C4Cc1ccc(Oc4cc(CC3N(CC2)C)ccc4OC)cc1)C,
fangchinoline,SARS,10.7150/ijbs.45538,Experimental,CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CCN6C)OC)O)OC)OC,73481,,1,Inhibit the expression of HCoV- OC43 spike and nucleocapsid protein.,,,,,COc1cc2CCN(C3c2c(c1O)Oc1cc2c(cc1OC)CCN(C2Cc1ccc(Oc2cc(C3)ccc2OC)cc1)C)C,
cepharanthine,SARS,10.7150/ijbs.45538,Experimental,CN1CCC2=CC3=C(C4=C2C1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)CC7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3,10206,,1,Inhibit the expression of HCoV- OC43 spike and nucleocapsid protein.,,,,,COc1cc2CCN(C3c2cc1Oc1c2c(CCN(C2Cc2ccc(Oc4cc(C3)ccc4OC)cc2)C)cc2c1OCO2)C,
pectolinarin,SARS,10.7150/ijbs.45538,Experimental,CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(C(=C4C(=C3)OC(=CC4=O)C5=CC=C(C=C5)OC)O)OC)O)O)O)O)O)O,168849,,1,Inhibit SARS-3CLpro activity,,,,,COc1c(OC2OC(COC3OC(C)C(C(C3O)O)O)C(C(C2O)O)O)cc2c(c1O)c(=O)cc(o2)c1ccc(cc1)OC,
epigallocatechin gallate,SARS,10.7150/ijbs.45538,Experimental,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,65064,,1,Inhibit SARS-3CLpro activity,,,,,Oc1cc(O)c2c(c1)OC(C(C2)OC(=O)c1cc(O)c(c(c1)O)O)c1cc(O)c(c(c1)O)O,
gallocatechin gallate,SARS,10.7150/ijbs.45538,Experimental,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,199472,,1,Inhibit SARS-3CLpro activity,,,,,Oc1cc(O)c2c(c1)OC(C(C2)OC(=O)c1cc(O)c(c(c1)O)O)c1cc(O)c(c(c1)O)O,
Emodin,SARS,10.7150/ijbs.45538,Experimental,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O,3220,,1,Inhibit the 3a ion channel of coronavirus SARS‐CoV and HCoV‐OC43,,,,,Cc1cc(O)c2c(c1)C(=O)c1c(C2=O)c(O)cc(c1)O,
Baicalin,SARS,10.7150/ijbs.45538,Experimental,C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O,64982,,1,Inhibit Angiotensin-converting enzyme (ACE),,,,,OC(=O)C1OC(Oc2cc3oc(cc(=O)c3c(c2O)O)c2ccccc2)C(C(C1O)O)O,
Imatinib mesylate,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O,123596,,1,,,,,,CS(=O)(=O)O.CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1nccc(n1)c1cccnc1)C,
gemcitabine hydrochloride,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F.Cl,60749,,1,,,,,,OCC1OC(C(C1O)(F)F)n1ccc(nc1=O)N.Cl,
toremifene citrate,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,3005572,,1,,,,,,OC(=O)C(CC(=O)O)(CC(=O)O)O.ClCCC(=C(c1ccccc1)c1ccc(cc1)OCCN(C)C)c1ccccc1,
Triflupromazine hydrochloride,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F.Cl,66069,,1,,,,,,CN(CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F)C.Cl,
Dasatinib,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,3062316,,1,,,,,,OCCN1CCN(CC1)c1cc(nc(n1)C)Nc1ncc(s1)C(=O)Nc1c(C)cccc1Cl,
Dimethyl sulfoxide,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,CS(=O)C,679,,1,,,,,,CS(=O)C,
Toremifene citrate,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,3005572,,1,,,,,,OC(=O)C(CC(=O)O)(CC(=O)O)O.ClCCC(=C(c1ccccc1)c1ccc(cc1)OCCN(C)C)c1ccccc1,
chloroquine,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,2719,,1,,,,,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,
Lasinavir,SARS-COV-2,https://chemrxiv.org/articles/Screening_of_Clinically_Approved_and_Investigation_Drugs_as_Potential_Inhibitors_of_COVID-19_Main_Protease_A_Virtual_Drug_Repurposing_Study/12032712,Simulation,CC(C)C(C(=O)NCCOC)NC(=O)C(CC1=C(C(=C(C=C1)OC)OC)OC)CC(C(CC2=CC=CC=C2)NC(=O)OC(C)(C)C)O,464372,,0,,,,,,COCCNC(=O)C(C(C)C)NC(=O)C(Cc1ccc(c(c1OC)OC)OC)CC(C(Cc1ccccc1)NC(=O)OC(C)(C)C)O,HIV Protease inhibitor
Brecanavir,SARS-COV-2,https://chemrxiv.org/articles/Screening_of_Clinically_Approved_and_Investigation_Drugs_as_Potential_Inhibitors_of_COVID-19_Main_Protease_A_Virtual_Drug_Repurposing_Study/12032712,Simulation,CC1=NC(=CS1)COC2=CC=C(C=C2)CC(C(CN(CC(C)C)S(=O)(=O)C3=CC4=C(C=C3)OCO4)O)NC(=O)OC5COC6C5CCO6,5743186,,0,,,,,,CC(CN(S(=O)(=O)c1ccc2c(c1)OCO2)CC(C(Cc1ccc(cc1)OCc1csc(n1)C)NC(=O)OC1COC2C1CCO2)O)C,Aspartic protease inhibitor for the treatment of HIV
Telinavir,SARS-COV-2,https://chemrxiv.org/articles/Screening_of_Clinically_Approved_and_Investigation_Drugs_as_Potential_Inhibitors_of_COVID-19_Main_Protease_A_Virtual_Drug_Repurposing_Study/12032713,Simulation,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)C(CC(=O)N)NC(=O)C2=NC3=CC=CC=C3C=C2)O)C(=O)NC(C)(C)C,382974,,0,,,,,,CC(CN(C(=O)NC(C)(C)C)CC(C(NC(=O)C(NC(=O)c1ccc2c(n1)cccc2)CC(=O)N)Cc1ccccc1)O)C,HIV Protease inhibitor
Rotigaptide,SARS-COV-2,https://chemrxiv.org/articles/Screening_of_Clinically_Approved_and_Investigation_Drugs_as_Potential_Inhibitors_of_COVID-19_Main_Protease_A_Virtual_Drug_Repurposing_Study/12032714,Simulation,CC(C(=O)NCC(=O)N)NC(=O)CNC(=O)C1CC(CN1C(=O)C2CCCN2C(=O)C(CC3=CC=C(C=C3)O)NC(=O)C)O,9938933,,0,,,,,,OC1CC(N(C1)C(=O)C1CCCN1C(=O)C(Cc1ccc(cc1)O)NC(=O)C)C(=O)NCC(=O)NC(C(=O)NCC(=O)N)C,Rotigaptide (ZP-123) is a drug under clinical investigation for the treatment of cardiac arrhythmias – specifically atrial fibrillation.
Pimelautide,SARS-COV-2,https://chemrxiv.org/articles/Screening_of_Clinically_Approved_and_Investigation_Drugs_as_Potential_Inhibitors_of_COVID-19_Main_Protease_A_Virtual_Drug_Repurposing_Study/12032715,Simulation,CCCCCCCCCCCC(=O)NC(C)C(=O)NC(CCC(=O)NC(CCCC(C(=O)N)NC(=O)CN)C(=O)O)C(=O)O,70697634,,0,,,,,,CCCCCCCCCCCC(=O)NC(C(=O)NC(C(=O)O)CCC(=O)NC(C(=O)O)CCCC(C(=O)N)NC(=O)CN)C,Immunostimulant. Pimelautide Builtin Adjuvants Associated with an HIV- 1-Derived Peptide
"1,3-Bis-(2-ethoxycarbonylchromon-5-yloxy)-2-(lysyloxy)propane",SARS-COV-2,https://chemrxiv.org/articles/Screening_of_Clinically_Approved_and_Investigation_Drugs_as_Potential_Inhibitors_of_COVID-19_Main_Protease_A_Virtual_Drug_Repurposing_Study/12032716,Simulation,CCOC(=O)C1=CC(=O)C2=C(O1)C=CC=C2OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)OCC)OC(=O)C(CCCCN)N.Cl.Cl,196638,,0,,,,,,NCCCCC(C(=O)OC(COc1cccc2c1c(=O)cc(o2)C(=O)OCC)COc1cccc2c1c(=O)cc(o2)C(=O)OCC)N.Cl.Cl,Orally-active pro-drug of disodiumcromoglycate (DSCG). DSCG is a commonly used anti-asthmatic medicine
Ociltide,SARS-COV-2,https://chemrxiv.org/articles/Screening_of_Clinically_Approved_and_Investigation_Drugs_as_Potential_Inhibitors_of_COVID-19_Main_Protease_A_Virtual_Drug_Repurposing_Study/12032717,Simulation,C1CSC(=O)C1NC(=O)C(CC2=CC=CC=C2)NC(=O)CNC(=O)C(CCCCNC=O)NC(=O)C(CC3=CC=C(C=C3)O)N,76965368,,0,,,,,,O=CNCCCCC(C(=O)NCC(=O)NC(C(=O)NC1CCSC1=O)Cc1ccccc1)NC(=O)C(Cc1ccc(cc1)O)N,Gut motility stimulator
Arzoxifene,SARS-COV-2,https://chemrxiv.org/articles/Screening_of_Clinically_Approved_and_Investigation_Drugs_as_Potential_Inhibitors_of_COVID-19_Main_Protease_A_Virtual_Drug_Repurposing_Study/12032718,Simulation,COC1=CC=C(C=C1)C2=C(C3=C(S2)C=C(C=C3)O)OC4=CC=C(C=C4)OCCN5CCCCC5,179337,,0,,,,,,COc1ccc(cc1)c1sc2c(c1Oc1ccc(cc1)OCCN1CCCCC1)ccc(c2)O,"Arzoxifene is a selective estrogen receptor modulator (SERM) which antagonizes estrogen in mammary and uterine tissue, but acts as an estrogen receptor agonist in bone tissue. Arzoxifene reduces bone loss and risk of osteoperosis and decreases serum cholesterol."
Tertamyloxycarbonyltetragastrin,SARS-COV-2,https://chemrxiv.org/articles/Screening_of_Clinically_Approved_and_Investigation_Drugs_as_Potential_Inhibitors_of_COVID-19_Main_Protease_A_Virtual_Drug_Repurposing_Study/12032719,Simulation,CCC(C)(C)OC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)N,,,0,,,,,,,Gastric stimulant
Truxicurium,SARS-COV-2,https://chemrxiv.org/articles/Screening_of_Clinically_Approved_and_Investigation_Drugs_as_Potential_Inhibitors_of_COVID-19_Main_Protease_A_Virtual_Drug_Repurposing_Study/12032720,Simulation,CC[N+](C)(CC)CCCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCCC[N+](C)(CC)CC)C3=CC=CC=C3,20290,,0,,,,,,CC[N+](CCCOC(=O)C1C(c2ccccc2)C(C1c1ccccc1)C(=O)OCCC[N+](CC)(CC)C)(CC)C,Ganglionic blocking agent
Ivermectin,SARS-COV-2,10.1016/j.antiviral.2020.104787,Experimental,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,6321424,,0,antiparasitic,,,,,COC1CC(OC2C(C)C=CC=C3COC4C3(O)C(C=C(C4O)C)C(=O)OC3CC(CC=C2C)OC2(C3)CCC(C(O2)C(CC)C)C)OC(C1OC1CC(OC)C(C(O1)C)O)C,
Oseltamivir,SARS-COV-2,10.1101/2020.03.09.20033068v2,,CCOC(=O)C1=CC(C(C(C1)N)NC(=O)C)OC(CC)CC,65028,,0,,,,,,CCOC(=O)C1=CC(C(C(C1)N)NC(=O)C)OC(CC)CC,
Ribavirin,SARS-COV-2,10.1101/2020.03.09.20033068v2,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,37542,,0,,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,
Lopinavir,SARS-COV-2,10.1101/2020.03.09.20033068v2,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,92727,,0,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
Ritonavir,SARS-COV-2,10.1101/2020.03.09.20033068v2,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,392622,,0,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,
Ganciclovir,SARS-COV-2,10.1101/2020.03.09.20033068v2,,OCC(OCn1cnc2c1nc(N)[nH]c2=O)CO,135398740,,0,,,,,,OCC(OCn1cnc2c1nc(N)[nH]c2=O)CO,
Lopinavir/Ritonavir,SARS-COV-2,10.1101/2020.03.18.20038190v2,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C.O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,11979606,,0,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C.O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,
Chloroquine phosphate,SARS-COV-2,10.1101/2020.03.18.20038190v2,,OP(=O)(O)O.OP(=O)(O)O.CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,64927,,0,,,,,,OP(=O)(O)O.OP(=O)(O)O.CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,
Umifenovir,SARS-COV-2,10.1101/2020.03.18.20038190v2,,CCOC(=O)c1c(CSc2ccccc2)n(c2c1c(CN(C)C)c(O)c(c2)Br)C,131411,,0,,,,,,CCOC(=O)c1c(CSc2ccccc2)n(c2c1c(CN(C)C)c(O)c(c2)Br)C,
Hydroxychloroquine,SARS-COV-2,10.1101/2020.03.18.20038190v2,,OCCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,3652,,0,,,,,,OCCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,
Favipiravir,SARS-COV-2,10.1101/2020.03.18.20038190v2,,Fc1c[nH]c(=O)c(n1)C(=O)N,492405,,0,,,,,,Fc1c[nH]c(=O)c(n1)C(=O)N,
Methylprednisolone,SARS-COV-2,10.1101/2020.03.18.20038190v2,,OCC(=O)C1(O)CCC2C1(C)CC(O)C1C2CC(C2=CC(=O)C=CC12C)C,6741,,0,,,,,,OCC(=O)C1(O)CCC2C1(C)CC(O)C1C2CC(C2=CC(=O)C=CC12C)C,
Remdesivir,SARS-COV-2,10.1101/2020.03.18.20038190v2,,CCC(COC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,121304016,,0,,,,,,CCC(COC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,
Oseltamivir,SARS-COV-2,10.1101/2020.03.18.20038190v2,,CCOC(=O)C1=CC(C(C(C1)N)NC(=O)C)OC(CC)CC,65028,,0,,,,,,CCOC(=O)C1=CC(C(C(C1)N)NC(=O)C)OC(CC)CC,
Baloxavir Marboxil,SARS-COV-2,10.1101/2020.03.18.20038190v2,,COC(=O)OCOc1c(=O)ccn2c1C(=O)N1CCOCC1N2C1c2ccccc2SCc2c1ccc(c2F)F,124081896,,0,,,,,,COC(=O)OCOc1c(=O)ccn2c1C(=O)N1CCOCC1N2C1c2ccccc2SCc2c1ccc(c2F)F,
Thalidomide,SARS-COV-2,10.1101/2020.03.18.20038190v2,,O=C1CCC(C(=O)N1)N1C(=O)c2c(C1=O)cccc2,5426,,0,,,,,,O=C1CCC(C(=O)N1)N1C(=O)c2c(C1=O)cccc2,
Darunavir,SARS-COV-2,10.1101/2020.03.18.20038190v2,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1COC2C1CCO2)O)C,213039,,,,,,,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1COC2C1CCO2)O)C,
cobicistat,,,,O=C(NC(Cc1ccccc1)CCC(Cc1ccccc1)NC(=O)C(NC(=O)N(Cc1csc(n1)C(C)C)C)CCN1CCOCC1)OCc1cncs1,25151504,,,,,,,,O=C(NC(Cc1ccccc1)CCC(Cc1ccccc1)NC(=O)C(NC(=O)N(Cc1csc(n1)C(C)C)C)CCN1CCOCC1)OCc1cncs1,
Thymosin,SARS-COV-2,10.1101/2020.03.18.20038190v2,,NCCCCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)O)CCC(=O)O)C)CCC(=O)O)CCC(=O)O)C(C)C)C(C)C)CCC(=O)O)CCCCN)CCCCN)CCC(=O)O)CCCCN)CC(C)C)CC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(O)C)NC(=O)C(C(CC)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(CS)N)CO)CC(=O)O)C)C)CC(=O)O)CO)CO)CCC(=O)O,44286042,,,,,,,,NCCCCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)O)CCC(=O)O)C)CCC(=O)O)CCC(=O)O)C(C)C)C(C)C)CCC(=O)O)CCCCN)CCCCN)CCC(=O)O)CCCCN)CC(C)C)CC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(O)C)NC(=O)C(C(CC)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(CS)N)CO)CC(=O)O)C)C)CC(=O)O)CO)CO)CCC(=O)O,
hydroxychloroquine,SARS-COV-2,10.1101/2020.03.25.008482v1,,OCCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,3652,,,,,,,,OCCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,
chloroquine phosphate,SARS-COV-2,10.1101/2020.03.25.008482v1,,OP(=O)(O)O.OP(=O)(O)O.CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,64927,,,,,,,,OP(=O)(O)O.OP(=O)(O)O.CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,
Decitabine,SARS-COV-2,preprints202003.0239.v1,,OCC1OC(CC1O)n1cnc(nc1=O)N,451668,,,,,,,,OCC1OC(CC1O)n1cnc(nc1=O)N,Proposed inhibitor of RdRp
Omeprazole,SARS-COV-2,preprints202003.0239.v1,,COc1ccc2c(c1)[nH]c(n2)S(=O)Cc1ncc(c(c1C)OC)C,4594,,,,,,,,COc1ccc2c(c1)[nH]c(n2)S(=O)Cc1ncc(c(c1C)OC)C,Proposed inhibitor of PLpro
Icatibant,SARS-COV-2,preprints202003.0239.v1,,OCC(C(=O)N1Cc2ccccc2CC1C(=O)N1C2CCCCC2CC1C(=O)NC(C(=O)O)CCCN=C(N)N)NC(=O)C(Cc1cccs1)NC(=O)CNC(=O)C1CC(CN1C(=O)C1CCCN1C(=O)C(NC(=O)C(CCCN=C(N)N)N)CCCN=C(N)N)O,6918173,,,,,,,,OCC(C(=O)N1Cc2ccccc2CC1C(=O)N1C2CCCCC2CC1C(=O)NC(C(=O)O)CCCN=C(N)N)NC(=O)C(Cc1cccs1)NC(=O)CNC(=O)C1CC(CN1C(=O)C1CCCN1C(=O)C(NC(=O)C(CCCN=C(N)N)N)CCCN=C(N)N)O,Proposed inhibitor of 3CLpro
Atazanavir,SARS-COV-2,preprints202003.0239.v1,,COC(=O)NC(C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)CC(C(Cc1ccccc1)NC(=O)C(C(C)(C)C)NC(=O)OC)O,148192,,,,,,,,COC(=O)NC(C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)CC(C(Cc1ccccc1)NC(=O)C(C(C)(C)C)NC(=O)OC)O,Proposed inhibitor of 3CLpro
Ceftolozane,SARS-COV-2,preprints202003.0239.v1,,NCCNC(=O)Nc1c[n+](n(c1N)C)CC1=C(C(=O)[O-])N2C(SC1)C(C2=O)NC(=O)C(=NOC(C(=O)O)(C)C)c1nsc(n1)N,53234134,,,,,,,,NCCNC(=O)Nc1c[n+](n(c1N)C)CC1=C(C(=O)[O-])N2C(SC1)C(C2=O)NC(=O)C(=NOC(C(=O)O)(C)C)c1nsc(n1)N,Proposed inhibitor of AAK1
Hesperidin,SARS-COV-2,preprints202003.0239.v1,,COc1ccc(cc1O)C1CC(=O)c2c(O1)cc(cc2O)OC1OC(COC2OC(C)C(C(C2O)O)O)C(C(C1O)O)O,10621,,,,,,,,COc1ccc(cc1O)C1CC(=O)c2c(O1)cc(cc2O)OC1OC(COC2OC(C)C(C(C2O)O)O)C(C(C1O)O)O,Proposed inhibitor of AAK1
Carfilzomib,SARS-COV-2,preprints202003.0239.v1,,CC(CC(C(=O)NC(C(=O)NC(C(=O)C1(C)CO1)CC(C)C)Cc1ccccc1)NC(=O)C(NC(=O)CN1CCOCC1)CCc1ccccc1)C,11556711,,,,,,,,CC(CC(C(=O)NC(C(=O)NC(C(=O)C1(C)CO1)CC(C)C)Cc1ccccc1)NC(=O)C(NC(=O)CN1CCOCC1)CCc1ccccc1)C,Proposed inhibitor of AAK1
Oseltamivir,SARS-COV-2,10.1016/j.jaut.2020.102433,,CCOC(=O)C1=CC(C(C(C1)N)NC(=O)C)OC(CC)CC,65028,,,,,,,,CCOC(=O)C1=CC(C(C(C1)N)NC(=O)C)OC(CC)CC,Used to treat SARS-COV-2
Lopinavir,SARS-COV-2,10.1016/j.jaut.2020.102433,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,92727,,,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,Used to treat SARS-COV-2
Ritonavir,SARS-COV-2,10.1016/j.jaut.2020.102433,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,392622,,,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,Used to treat SARS-COV-2
Ganciclovir,SARS-COV-2,10.1016/j.jaut.2020.102433,,OCC(OCn1cnc2c1nc(N)[nH]c2=O)CO,135398740,,,,,,,,OCC(OCn1cnc2c1nc(N)[nH]c2=O)CO,Used to treat SARS-COV-2
Remdesivir,SARS-COV-2,10.1016/j.jaut.2020.102433,,CCC(COC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,121304016,,,,,,,,CCC(COC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,Highly effective conrolling in vitro; has safety track record
Chloroquine,SARS-COV-2,10.1016/j.jaut.2020.102433,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,2719,,,,,,,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,Highly effective conrolling in vitro; has safety track record
EIDD-2801,SARS-COV-2,10.1016/j.jaut.2020.102433,,ONc1ccn(c(=O)n1)C1OC(C(C1O)O)COC(=O)C(C)C,145996610,,,,,,,,ONc1ccn(c(=O)n1)C1OC(C(C1O)O)COC(=O)C(C)C,Effective treating influenza virus; should be considered to treat SARS-COV-2
Cepharanthine,SARS-COV-2,preprints202003.0024.v1,,COc1cc2CCN(C3c2cc1Oc1c2c(CCN(C2Cc2ccc(Oc4cc(C3)ccc4OC)cc2)C)cc2c1OCO2)C,10206,,,,,,,,COc1cc2CCN(C3c2cc1Oc1c2c(CCN(C2Cc2ccc(Oc4cc(C3)ccc4OC)cc2)C)cc2c1OCO2)C,Block protien NSP12-NSP7 and NSPAS-NSP8 interface
Tegobuvir,SARS-COV-2,preprints202003.0024.v1,,Fc1ccccc1c1nc2c(n1)cn(cc2)Cc1ccc(nn1)c1ccc(cc1C(F)(F)F)C(F)(F)F,23649154,,,,,,,,Fc1ccccc1c1nc2c(n1)cn(cc2)Cc1ccc(nn1)c1ccc(cc1C(F)(F)F)C(F)(F)F,Block protien NSP12-NSP7 and NSPAS-NSP8 interface
Saquinavir,SARS-COV-2,preprints202003.0024.v1,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,441243,,,,,,,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,Can bind to NSP12-NSP7 interface
Tipranavir,SARS-COV-2,preprints202003.0024.v1,,CCCC1(CCc2ccccc2)CC(=C(C(=O)O1)C(c1cccc(c1)NS(=O)(=O)c1ccc(cn1)C(F)(F)F)CC)O,54682461,,,,,,,,CCCC1(CCc2ccccc2)CC(=C(C(=O)O1)C(c1cccc(c1)NS(=O)(=O)c1ccc(cn1)C(F)(F)F)CC)O,Can bind to NSP12-NSP7 interface
Lonafarnib,SARS-COV-2,preprints202003.0024.v1,,Clc1cc(Br)c2c(c1)CCc1c(C2C2CCN(CC2)C(=O)CC2CCN(CC2)C(=O)N)ncc(c1)Br,148195,,,,,,,,Clc1cc(Br)c2c(c1)CCc1c(C2C2CCN(CC2)C(=O)CC2CCN(CC2)C(=O)N)ncc(c1)Br,Can bind to NSP12-NSP7 interface
Filibuvir,SARS-COV-2,preprints202003.0024.v1,,CCc1cc(CCC2(CC(=C(C(=O)O2)Cc2nn3c(n2)nc(cc3C)C)O)C2CCCC2)cc(n1)CC,54708673,,,,,,,,CCc1cc(CCC2(CC(=C(C(=O)O2)Cc2nn3c(n2)nc(cc3C)C)O)C2CCCC2)cc(n1)CC,Can bind to NSP12-NSP7 interface
Olysio,SARS-COV-2,preprints202003.0024.v1,,COc1ccc2c(c1C)nc(cc2OC1CC2C(C1)C(=O)N(C)CCCCC=CC1C(NC2=O)(C1)C(=O)NS(=O)(=O)C1CC1)c1scc(n1)C(C)C,24873435,,,,,,,,COc1ccc2c(c1C)nc(cc2OC1CC2C(C1)C(=O)N(C)CCCCC=CC1C(NC2=O)(C1)C(=O)NS(=O)(=O)C1CC1)c1scc(n1)C(C)C,Can bind to NSP12-NSP7 interface
Beclabuvir,SARS-COV-2,preprints202002.0418.v2,,COc1ccc2c(c1)C1CC1(Cn1c2c(C2CCCCC2)c2c1cc(cc2)C(=O)NS(=O)(=O)N(C)C)C(=O)N1C2CCC1CN(C2)C,49773361,,,,,,,,COc1ccc2c(c1)C1CC1(Cn1c2c(C2CCCCC2)c2c1cc(cc2)C(=O)NS(=O)(=O)N(C)C)C(=O)N1C2CCC1CN(C2)C,Best drug with binding energy for COVID-19 therapy
Saquinavir,SARS-COV-2,preprints202002.0418.v2,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,441243,,,,,,,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,Best drug with binding energy for COVID-19 therapy
Methylprednisolone,SARS-COV-2,preprints202002.0418.v2,,OCC(=O)C1(O)CCC2C1(C)CC(O)C1C2CC(C2=CC(=O)C=CC12C)C,6741,,,,,,,,OCC(=O)C1(O)CCC2C1(C)CC(O)C1C2CC(C2=CC(=O)C=CC12C)C,Successfully used together with Thalidomid in one case of COVID-19
Thalidomid,SARS-COV-2,preprints202002.0418.v2,,,,,,,,,,,,Successfully used together with Methylprednisolone in one case of COVID-19
Nilotinib,SARS-COV-2,preprints202002.0418.v2,,Cc1ncn(c1)c1cc(NC(=O)c2ccc(c(c2)Nc2nccc(n2)c2cccnc2)C)cc(c1)C(F)(F)F,644241,,,,,,,,Cc1ncn(c1)c1cc(NC(=O)c2ccc(c(c2)Nc2nccc(n2)c2cccnc2)C)cc(c1)C(F)(F)F,"Potential drug for COVID-19 therapy, high scoring binding energy"
Tadalafil,SARS-COV-2,preprints202002.0418.v2,,O=C1N(C)CC(=O)N2C1Cc1c(C2c2ccc3c(c2)OCO3)[nH]c2c1cccc2,110635,,,,,,,,O=C1N(C)CC(=O)N2C1Cc1c(C2c2ccc3c(c2)OCO3)[nH]c2c1cccc2,"Potential drug for COVID-19 therapy, high scoring binding energy"
Lifitegrast,SARS-COV-2,preprints202002.0418.v2,,OC(=O)C(NC(=O)c1c(Cl)cc2c(c1Cl)CCN(C2)C(=O)c1ccc2c(c1)occ2)Cc1cccc(c1)S(=O)(=O)C,11965427,,,,,,,,OC(=O)C(NC(=O)c1c(Cl)cc2c(c1Cl)CCN(C2)C(=O)c1ccc2c(c1)occ2)Cc1cccc(c1)S(=O)(=O)C,"Potential drug for COVID-19 therapy, high scoring binding energy"
Digitoxin,SARS-COV-2,preprints202002.0418.v2,,O=C1OCC(=C1)C1CCC2(C1(C)CCC1C2CCC2C1(C)CCC(C2)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)O)O,441207,,,,,,,,O=C1OCC(=C1)C1CCC2(C1(C)CCC1C2CCC2C1(C)CCC(C2)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)O)O,"Potential drug for COVID-19 therapy, high scoring binding energy"
Tirilazad,SARS-COV-2,preprints202002.0418.v2,,O=C1C=CC2(C(=C1)CCC1C2=CCC2(C1CC(C2C(=O)CN1CCN(CC1)c1cc(nc(n1)N1CCCC1)N1CCCC1)C)C)C,104903,,,,,,,,O=C1C=CC2(C(=C1)CCC1C2=CCC2(C1CC(C2C(=O)CN1CCN(CC1)c1cc(nc(n1)N1CCCC1)N1CCCC1)C)C)C,"Potential drug for COVID-19 therapy, high scoring binding energy"
Danoprevir/Ganovo,SARS-COV-2,10.1101/2020.03.22.20034041,,,,,,,,,,,,
Ritonavir,SARS-COV-2,10.1101/2020.03.22.20034041,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,392622,,,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,
Catechin Gallate,SARS,10.2147/IJN.S31379,,Oc1cc(O)c2c(c1)OC(C(C2)OC(=O)c1cc(O)c(c(c1)O)O)c1ccc(c(c1)O)O,6419835,,,,,,,,Oc1cc(O)c2c(c1)OC(C(C2)OC(=O)c1cc(O)c(c(c1)O)O)c1ccc(c(c1)O)O,Inhibitor screning for SARS-CoV N protein
Gallocatechin Gallate,SARS,10.2147/IJN.S31379,,Oc1cc(O)c2c(c1)OC(C(C2)OC(=O)c1cc(O)c(c(c1)O)O)c1cc(O)c(c(c1)O)O,199472,,,,,,,,Oc1cc(O)c2c(c1)OC(C(C2)OC(=O)c1cc(O)c(c(c1)O)O)c1cc(O)c(c(c1)O)O,Inhibitor screning for SARS-CoV N protein
Lopinavir,SARS/MERS,1-s2.0-S0166354213002234,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,92727,,,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,Antiviral treatment
Ritonavir,SARS/MERS,1-s2.0-S0166354213002234,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,392622,,,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,Antiviral treatment
Peptidic Ketomide,SARS/MERS,1-s2.0-S0166354213002234,,,,,,,,,,,,Antiviral treatment
,SARS/MERS,1-s2.0-S0166354213003355,,,,,,,,,,,,
,SARS-CoV-2,2020.03.03.972133v1,,,,,,,,,,,,ADQN-FBDD is a deep RL method for structure-based drug discoveries in a timely manner. Molecular fragment-based growing.
Losartan,SARS-CoV-2,ddr.21656,,CCCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)CO)Cl,3961,,,,,,,,CCCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)CO)Cl,Therapudic for reducing aggressiveness and mortality of SARS-CoV-2
Telmisartan,SARS-CoV-2,ddr.21656,,CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2,65999,,,,,,,,CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2,Therapudic for reducing aggressiveness and mortality of SARS-CoV-2
Chloroquine,SARS-CoV-2,ddr.21656,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,2719,,,,,,,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,Antivirals
Favipiravir,SARS-CoV-2,ddr.21656,,Fc1c[nH]c(=O)c(n1)C(=O)N,492405,,,,,,,,Fc1c[nH]c(=O)c(n1)C(=O)N,Antivirals
Remdesivir,SARS-CoV-2,ddr.21656,,CCC(COC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,121304016,,,,,,,,CCC(COC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,Antivirals
Kaletra,SARS-COV-2,COVID-19_paper-final_01-03-20_CHA,,,,,,,,,,,,Combination of Lopinavir and Ritonavir. Used in China/South Korea against COVID-19 and showed viral load decreased. Able to be quickly produced and distributed.
Atazanavir,SARS-COV-2,COVID-19_paper-final_01-03-20_CHA,,COC(=O)NC(C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)CC(C(Cc1ccccc1)NC(=O)C(C(C)(C)C)NC(=O)OC)O,148192,,,,,,,,COC(=O)NC(C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)CC(C(Cc1ccccc1)NC(=O)C(C(C)(C)C)NC(=O)OC)O,Less commonly used. Good docking results.
Carfilzomib,SARS-COV-2,COVID-19_paper-final_01-03-20_CHA,,CC(CC(C(=O)NC(C(=O)NC(C(=O)C1(C)CO1)CC(C)C)Cc1ccccc1)NC(=O)C(NC(=O)CN1CCOCC1)CCc1ccccc1)C,11556711,,,,,,,,CC(CC(C(=O)NC(C(=O)NC(C(=O)C1(C)CO1)CC(C)C)Cc1ccccc1)NC(=O)C(NC(=O)CN1CCOCC1)CCc1ccccc1)C,Comparable to Ritonavir; possible durg to use against SARS-COV-2
Cobicistat,SARS-COV-2,COVID-19_paper-final_01-03-20_CHA,,O=C(NC(Cc1ccccc1)CCC(Cc1ccccc1)NC(=O)C(NC(=O)N(Cc1csc(n1)C(C)C)C)CCN1CCOCC1)OCc1cncs1,25151504,,,,,,,,O=C(NC(Cc1ccccc1)CCC(Cc1ccccc1)NC(=O)C(NC(=O)N(Cc1csc(n1)C(C)C)C)CCN1CCOCC1)OCc1cncs1,Comparable to Ritonavir; possible durg to use against SARS-COV-2
Ombitasvir,SARS-COV-2,COVID-19_paper-final_01-03-20_CHA,,COC(=O)NC(C(=O)N1CCCC1C(=O)Nc1ccc(cc1)C1CCC(N1c1ccc(cc1)C(C)(C)C)c1ccc(cc1)NC(=O)C1CCCN1C(=O)C(C(C)C)NC(=O)OC)C(C)C,54767916,,,,,,,,COC(=O)NC(C(=O)N1CCCC1C(=O)Nc1ccc(cc1)C1CCC(N1c1ccc(cc1)C(C)(C)C)c1ccc(cc1)NC(=O)C1CCCN1C(=O)C(C(C)C)NC(=O)OC)C(C)C,Comparable to Ritonavir; possible durg to use against SARS-COV-2
Kaletra,SARS,10.1007+s10156-003-0296-9,,,,,,,,,,,,Used in combination with Ribavirin in Hong Kong and might reduce intubation and mortality rates.
Ribavirin,SARS,10.1007+s10156-003-0296-9,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,37542,,,,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,Used in combination with Kaletra in Hong Kong and might reduce intubation and mortality rates.
Glycyrrhizin,SARS,10.1007+s10156-003-0296-9,,OC1C(OC2OC(C(=O)O)C(C(C2O)O)O)C(OC(C1O)C(=O)O)OC1CCC2(C(C1(C)C)CCC1(C2C(=O)C=C2C1(C)CCC1(C2CC(C)(CC1)C(=O)O)C)C)C,14982,,,,,,,,OC1C(OC2OC(C(=O)O)C(C(C2O)O)O)C(OC(C1O)C(=O)O)OC1CCC2(C(C1(C)C)CCC1(C2C(=O)C=C2C1(C)CCC1(C2CC(C)(CC1)C(=O)O)C)C)C,Active agent against SARS-CoV
Chlorpromazine,MERS,1-s2.0-S235277141630074X,,CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C,2726,,,,,,,,CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C,Interrupts assembly clathrin-coated pits at plasma membrane. Used early; short window of therapeutic window.
Chloroquine,MERS,1-s2.0-S235277141630074X,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,2719,,,,,,,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,Plays role in endosomal acidification. Used early; short window of therapeutic window.
Beclabuvir,SARS-COV-2,preprints202002.0418.v2,,COc1ccc2c(c1)C1CC1(Cn1c2c(C2CCCCC2)c2c1cc(cc2)C(=O)NS(=O)(=O)N(C)C)C(=O)N1C2CCC1CN(C2)C,49773361,,,,,,,,COc1ccc2c(c1)C1CC1(Cn1c2c(C2CCCCC2)c2c1cc(cc2)C(=O)NS(=O)(=O)N(C)C)C(=O)N1C2CCC1CN(C2)C,Best drug with binding energy for COVID-19 therapy
Saquinavir,SARS-COV-2,preprints202002.0418.v2,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,441243,,,,,,,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,Best drug with binding energy for COVID-19 therapy
Methylprednisolone,SARS-COV-2,preprints202002.0418.v2,,OCC(=O)C1(O)CCC2C1(C)CC(O)C1C2CC(C2=CC(=O)C=CC12C)C,6741,,,,,,,,OCC(=O)C1(O)CCC2C1(C)CC(O)C1C2CC(C2=CC(=O)C=CC12C)C,Successfully used together with Thalidomid in one case of COVID-19
Thalidomid,SARS-COV-2,preprints202002.0418.v2,,,,,,,,,,,,Successfully used together with Methylprednisolone in one case of COVID-19
Nilotinib,SARS-COV-2,preprints202002.0418.v2,,Cc1ncn(c1)c1cc(NC(=O)c2ccc(c(c2)Nc2nccc(n2)c2cccnc2)C)cc(c1)C(F)(F)F,644241,,,,,,,,Cc1ncn(c1)c1cc(NC(=O)c2ccc(c(c2)Nc2nccc(n2)c2cccnc2)C)cc(c1)C(F)(F)F,"Potential drug for COVID-19 therapy, high scoring binding energy"
Tadalafil,SARS-COV-2,preprints202002.0418.v2,,O=C1N(C)CC(=O)N2C1Cc1c(C2c2ccc3c(c2)OCO3)[nH]c2c1cccc2,110635,,,,,,,,O=C1N(C)CC(=O)N2C1Cc1c(C2c2ccc3c(c2)OCO3)[nH]c2c1cccc2,"Potential drug for COVID-19 therapy, high scoring binding energy"
Lifitegrast,SARS-COV-2,preprints202002.0418.v2,,OC(=O)C(NC(=O)c1c(Cl)cc2c(c1Cl)CCN(C2)C(=O)c1ccc2c(c1)occ2)Cc1cccc(c1)S(=O)(=O)C,11965427,,,,,,,,OC(=O)C(NC(=O)c1c(Cl)cc2c(c1Cl)CCN(C2)C(=O)c1ccc2c(c1)occ2)Cc1cccc(c1)S(=O)(=O)C,"Potential drug for COVID-19 therapy, high scoring binding energy"
Digitoxin,SARS-COV-2,preprints202002.0418.v2,,O=C1OCC(=C1)C1CCC2(C1(C)CCC1C2CCC2C1(C)CCC(C2)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)O)O,441207,,,,,,,,O=C1OCC(=C1)C1CCC2(C1(C)CCC1C2CCC2C1(C)CCC(C2)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)O)O,"Potential drug for COVID-19 therapy, high scoring binding energy"
Tirilazad,SARS-COV-2,preprints202002.0418.v2,,O=C1C=CC2(C(=C1)CCC1C2=CCC2(C1CC(C2C(=O)CN1CCN(CC1)c1cc(nc(n1)N1CCCC1)N1CCCC1)C)C)C,104903,,,,,,,,O=C1C=CC2(C(=C1)CCC1C2=CCC2(C1CC(C2C(=O)CN1CCN(CC1)c1cc(nc(n1)N1CCCC1)N1CCCC1)C)C)C,"Potential drug for COVID-19 therapy, high scoring binding energy"
Cepharanthine,SARS-COV-2,preprints202003.0024.v1,,COc1cc2CCN(C3c2cc1Oc1c2c(CCN(C2Cc2ccc(Oc4cc(C3)ccc4OC)cc2)C)cc2c1OCO2)C,10206,,,,,,,,COc1cc2CCN(C3c2cc1Oc1c2c(CCN(C2Cc2ccc(Oc4cc(C3)ccc4OC)cc2)C)cc2c1OCO2)C,Block protien NSP12-NSP7 and NSPAS-NSP8 interface
Tegobuvir,SARS-COV-2,preprints202003.0024.v1,,Fc1ccccc1c1nc2c(n1)cn(cc2)Cc1ccc(nn1)c1ccc(cc1C(F)(F)F)C(F)(F)F,23649154,,,,,,,,Fc1ccccc1c1nc2c(n1)cn(cc2)Cc1ccc(nn1)c1ccc(cc1C(F)(F)F)C(F)(F)F,Block protien NSP12-NSP7 and NSPAS-NSP8 interface
Saquinavir,SARS-COV-2,preprints202003.0024.v1,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,441243,,,,,,,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,Can bind to NSP12-NSP7 interface
Tipranavir,SARS-COV-2,preprints202003.0024.v1,,CCCC1(CCc2ccccc2)CC(=C(C(=O)O1)C(c1cccc(c1)NS(=O)(=O)c1ccc(cn1)C(F)(F)F)CC)O,54682461,,,,,,,,CCCC1(CCc2ccccc2)CC(=C(C(=O)O1)C(c1cccc(c1)NS(=O)(=O)c1ccc(cn1)C(F)(F)F)CC)O,Can bind to NSP12-NSP7 interface
Lonafarnib,SARS-COV-2,preprints202003.0024.v1,,Clc1cc(Br)c2c(c1)CCc1c(C2C2CCN(CC2)C(=O)CC2CCN(CC2)C(=O)N)ncc(c1)Br,148195,,,,,,,,Clc1cc(Br)c2c(c1)CCc1c(C2C2CCN(CC2)C(=O)CC2CCN(CC2)C(=O)N)ncc(c1)Br,Can bind to NSP12-NSP7 interface
Filibuvir,SARS-COV-2,preprints202003.0024.v1,,CCc1cc(CCC2(CC(=C(C(=O)O2)Cc2nn3c(n2)nc(cc3C)C)O)C2CCCC2)cc(n1)CC,54708673,,,,,,,,CCc1cc(CCC2(CC(=C(C(=O)O2)Cc2nn3c(n2)nc(cc3C)C)O)C2CCCC2)cc(n1)CC,Can bind to NSP12-NSP7 interface
Olysio,SARS-COV-2,preprints202003.0024.v1,,COc1ccc2c(c1C)nc(cc2OC1CC2C(C1)C(=O)N(C)CCCCC=CC1C(NC2=O)(C1)C(=O)NS(=O)(=O)C1CC1)c1scc(n1)C(C)C,24873435,,,,,,,,COc1ccc2c(c1C)nc(cc2OC1CC2C(C1)C(=O)N(C)CCCCC=CC1C(NC2=O)(C1)C(=O)NS(=O)(=O)C1CC1)c1scc(n1)C(C)C,Can bind to NSP12-NSP7 interface
interferon,MERS-CoV/SARS-CoV,10.1128/AAC.03036-14,Experimental,,,,,,,,,,,
Decitabine,SARS-COV-2,preprints202003.0239.v1,,OCC1OC(CC1O)n1cnc(nc1=O)N,451668,,,,,,,,OCC1OC(CC1O)n1cnc(nc1=O)N,Proposed inhibitor of RdRp
Omeprazole,SARS-COV-2,preprints202003.0239.v1,,COc1ccc2c(c1)[nH]c(n2)S(=O)Cc1ncc(c(c1C)OC)C,4594,,,,,,,,COc1ccc2c(c1)[nH]c(n2)S(=O)Cc1ncc(c(c1C)OC)C,Proposed inhibitor of PLpro
Icatibant,SARS-COV-2,preprints202003.0239.v1,,OCC(C(=O)N1Cc2ccccc2CC1C(=O)N1C2CCCCC2CC1C(=O)NC(C(=O)O)CCCN=C(N)N)NC(=O)C(Cc1cccs1)NC(=O)CNC(=O)C1CC(CN1C(=O)C1CCCN1C(=O)C(NC(=O)C(CCCN=C(N)N)N)CCCN=C(N)N)O,6918173,,,,,,,,OCC(C(=O)N1Cc2ccccc2CC1C(=O)N1C2CCCCC2CC1C(=O)NC(C(=O)O)CCCN=C(N)N)NC(=O)C(Cc1cccs1)NC(=O)CNC(=O)C1CC(CN1C(=O)C1CCCN1C(=O)C(NC(=O)C(CCCN=C(N)N)N)CCCN=C(N)N)O,Proposed inhibitor of 3CLpro
Atazanavir,SARS-COV-2,preprints202003.0239.v1,,COC(=O)NC(C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)CC(C(Cc1ccccc1)NC(=O)C(C(C)(C)C)NC(=O)OC)O,148192,,,,,,,,COC(=O)NC(C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)CC(C(Cc1ccccc1)NC(=O)C(C(C)(C)C)NC(=O)OC)O,Proposed inhibitor of 3CLpro
Ceftolozane,SARS-COV-2,preprints202003.0239.v1,,NCCNC(=O)Nc1c[n+](n(c1N)C)CC1=C(C(=O)[O-])N2C(SC1)C(C2=O)NC(=O)C(=NOC(C(=O)O)(C)C)c1nsc(n1)N,53234134,,,,,,,,NCCNC(=O)Nc1c[n+](n(c1N)C)CC1=C(C(=O)[O-])N2C(SC1)C(C2=O)NC(=O)C(=NOC(C(=O)O)(C)C)c1nsc(n1)N,Proposed inhibitor of AAK1
Hesperidin,SARS-COV-2,preprints202003.0239.v1,,COc1ccc(cc1O)C1CC(=O)c2c(O1)cc(cc2O)OC1OC(COC2OC(C)C(C(C2O)O)O)C(C(C1O)O)O,10621,,,,,,,,COc1ccc(cc1O)C1CC(=O)c2c(O1)cc(cc2O)OC1OC(COC2OC(C)C(C(C2O)O)O)C(C(C1O)O)O,Proposed inhibitor of AAK1
Carfilzomib,SARS-COV-2,preprints202003.0239.v1,,CC(CC(C(=O)NC(C(=O)NC(C(=O)C1(C)CO1)CC(C)C)Cc1ccccc1)NC(=O)C(NC(=O)CN1CCOCC1)CCc1ccccc1)C,11556711,,,,,,,,CC(CC(C(=O)NC(C(=O)NC(C(=O)C1(C)CO1)CC(C)C)Cc1ccccc1)NC(=O)C(NC(=O)CN1CCOCC1)CCc1ccccc1)C,Proposed inhibitor of AAK1
,MERS,10.1016+j.jfma.2013.11.006,,,,,,,,,,,,Identified MERS-CoV binds to DPP4 and structure of MERS-CoV RBD
Ribavirin,SARS,10.3201/eid1004.030458,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,37542,,,,,,,,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,Completely inhibits CPE
Kaletra,MERS,10.1093+infdis+jiv392,,,,,,,,,,,,Treated animals had lowest mean viral loads in lung and extrapulmonary tissues
Lopinavir,MERS,10.1038/nrd.2015.37,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,92727,,,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,Protective effects against MERS
Ritonavir,MERS,10.1038/nrd.2015.37,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,392622,,,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,Protective effects against MERS
Abemaciclib,SARS-COV-2,10.1101/2020.03.20.999730,,CCN1CCN(CC1)Cc1ccc(nc1)Nc1ncc(c(n1)c1cc(F)c2c(c1)n(C(C)C)c(n2)C)F,46220502,,,,,,,,CCN1CCN(CC1)Cc1ccc(nc1)Nc1ncc(c(n1)c1cc(F)c2c(c1)n(C(C)C)c(n2)C)F,
Amodiaquine dihydrocholoride,SARS-COV-2,10.1101/2020.03.20.999730,,,,,,,,,,,,Used to treat SARS-COV-2
Anidulafungin,SARS-COV-2,10.1101/2020.03.20.999730,,CCCCCOc1ccc(cc1)c1ccc(cc1)c1ccc(cc1)C(=O)NC1CC(O)C(O)NC(=O)C2C(O)C(CN2C(=O)C(NC(=O)C(NC(=O)C2N(C(=O)C(NC1=O)C(O)C)CC(C2)O)C(C(c1ccc(cc1)O)O)O)C(O)C)C,166548,,,,,,,,CCCCCOc1ccc(cc1)c1ccc(cc1)c1ccc(cc1)C(=O)NC1CC(O)C(O)NC(=O)C2C(O)C(CN2C(=O)C(NC(=O)C(NC(=O)C2N(C(=O)C(NC1=O)C(O)C)CC(C2)O)C(C(c1ccc(cc1)O)O)O)C(O)C)C,Used to treat SARS-COV-2
Bazedoxifene,SARS-COV-2,10.1101/2020.03.20.999730,,Oc1ccc2c(c1)c(C)c(n2Cc1ccc(cc1)OCCN1CCCCCC1)c1ccc(cc1)O,154257,,,,,,,,Oc1ccc2c(c1)c(C)c(n2Cc1ccc(cc1)OCCN1CCCCCC1)c1ccc(cc1)O,Used to treat SARS-COV-2
Berbamine hydrochloride,SARS-COV-2,10.1101/2020.03.20.999730,,COc1c(OC)cc2c3c1Oc1cc4c(cc1OC)CCN(C4Cc1ccc(Oc4cc(CC3N(CC2)C)ccc4O)cc1)C.Cl,56845155,,,,,,,,COc1c(OC)cc2c3c1Oc1cc4c(cc1OC)CCN(C4Cc1ccc(Oc4cc(CC3N(CC2)C)ccc4O)cc1)C.Cl,Used to treat SARS-COV-2
Camostat,SARS-COV-2,10.1101/2020.03.20.999730,,CN(C(=O)COC(=O)Cc1ccc(cc1)OC(=O)c1ccc(cc1)N=C(N)N)C,2536,,,,,,,,CN(C(=O)COC(=O)Cc1ccc(cc1)OC(=O)c1ccc(cc1)N=C(N)N)C,Highly effective conrolling in vitro; has safety track record
Cepharanthine,SARS-COV-2,10.1101/2020.03.20.999730,,COc1cc2CCN(C3c2cc1Oc1c2c(CCN(C2Cc2ccc(Oc4cc(C3)ccc4OC)cc2)C)cc2c1OCO2)C,10206,,,,,,,,COc1cc2CCN(C3c2cc1Oc1c2c(CCN(C2Cc2ccc(Oc4cc(C3)ccc4OC)cc2)C)cc2c1OCO2)C,Highly effective conrolling in vitro; has safety track record
Chloroquine diphosphate,SARS-COV-2,10.1101/2020.03.20.999730,,OP(=O)(O)O.OP(=O)(O)O.CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,64927,,,,,,,,OP(=O)(O)O.OP(=O)(O)O.CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,Effective treating influenza virus; should be considered to treat SARS-COV-2
Ciclesonide,SARS-COV-2,10.1101/2020.03.20.999730,,O=C(C(C)C)OCC(=O)C12OC(OC1CC1C2(C)CC(O)C2C1CCC1=CC(=O)C=CC21C)C1CCCCC1,6918155,,,,,,,,O=C(C(C)C)OCC(=O)C12OC(OC1CC1C2(C)CC(O)C2C1CCC1=CC(=O)C=CC21C)C1CCCCC1,
Clomiphene citrate,SARS-COV-2,10.1101/2020.03.20.999730,,OC(=O)C(CC(=O)O)(CC(=O)O)O.CCN(CCOc1ccc(cc1)C(=C(c1ccccc1)Cl)c1ccccc1)CC,3033832,,,,,,,,OC(=O)C(CC(=O)O)(CC(=O)O)O.CCN(CCOc1ccc(cc1)C(=C(c1ccccc1)Cl)c1ccccc1)CC,
Cyclosporine,SARS-COV-2,10.1101/2020.03.20.999730,,CC=CCC(C(C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)O)C,5284373,,,,,,,,CC=CCC(C(C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)O)C,
Digitoxin,SARS-COV-2,10.1101/2020.03.20.999730,,O=C1OCC(=C1)C1CCC2(C1(C)CCC1C2CCC2C1(C)CCC(C2)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)O)O,441207,,,,,,,,O=C1OCC(=C1)C1CCC2(C1(C)CCC1C2CCC2C1(C)CCC(C2)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)O)O,
Digoxin,SARS-COV-2,10.1101/2020.03.20.999730,,O=C1OCC(=C1)C1CCC2(C1(C)C(O)CC1C2CCC2C1(C)CCC(C2)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)O)O,2724385,,,,,,,,O=C1OCC(=C1)C1CCC2(C1(C)C(O)CC1C2CCC2C1(C)CCC(C2)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)O)O,
Dihydrogambogic acid,SARS-COV-2,10.1101/2020.03.20.999730,,CC(=CCc1c2OC34C5(CC=C(C(=O)O)C)OC(C4CC(C5O)C=C3C(=O)c2c(c2c1OC(C)(CCC=C(C)C)C=C2)O)(C)C)C,6857793,,,,,,,,CC(=CCc1c2OC34C5(CC=C(C(=O)O)C)OC(C4CC(C5O)C=C3C(=O)c2c(c2c1OC(C)(CCC=C(C)C)C=C2)O)(C)C)C,
Droloxifene,SARS-COV-2,10.1101/2020.03.20.999730,,CCC(=C(c1cccc(c1)O)c1ccc(cc1)OCCN(C)C)c1ccccc1,3033767,,,,,,,,CCC(=C(c1cccc(c1)O)c1ccc(cc1)OCCN(C)C)c1ccccc1,
Dronedarone HCl,SARS-COV-2,10.1101/2020.03.20.999730,,CCCCc1oc2c(c1C(=O)c1ccc(cc1)OCCCN(CCCC)CCCC)cc(cc2)NS(=O)(=O)C.Cl,219025,,,,,,,,CCCCc1oc2c(c1C(=O)c1ccc(cc1)OCCCN(CCCC)CCCC)cc(cc2)NS(=O)(=O)C.Cl,
Ebastine,SARS-COV-2,10.1101/2020.03.20.999730,,O=C(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,3191,,,,,,,,O=C(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,
Eltrombopag,SARS-COV-2,10.1101/2020.03.20.999730,,OC(=O)c1cccc(c1)c1cccc(c1O)N=Nc1c(C)[nH]n(c1=O)c1ccc(c(c1)C)C,135449332,,,,,,,,OC(=O)c1cccc(c1)c1cccc(c1O)N=Nc1c(C)[nH]n(c1=O)c1ccc(c(c1)C)C,
Gilteritinib,SARS-COV-2,10.1101/2020.03.20.999730,,COc1cc(ccc1N1CCC(CC1)N1CCN(CC1)C)Nc1nc(NC2CCOCC2)c(nc1C(=O)N)CC,49803313,,,,,,,,COc1cc(ccc1N1CCC(CC1)N1CCN(CC1)C)Nc1nc(NC2CCOCC2)c(nc1C(=O)N)CC,
Hexachlorophene,SARS-COV-2,10.1101/2020.03.20.999730,,Clc1cc(Cl)c(c(c1O)Cc1c(O)c(Cl)cc(c1Cl)Cl)Cl,3598,,,,,,,,Clc1cc(Cl)c(c(c1O)Cc1c(O)c(Cl)cc(c1Cl)Cl)Cl,
Hydroxyprogesterone caproate,SARS-COV-2,10.1101/2020.03.20.999730,,CCCCCC(=O)OC1(CCC2C1(C)CCC1C2CCC2=CC(=O)CCC12C)C(=O)C,169870,,,,,,,,CCCCCC(=O)OC1(CCC2C1(C)CCC1C2CCC2=CC(=O)CCC12C)C(=O)C,
Isoosajin,SARS-COV-2,10.1101/2020.03.20.999730,,Oc1ccc(cc1)c1coc2c(c1=O)c1OC(C)(C)CCc1c1c2C=CC(O1)(C)C,1069873,,,,,,,,Oc1ccc(cc1)c1coc2c(c1=O)c1OC(C)(C)CCc1c1c2C=CC(O1)(C)C,
Isopomiferin,SARS-COV-2,10.1101/2020.03.20.999730,,Oc1ccc(cc1O)c1coc2c(c1=O)c1OC(C)(C)CCc1c1c2C=CC(O1)(C)C,20055152,,,,,,,,Oc1ccc(cc1O)c1coc2c(c1=O)c1OC(C)(C)CCc1c1c2C=CC(O1)(C)C,
Ivacaftor,SARS-COV-2,10.1101/2020.03.20.999730,,O=C(c1c[nH]c2c(c1=O)cccc2)Nc1cc(O)c(cc1C(C)(C)C)C(C)(C)C,16220172,,,,,,,,O=C(c1c[nH]c2c(c1=O)cccc2)Nc1cc(O)c(cc1C(C)(C)C)C(C)(C)C,
Lanatoside C,SARS-COV-2,10.1101/2020.03.20.999730,,OCC1OC(OC2C(C)OC(CC2OC(=O)C)OC2C(O)CC(OC2C)OC2C(O)CC(OC2C)OC2CCC3(C(C2)CCC2C3CC(O)C3(C2(O)CCC3C2=CC(=O)OC2)C)C)C(C(C1O)O)O,656630,,,,,,,,OCC1OC(OC2C(C)OC(CC2OC(=O)C)OC2C(O)CC(OC2C)OC2C(O)CC(OC2C)OC2CCC3(C(C2)CCC2C3CC(O)C3(C2(O)CCC3C2=CC(=O)OC2)C)C)C(C(C1O)O)O,
LDK378,SARS-COV-2,10.1101/2020.03.20.999730,,CC(Oc1cc(C2CCNCC2)c(cc1Nc1ncc(c(n1)Nc1ccccc1S(=O)(=O)C(C)C)Cl)C)C,57379345,,,,,,,,CC(Oc1cc(C2CCNCC2)c(cc1Nc1ncc(c(n1)Nc1ccccc1S(=O)(=O)C(C)C)Cl)C)C,
Loperamid hydrochloride,SARS-COV-2,10.1101/2020.03.20.999730,,Clc1ccc(cc1)C1(O)CCN(CC1)CCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1.Cl.Cl,67764865,,,,,,,,Clc1ccc(cc1)C1(O)CCN(CC1)CCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1.Cl.Cl,
Lopinavir,SARS-COV-2,10.1101/2020.03.20.999730,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,92727,,,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
Lusutrombopag,SARS-COV-2,10.1101/2020.03.20.999730,,CCCCCCOC(c1cccc(c1OC)c1csc(n1)NC(=O)c1cc(Cl)c(c(c1)Cl)C=C(C(=O)O)C)C,49843517,,,,,,,,CCCCCCOC(c1cccc(c1OC)c1csc(n1)NC(=O)c1cc(Cl)c(c(c1)Cl)C=C(C(=O)O)C)C,
Mefloquine,SARS-COV-2,10.1101/2020.03.20.999730,,OC(c1cc(nc2c1cccc2C(F)(F)F)C(F)(F)F)C1CCCCN1,40692,,,,,,,,OC(c1cc(nc2c1cccc2C(F)(F)F)C(F)(F)F)C1CCCCN1,
Mequitazine,SARS-COV-2,10.1101/2020.03.20.999730,,c1ccc2c(c1)N(CC1CN3CCC1CC3)c1c(S2)cccc1,4066,,,,,,,,c1ccc2c(c1)N(CC1CN3CCC1CC3)c1c(S2)cccc1,
Niclosamide,SARS-COV-2,10.1101/2020.03.20.999730,,Clc1ccc(c(c1)C(=O)Nc1ccc(cc1Cl)[N+](=O)[O-])O,4477,,,,,,,,Clc1ccc(c(c1)C(=O)Nc1ccc(cc1Cl)[N+](=O)[O-])O,
Osajin,SARS-COV-2,10.1101/2020.03.20.999730,,CC(=CCc1c2OC(C)(C)C=Cc2c2c(c1O)c(=O)c(co2)c1ccc(cc1)O)C,95168,,,,,,,,CC(=CCc1c2OC(C)(C)C=Cc2c2c(c1O)c(=O)c(co2)c1ccc(cc1)O)C,
Osimertinib mesylate,SARS-COV-2,10.1101/2020.03.20.999730,,CS(=O)(=O)O.C=CC(=O)Nc1cc(Nc2nccc(n2)c2cn(c3c2cccc3)C)c(cc1N(CCN(C)C)C)OC,78357807,,,,,,,,CS(=O)(=O)O.C=CC(=O)Nc1cc(Nc2nccc(n2)c2cn(c3c2cccc3)C)c(cc1N(CCN(C)C)C)OC,
Ouabain,SARS-COV-2,10.1101/2020.03.20.999730,,OCC12C(O)CC(CC2(O)CCC2C1C(O)CC1(C2(O)CCC1C1=CC(=O)OC1)C)OC1OC(C)C(C(C1O)O)O,439501,,,,,,,,OCC12C(O)CC(CC2(O)CCC2C1C(O)CC1(C2(O)CCC1C1=CC(=O)OC1)C)OC1OC(C)C(C(C1O)O)O,
Oxyclozanide,SARS-COV-2,10.1101/2020.03.20.999730,,Clc1cc(NC(=O)c2c(O)c(Cl)cc(c2Cl)Cl)c(c(c1)Cl)O,16779,,,,,,,,Clc1cc(NC(=O)c2c(O)c(Cl)cc(c2Cl)Cl)c(c(c1)Cl)O,
Penfluridol,SARS-COV-2,10.1101/2020.03.20.999730,,Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)(O)c1ccc(c(c1)C(F)(F)F)Cl,33630,,,,,,,,Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)(O)c1ccc(c(c1)C(F)(F)F)Cl,
Perhexiline maleate,SARS-COV-2,10.1101/2020.03.20.999730,,C1CCC(NC1)CC(C1CCCCC1)C1CCCCC1.OC(=O)C=CC(=O)O,5284439,,,,,,,,C1CCC(NC1)CC(C1CCCCC1)C1CCCCC1.OC(=O)C=CC(=O)O,
Phenazopyridine hydrochloride,SARS-COV-2,10.1101/2020.03.20.999730,,Nc1ccc(c(n1)N)N=Nc1ccccc1.Cl,8691,,,,,,,,Nc1ccc(c(n1)N)N=Nc1ccccc1.Cl,
Pralatrexate,SARS-COV-2,10.1101/2020.03.20.999730,,C#CCC(c1ccc(cc1)C(=O)NC(C(=O)O)CCC(=O)O)Cc1cnc2c(n1)c(N)nc(n2)N,148121,,,,,,,,C#CCC(c1ccc(cc1)C(=O)NC(C(=O)O)CCC(=O)O)Cc1cnc2c(n1)c(N)nc(n2)N,
Proscillaridin,SARS-COV-2,10.1101/2020.03.20.999730,,OC1C(OC2CCC3(C(=C2)CCC2C3CCC3(C2(O)CCC3c2ccc(=O)oc2)C)C)OC(C(C1O)O)C,5284613,,,,,,,,OC1C(OC2CCC3(C(=C2)CCC2C3CCC3(C2(O)CCC3c2ccc(=O)oc2)C)C)OC(C(C1O)O)C,
Pyronaridine tetraphosphate,SARS-COV-2,10.1101/2020.03.20.999730,,OP(=O)(O)O.OP(=O)(O)O.OP(=O)(O)O.OP(=O)(O)O.COc1ccc2c(n1)c(Nc1cc(CN3CCCC3)c(c(c1)CN1CCCC1)O)c1c(n2)cc(cc1)Cl,156867,,,,,,,,OP(=O)(O)O.OP(=O)(O)O.OP(=O)(O)O.OP(=O)(O)O.COc1ccc2c(n1)c(Nc1cc(CN3CCCC3)c(c(c1)CN1CCCC1)O)c1c(n2)cc(cc1)Cl,
Quinacrine hydrochloride,SARS-COV-2,10.1101/2020.03.20.999730,,CCN(CCCC(Nc1c2cc(OC)ccc2nc2c1ccc(c2)Cl)C)CC.Cl.Cl,6239,,,,,,,,CCN(CCCC(Nc1c2cc(OC)ccc2nc2c1ccc(c2)Cl)C)CC.Cl.Cl,
Remdesivir (GS-5734),SARS-COV-2,10.1101/2020.03.20.999730,,,,,,,,,,,,
"Salinomycin, sodium",SARS-COV-2,10.1101/2020.03.20.999730,,CCC(C1OC2(C=CC(C3(O2)CCC(O3)(C)C2CCC(C(O2)C)(O)CC)O)C(CC1C)C)C(=O)C(C(C(C1OC(CCC1C)C(C(=O)[O-])CC)C)O)C.[Na+],23682228,,,,,,,,CCC(C1OC2(C=CC(C3(O2)CCC(O3)(C)C2CCC(C(O2)C)(O)CC)O)C(CC1C)C)C(=O)C(C(C(C1OC(CCC1C)C(C(=O)[O-])CC)C)O)C.[Na+],
Tetrandrine,SARS-COV-2,10.1101/2020.03.20.999730,,COc1c(OC)cc2c3c1Oc1cc4c(cc1OC)CCN(C4Cc1ccc(Oc4cc(CC3N(CC2)C)ccc4OC)cc1)C,73078,,,,,,,,COc1c(OC)cc2c3c1Oc1cc4c(cc1OC)CCN(C4Cc1ccc(Oc4cc(CC3N(CC2)C)ccc4OC)cc1)C,
Thioridazine hydrochloride,SARS-COV-2,10.1101/2020.03.20.999730,,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1.Cl,66062,,,,,,,,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1.Cl,
Tilorone,SARS-COV-2,10.1101/2020.03.20.999730,,CCN(CCOc1ccc2c(c1)C(=O)c1c2ccc(c1)OCCN(CC)CC)CC,5475,,,,,,,,CCN(CCOc1ccc2c(c1)C(=O)c1c2ccc(c1)OCCN(CC)CC)CC,
Toremiphene citrate,SARS-COV-2,10.1101/2020.03.20.999730,,,,,,,,,,,,
Triparanol,SARS-COV-2,10.1101/2020.03.20.999730,,CCN(CCOc1ccc(cc1)C(c1ccc(cc1)C)(Cc1ccc(cc1)Cl)O)CC,6536,,,,,,,,CCN(CCOc1ccc(cc1)C(c1ccc(cc1)C)(Cc1ccc(cc1)Cl)O)CC,
Meplazumab,SARS-COV-2,10.1101/2020.03.21.20040691,,,,,,,,,,,,
Saquinavir,SARS-COV-2,10.1101/2020.04.05.20054254,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,441243,,,,,,,,NC(=O)CC(C(=O)NC(C(CN1CC2CCCCC2CC1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,
Atazanavir,SARS-COV-2,10.1101/2020.04.05.20054254,,COC(=O)NC(C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)CC(C(Cc1ccccc1)NC(=O)C(C(C)(C)C)NC(=O)OC)O,148192,,,,,,,,COC(=O)NC(C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)CC(C(Cc1ccccc1)NC(=O)C(C(C)(C)C)NC(=O)OC)O,
Lopinavir,SARS-COV-2,10.1101/2020.04.05.20054254,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,92727,,,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
Tipranavir,SARS-COV-2,10.1101/2020.04.05.20054254,,CCCC1(CCc2ccccc2)CC(=C(C(=O)O1)C(c1cccc(c1)NS(=O)(=O)c1ccc(cn1)C(F)(F)F)CC)O,54682461,,,,,,,,CCCC1(CCc2ccccc2)CC(=C(C(=O)O1)C(c1cccc(c1)NS(=O)(=O)c1ccc(cn1)C(F)(F)F)CC)O,
Amprenavir,SARS-COV-2,10.1101/2020.04.05.20054254,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1CCOC1)O)C,65016,,,,,,,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1CCOC1)O)C,
Fosamprenavir,SARS-COV-2,10.1101/2020.04.05.20054254,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1CCOC1)OP(=O)(O)O)C,131536,,,,,,,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1CCOC1)OP(=O)(O)O)C,
Ritonavir,SARS-COV-2,10.1101/2020.04.05.20054254,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,392622,,,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,
Darunavir,SARS-COV-2,10.1101/2020.04.05.20054254,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1COC2C1CCO2)O)C,213039,,,,,,,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1COC2C1CCO2)O)C,
Paritaprevir,SARS-COV-2,10.1101/2020.04.05.20054254,,Cc1ncc(nc1)C(=O)NC1CCCCCC=CC2C(NC(=O)C3N(C1=O)CC(C3)Oc1nc3ccccc3c3c1cccc3)(C2)C(=O)NS(=O)(=O)C1CC1,45110509,,,,,,,,Cc1ncc(nc1)C(=O)NC1CCCCCC=CC2C(NC(=O)C3N(C1=O)CC(C3)Oc1nc3ccccc3c3c1cccc3)(C2)C(=O)NS(=O)(=O)C1CC1,
Azithromycine,SARS-COV-2,10.1101/2020.04.03.023846,,CCC1OC(=O)C(C)C(OC2OC(C)C(C(C2)(C)OC)O)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(CC(CN(C(C(C1(C)O)O)C)C)C)(C)O,447043,,,,,,,,CCC1OC(=O)C(C)C(OC2OC(C)C(C(C2)(C)OC)O)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(CC(CN(C(C(C1(C)O)O)C)C)C)(C)O,
Opipramol,SARS-COV-2,10.1101/2020.04.03.023846,,OCCN1CCN(CC1)CCCN1c2ccccc2C=Cc2c1cccc2,9417,,,,,,,,OCCN1CCN(CC1)CCCN1c2ccccc2C=Cc2c1cccc2,
Quinidine,SARS-COV-2,10.1101/2020.04.03.023846,,C=CC1CN2CCC1CC2C(c1ccnc2c1cc(OC)cc2)O,441074,,,,,,,,C=CC1CN2CCC1CC2C(c1ccnc2c1cc(OC)cc2)O,
Omeprazol,SARS-COV-2,10.1101/2020.04.03.023846,,COc1ccc2c(c1)[nH]c(n2)S(=O)Cc1ncc(c(c1C)OC)C,4594,,,,,,,,COc1ccc2c(c1)[nH]c(n2)S(=O)Cc1ncc(c(c1C)OC)C,
Oxprenolol hydrochloride,SARS-COV-2,10.1101/2020.04.03.023846,,C=CCOc1ccccc1OCC(CNC(C)C)O.Cl,71172,,,,,,,,C=CCOc1ccccc1OCC(CNC(C)C)O.Cl,
Clemizole hydrochloride,SARS-COV-2,10.1101/2020.04.03.023846,,Clc1ccc(cc1)Cn1c(CN2CCCC2)nc2c1cccc2.Cl,5309446,,,,,,,,Clc1ccc(cc1)Cn1c(CN2CCCC2)nc2c1cccc2.Cl,
Alprostadil,SARS-COV-2,10.1101/2020.04.03.023846,,CCCCCC(C=CC1C(O)CC(=O)C1CCCCCCC(=O)O)O,5280723,,,,,,,,CCCCCC(C=CC1C(O)CC(=O)C1CCCCCCC(=O)O)O,
Dolutegravir,SARS-COV-2,10.1101/2020.04.03.023846,,Fc1ccc(c(c1)F)CNC(=O)c1cn2CC3OCCC(N3C(=O)c2c(c1=O)O)C,54726191,,,,,,,,Fc1ccc(c(c1)F)CNC(=O)c1cn2CC3OCCC(N3C(=O)c2c(c1=O)O)C,
Sulfadoxine,SARS-COV-2,10.1101/2020.04.03.023846,,COc1c(OC)ncnc1NS(=O)(=O)c1ccc(cc1)N,17134,,,,,,,,COc1c(OC)ncnc1NS(=O)(=O)c1ccc(cc1)N,
Arbidol,SARS-COV-2,10.1101/2020.04.03.023846,,CCOC(=O)c1c(CSc2ccccc2)n(c2c1c(CN(C)C)c(O)c(c2)Br)C,131411,,,,,,,,CCOC(=O)c1c(CSc2ccccc2)n(c2c1c(CN(C)C)c(O)c(c2)Br)C,
Remdesivir 5,SARS-COV-2,10.1101/2020.04.03.023846,,,,,,,,,,,,
Oxymetholone,SARS-COV-2,10.1101/2020.04.03.023846,,OC=C1CC2(C)C(CC1=O)CCC1C2CCC2(C1CCC2(C)O)C,5281034,,,,,,,,OC=C1CC2(C)C(CC1=O)CCC1C2CCC2(C1CCC2(C)O)C,
Equilin,SARS-COV-2,10.1101/2020.04.03.023846,,Oc1ccc2c(c1)CC=C1C2CCC2(C1CCC2=O)C,223368,,,,,,,,Oc1ccc2c(c1)CC=C1C2CCC2(C1CCC2=O)C,
Pregnenolone,SARS-COV-2,10.1101/2020.04.03.023846,,OC1CCC2(C(=CCC3C2CCC2(C3CCC2C(=O)C)C)C1)C,8955,,,,,,,,OC1CCC2(C(=CCC3C2CCC2(C3CCC2C(=O)C)C)C1)C,
Formestane,SARS-COV-2,10.1101/2020.04.03.023846,,O=C1CCC2(C(=C1O)CCC1C2CCC2(C1CCC2=O)C)C,11273,,,,,,,,O=C1CCC2(C(=C1O)CCC1C2CCC2(C1CCC2=O)C)C,
Exemestane,SARS-COV-2,10.1101/2020.04.03.023846,,O=C1C=CC2(C(=C1)C(=C)CC1C2CCC2(C1CCC2=O)C)C,60198,,,,,,,,O=C1C=CC2(C(=C1)C(=C)CC1C2CCC2(C1CCC2=O)C)C,
Methandrostenolone,SARS-COV-2,10.1101/2020.04.03.023846,,O=C1C=CC2(C(=C1)CCC1C2CCC2(C1CCC2(C)O)C)C,6300,,,,,,,,O=C1C=CC2(C(=C1)CCC1C2CCC2(C1CCC2(C)O)C)C,
Prednicarbate,SARS-COV-2,10.1101/2020.04.03.023846,,CCOC(=O)OC1(CCC2C1(C)CC(O)C1C2CCC2=CC(=O)C=CC12C)C(=O)COC(=O)CC,6714002,,,,,,,,CCOC(=O)OC1(CCC2C1(C)CC(O)C1C2CCC2=CC(=O)C=CC12C)C(=O)COC(=O)CC,
Desonide,SARS-COV-2,10.1101/2020.04.03.023846,,OCC(=O)C12OC(OC1CC1C2(C)CC(O)C2C1CCC1=CC(=O)C=CC21C)(C)C,5311066,,,,,,,,OCC(=O)C12OC(OC1CC1C2(C)CC(O)C2C1CCC1=CC(=O)C=CC21C)(C)C,
Misoprostol,SARS-COV-2,10.1101/2020.04.03.023846,,CCCCC(CC=CC1C(O)CC(=O)C1CCCCCCC(=O)OC)(O)C,5282381,,,,,,,,CCCCC(CC=CC1C(O)CC(=O)C1CCCCCCC(=O)OC)(O)C,
Vonoprazan,SARS-COV-2,10.1101/2020.04.03.023846,,CNCc1cc(n(c1)S(=O)(=O)c1cccnc1)c1ccccc1F,15981397,,,,,,,,CNCc1cc(n(c1)S(=O)(=O)c1cccnc1)c1ccccc1F,
Darunavir,SARS-COV-2,10.1101/2020.04.03.023846,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1COC2C1CCO2)O)C,213039,,,,,,,,CC(CN(S(=O)(=O)c1ccc(cc1)N)CC(C(Cc1ccccc1)NC(=O)OC1COC2C1CCO2)O)C,
Prothionamide,SARS-COV-2,10.1101/2020.04.03.023846,,CCCc1cc(ccn1)C(=S)N,666418,,,,,,,,CCCc1cc(ccn1)C(=S)N,
Levofloxacin,SARS-COV-2,10.1101/2020.04.03.023846,,CN1CCN(CC1)c1c(F)cc2c3c1OCC(n3cc(c2=O)C(=O)O)C,149096,,,,,,,,CN1CCN(CC1)c1c(F)cc2c3c1OCC(n3cc(c2=O)C(=O)O)C,
Enoxacin,SARS-COV-2,10.1101/2020.04.03.023846,,CCn1cc(C(=O)O)c(=O)c2c1nc(N1CCNCC1)c(c2)F,3229,,,,,,,,CCn1cc(C(=O)O)c(=O)c2c1nc(N1CCNCC1)c(c2)F,
Sparfloxacin,SARS-COV-2,10.1101/2020.04.03.023846,,CC1NC(C)CN(C1)c1c(F)c(N)c2c(c1F)n(cc(c2=O)C(=O)O)C1CC1,60464,,,,,,,,CC1NC(C)CN(C1)c1c(F)c(N)c2c(c1F)n(cc(c2=O)C(=O)O)C1CC1,
D-cycloserine,SARS-COV-2,10.1101/2020.04.03.023846,,NC1CONC1=O,6234,,,,,,,,NC1CONC1=O,
L-Cycloserine,SARS-COV-2,10.1101/2020.04.03.023846,,NC1CONC1=O,449215,,,,,,,,NC1CONC1=O,
Spiramycin,SARS-COV-2,10.1101/2020.04.03.023846,,O=CCC1CC(C)C(C=CC=CCC(OC(=O)CC(C(C1OC1OC(C)C(C(C1O)N(C)C)OC1CC(C)(O)C(C(O1)C)O)OC)O)C)OC1CCC(C(O1)C)N(C)C,6419898,,,,,,,,O=CCC1CC(C)C(C=CC=CCC(OC(=O)CC(C(C1OC1OC(C)C(C(C1O)N(C)C)OC1CC(C)(O)C(C(O1)C)O)OC)O)C)OC1CCC(C(O1)C)N(C)C,
Cefamandole,SARS-COV-2,10.1101/2020.04.03.023846,,OC(C(=O)NC1C(=O)N2C1SCC(=C2C(=O)O)CSc1nnnn1C)c1ccccc1,456255,,,,,,,,OC(C(=O)NC1C(=O)N2C1SCC(=C2C(=O)O)CSc1nnnn1C)c1ccccc1,
Benzathine,SARS-COV-2,10.1101/2020.04.03.023846,,N(Cc1ccccc1)CCNCc1ccccc1,8793,,,,,,,,N(Cc1ccccc1)CCNCc1ccccc1,
Merbromin,SARS-COV-2,10.1101/2020.04.03.023846,,O=C1OC2(c3c1cccc3)c1cc(Br)c(cc1Oc1c2cc(Br)c(c1[Hg])[O-])[O-].O.[Na+].[Na+],8505,,,,,,,,O=C1OC2(c3c1cccc3)c1cc(Br)c(cc1Oc1c2cc(Br)c(c1[Hg])[O-])[O-].O.[Na+].[Na+],
Ifenprodil tartrate,SARS-COV-2,10.1101/2020.04.03.023846,,OC(C(C(=O)O)O)C(=O)O.Oc1ccc(cc1)C(C(N1CCC(CC1)Cc1ccccc1)C)O.Oc1ccc(cc1)C(C(N1CCC(CC1)Cc1ccccc1)C)O,656586,,,,,,,,OC(C(C(=O)O)O)C(=O)O.Oc1ccc(cc1)C(C(N1CCC(CC1)Cc1ccccc1)C)O.Oc1ccc(cc1)C(C(N1CCC(CC1)Cc1ccccc1)C)O,
Nylidrin,SARS-COV-2,10.1101/2020.04.03.023846,,CC(NC(C(c1ccc(cc1)O)O)C)CCc1ccccc1,4567,,,,,,,,CC(NC(C(c1ccc(cc1)O)O)C)CCc1ccccc1,
Cyclopentolate,SARS-COV-2,10.1101/2020.04.03.023846,,CN(CCOC(=O)C(C1(O)CCCC1)c1ccccc1)C,2905,,,,,,,,CN(CCOC(=O)C(C1(O)CCCC1)c1ccccc1)C,
(S)-(-)-Propranolol hydrochloride,SARS-COV-2,10.1101/2020.04.03.023846,,OC(COc1cccc2c1cccc2)CNC(C)C.Cl,165193,,,,,,,,OC(COc1cccc2c1cccc2)CNC(C)C.Cl,
Ranolazine,SARS-COV-2,10.1101/2020.04.03.023846,,COc1ccccc1OCC(CN1CCN(CC1)CC(=O)Nc1c(C)cccc1C)O,56959,,,,,,,,COc1ccccc1OCC(CN1CCN(CC1)CC(=O)Nc1c(C)cccc1C)O,
Candesartan,SARS-COV-2,10.1101/2020.04.03.023846,,CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)c(ccc2)C(=O)O,2541,,,,,,,,CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)c(ccc2)C(=O)O,
Olmesartan,SARS-COV-2,10.1101/2020.04.03.023846,,CCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)C(=O)O)C(O)(C)C,158781,,,,,,,,CCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)C(=O)O)C(O)(C)C,
Ambrisentan,SARS-COV-2,10.1101/2020.04.03.023846,,COC(C(C(=O)O)Oc1nc(C)cc(n1)C)(c1ccccc1)c1ccccc1,6918493,,,,,,,,COC(C(C(=O)O)Oc1nc(C)cc(n1)C)(c1ccccc1)c1ccccc1,
Fosinopril,SARS-COV-2,10.1101/2020.04.03.023846,,CCC(=O)OC(C(C)C)OP(=O)(CC(=O)N1CC(CC1C(=O)O)C1CCCCC1)CCCCc1ccccc1,55891,,,,,,,,CCC(=O)OC(C(C)C)OP(=O)(CC(=O)N1CC(CC1C(=O)O)C1CCCCC1)CCCCc1ccccc1,
Fenoldopam,SARS-COV-2,10.1101/2020.04.03.023846,,Oc1ccc(cc1)C1CNCCc2c1cc(O)c(c2Cl)O,3341,,,,,,,,Oc1ccc(cc1)C1CNCCc2c1cc(O)c(c2Cl)O,
Meptazinol,SARS-COV-2,10.1101/2020.04.03.023846,,CCC1(CCCCN(C1)C)c1cccc(c1)O,41049,,,,,,,,CCC1(CCCCN(C1)C)c1cccc(c1)O,
Nalmefene hydrochloride,SARS-COV-2,10.1101/2020.04.03.023846,,C=C1CCC2(C34C1Oc1c4c(CC2N(CC3)CC2CC2)ccc1O)O.Cl,5388881,,,,,,,,C=C1CCC2(C34C1Oc1c4c(CC2N(CC3)CC2CC2)ccc1O)O.Cl,
Mirtazapine,SARS-COV-2,10.1101/2020.04.03.023846,,CN1CCN2C(C1)c1ccccc1Cc1c2nccc1,4205,,,,,,,,CN1CCN2C(C1)c1ccccc1Cc1c2nccc1,
Olanzapine,SARS-COV-2,10.1101/2020.04.03.023846,,CN1CCN(CC1)C1=Nc2ccccc2Nc2c1cc(s2)C,135398745,,,,,,,,CN1CCN(CC1)C1=Nc2ccccc2Nc2c1cc(s2)C,
Tacrine,SARS-COV-2,10.1101/2020.04.03.023846,,Nc1c2CCCCc2nc2c1cccc2,1935,,,,,,,,Nc1c2CCCCc2nc2c1cccc2,
Promazine,SARS-COV-2,10.1101/2020.04.03.023846,,CN(CCCN1c2ccccc2Sc2c1cccc2)C,4926,,,,,,,,CN(CCCN1c2ccccc2Sc2c1cccc2)C,
Clebopride,SARS-COV-2,10.1101/2020.04.03.023846,,COc1cc(N)c(cc1C(=O)NC1CCN(CC1)Cc1ccccc1)Cl,2780,,,,,,,,COc1cc(N)c(cc1C(=O)NC1CCN(CC1)Cc1ccccc1)Cl,
Donepezil,SARS-COV-2,10.1101/2020.04.03.023846,,COc1cc2c(cc1OC)CC(C2=O)CC1CCN(CC1)Cc1ccccc1,3152,,,,,,,,COc1cc2c(cc1OC)CC(C2=O)CC1CCN(CC1)Cc1ccccc1,
Tolperisone,SARS-COV-2,10.1101/2020.04.03.023846,,CC(C(=O)c1ccc(cc1)C)CN1CCCCC1,5511,,,,,,,,CC(C(=O)c1ccc(cc1)C)CN1CCCCC1,
Idazoxan,SARS-COV-2,10.1101/2020.04.03.023846,,C1CN=C(N1)C1COc2c(O1)cccc2,54459,,,,,,,,C1CN=C(N1)C1COc2c(O1)cccc2,
Ondansetron,SARS-COV-2,10.1101/2020.04.03.023846,,O=C1C(CCc2c1c1ccccc1n2C)Cn1ccnc1C,4595,,,,,,,,O=C1C(CCc2c1c1ccccc1n2C)Cn1ccnc1C,
Eletriptan,SARS-COV-2,10.1101/2020.04.03.023846,,CN1CCCC1Cc1c[nH]c2c1cc(cc2)CCS(=O)(=O)c1ccccc1,77993,,,,,,,,CN1CCCC1Cc1c[nH]c2c1cc(cc2)CCS(=O)(=O)c1ccccc1,
Phentermine,SARS-COV-2,10.1101/2020.04.03.023846,,CC(Cc1ccccc1)(N)C,4771,,,,,,,,CC(Cc1ccccc1)(N)C,
Buspirone,SARS-COV-2,10.1101/2020.04.03.023846,,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,2477,,,,,,,,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,
Nabumetone,SARS-COV-2,10.1101/2020.04.03.023846,,COc1ccc2c(c1)ccc(c2)CCC(=O)C,4409,,,,,,,,COc1ccc2c(c1)ccc(c2)CCC(=O)C,
Tolterodine,SARS-COV-2,10.1101/2020.04.03.023846,,Cc1ccc(c(c1)C(c1ccccc1)CCN(C(C)C)C(C)C)O,443879,,,,,,,,Cc1ccc(c(c1)C(c1ccccc1)CCN(C(C)C)C(C)C)O,
Benoxinate,SARS-COV-2,10.1101/2020.04.03.023846,,CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC,4633,,,,,,,,CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC,
Meprylcaine,SARS-COV-2,10.1101/2020.04.03.023846,,CCCNC(COC(=O)c1ccccc1)(C)C,4065,,,,,,,,CCCNC(COC(=O)c1ccccc1)(C)C,
Dyclonine,SARS-COV-2,10.1101/2020.04.03.023846,,CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1,3180,,,,,,,,CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1,
Eperisone,SARS-COV-2,10.1101/2020.04.03.023846,,CCc1ccc(cc1)C(=O)C(CN1CCCCC1)C,3236,,,,,,,,CCc1ccc(cc1)C(=O)C(CN1CCCCC1)C,
Cisatracurium,SARS-COV-2,10.1101/2020.04.03.023846,,COc1cc2c(cc1OC)CC[N+](C2Cc1ccc(c(c1)OC)OC)(C)CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCc2c(C1Cc1ccc(c(c1)OC)OC)cc(c(c2)OC)OC,62887,,,,,,,,COc1cc2c(cc1OC)CC[N+](C2Cc1ccc(c(c1)OC)OC)(C)CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCc2c(C1Cc1ccc(c(c1)OC)OC)cc(c(c2)OC)OC,
Formoterol,SARS-COV-2,10.1101/2020.04.03.023846,,O=CNc1cc(ccc1O)C(CNC(Cc1ccc(cc1)OC)C)O,3083544,,,,,,,,O=CNc1cc(ccc1O)C(CNC(Cc1ccc(cc1)OC)C)O,
Ambroxol,SARS-COV-2,10.1101/2020.04.03.023846,,OC1CCC(CC1)NCc1cc(Br)cc(c1N)Br,2132,,,,,,,,OC1CCC(CC1)NCc1cc(Br)cc(c1N)Br,
Levalbuterol,SARS-COV-2,10.1101/2020.04.03.023846,,OCc1cc(ccc1O)C(CNC(C)(C)C)O,123600,,,,,,,,OCc1cc(ccc1O)C(CNC(C)(C)C)O,
Dimenhydrinate,SARS-COV-2,10.1101/2020.04.03.023846,,Clc1[nH]c2c(n1)n(C)c(=O)n(c2=O)C.CN(CCOC(c1ccccc1)c1ccccc1)C,10660,,,,,,,,Clc1[nH]c2c(n1)n(C)c(=O)n(c2=O)C.CN(CCOC(c1ccccc1)c1ccccc1)C,
Tripelennamine,SARS-COV-2,10.1101/2020.04.03.023846,,CN(CCN(c1ccccn1)Cc1ccccc1)C,5587,,,,,,,,CN(CCN(c1ccccn1)Cc1ccccc1)C,
Chloroquine,SARS-COV-2,10.1101/2020.04.03.023846,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,2719,,,,,,,,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,
Hydroxychloroquine,SARS-COV-2,10.1101/2020.04.03.023846,,OCCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,3652,,,,,,,,OCCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,
Artenimol,SARS-COV-2,10.1101/2020.04.03.023846,,OC1OC2OC3(C)CCC4C2(C(C1C)CCC4C)OO3,3000518,,,,,,,,OC1OC2OC3(C)CCC4C2(C(C1C)CCC4C)OO3,
Dipivefrin,SARS-COV-2,10.1101/2020.04.03.023846,,CNCC(c1ccc(c(c1)OC(=O)C(C)(C)C)OC(=O)C(C)(C)C)O,3105,,,,,,,,CNCC(c1ccc(c(c1)OC(=O)C(C)(C)C)OC(=O)C(C)(C)C)O,
Ethoxzolamide,SARS-COV-2,10.1101/2020.04.03.023846,,CCOc1ccc2c(c1)sc(n2)S(=O)(=O)N,3295,,,,,,,,CCOc1ccc2c(c1)sc(n2)S(=O)(=O)N,
Oxiglutatione,SARS-COV-2,10.1101/2020.04.03.023846,,O=C(NC(C(=O)NCC(=O)O)CSSCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)CCC(C(=O)O)N,65359,,,,,,,,O=C(NC(C(=O)NCC(=O)O)CSSCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)CCC(C(=O)O)N,
Isotretinoin,SARS-COV-2,10.1101/2020.04.03.023846,,CC(=CC=CC(=CC(=O)O)C)C=CC1=C(C)CCCC1(C)C,5282379,,,,,,,,CC(=CC=CC(=CC(=O)O)C)C=CC1=C(C)CCCC1(C)C,
Anthralin,SARS-COV-2,10.1101/2020.04.03.023846,,Oc1cccc2c1C(=O)c1c(C2)cccc1O,2202,,,,,,,,Oc1cccc2c1C(=O)c1c(C2)cccc1O,
Ibudilast,SARS-COV-2,10.1101/2020.04.03.023846,,CC(C(=O)c1c(nn2c1cccc2)C(C)C)C,3671,,,,,,,,CC(C(=O)c1c(nn2c1cccc2)C(C)C)C,
Fursultiamine,SARS-COV-2,10.1101/2020.04.03.023846,,OCCC(=C(N(Cc1cnc(nc1N)C)C=O)C)SSCC1CCCO1,3002119,,,,,,,,OCCC(=C(N(Cc1cnc(nc1N)C)C=O)C)SSCC1CCCO1,
Anethole-trithione,SARS-COV-2,10.1101/2020.04.03.023846,,CC=Cc1ccc(cc1)OC,637563,,,,,,,,CC=Cc1ccc(cc1)OC,
Zoledronic acid,SARS-COV-2,10.1101/2020.04.03.023846,,OP(=O)(C(P(=O)(O)O)(Cn1cncc1)O)O,68740,,,,,,,,OP(=O)(C(P(=O)(O)O)(Cn1cncc1)O)O,
Oxyphenisatin,SARS-COV-2,10.1101/2020.04.03.023846,,Oc1ccc(cc1)C1(c2ccc(cc2)O)C(=O)Nc2c1cccc2,31315,,,,,,,,Oc1ccc(cc1)C1(c2ccc(cc2)O)C(=O)Nc2c1cccc2,
Cyclofenil,SARS-COV-2,10.1101/2020.04.03.023846,,CC(=O)Oc1ccc(cc1)C(=C1CCCCC1)c1ccc(cc1)OC(=O)C,2898,,,,,,,,CC(=O)Oc1ccc(cc1)C(=C1CCCCC1)c1ccc(cc1)OC(=O)C,
Lopinavir,SARS-COV-2,10.1101/2020.04.06.026476,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,92727,,,,,,,,O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,
Nelfinavir,SARS-COV-2,10.1101/2020.04.06.026476,,OC(C(NC(=O)c1cccc(c1C)O)CSc1ccccc1)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C,64143,,,,,,,,OC(C(NC(=O)c1cccc(c1C)O)CSc1ccccc1)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C,
Merimepodib (MMPD),SARS-COV-2,10.1101/2020.04.07.028589,,,,,,,,,,,,
Ebselen,SARS-COV-2,s41586-020-2223-y,,O=c1c2ccccc2[se]n1c1ccccc1,3194,,,,,,,,O=c1c2ccccc2[se]n1c1ccccc1,
Disulfiram,SARS-COV-2,s41586-020-2223-y,,CCN(C(=S)SSC(=S)N(CC)CC)CC,3117,,,,,,,,CCN(C(=S)SSC(=S)N(CC)CC)CC,
Tideglusib,SARS-COV-2,s41586-020-2223-y,,O=c1sn(c(=O)n1Cc1ccccc1)c1cccc2c1cccc2,11313622,,,,,,,,O=c1sn(c(=O)n1Cc1ccccc1)c1cccc2c1cccc2,
Carmofur,SARS-COV-2,s41586-020-2223-y,,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,2577,,,,,,,,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,
Shikonin,SARS-COV-2,s41586-020-2223-y,,CC(=CCC(C1=CC(=O)c2c(C1=O)c(O)ccc2O)O)C,479503,,,,,,,,CC(=CCC(C1=CC(=O)c2c(C1=O)c(O)ccc2O)O)C,
PX-12,SARS-COV-2,s41586-020-2223-y,,CCC(SSc1ncc[nH]1)C,219104,,,,,,,,CCC(SSc1ncc[nH]1)C,
Amantadine,SARS-COV-2,10.1101/2020.04.05.026187,,NC12CC3CC(C2)CC(C1)C3,2130,,,,,,,,NC12CC3CC(C2)CC(C1)C3,
Atazanavir (ATV),SARS-COV-2,10.1101/2020.04.04.020925,,,,,,,,,,,,
Ritonavir (RTV),SARS-COV-2,10.1101/2020.04.04.020925,,,,,,,,,,,,
Spermidine,SARS-COV-2,10.1101/2020.04.15.997254,,NCCCNCCCCN,1102,,,,,,,,NCCCNCCCCN,
MK-2206,SARS-COV-2,10.1101/2020.04.15.997254,,O=c1[nH]nc2n1ccc1c2cc(c(n1)c1ccc(cc1)C1(N)CCC1)c1ccccc1,24964624,,,,,,,,O=c1[nH]nc2n1ccc1c2cc(c(n1)c1ccc(cc1)C1(N)CCC1)c1ccccc1,
Niclosamide,SARS-COV-2,10.1101/2020.04.15.997254,,Clc1ccc(c(c1)C(=O)Nc1ccc(cc1Cl)[N+](=O)[O-])O,4477,,,,,,,,Clc1ccc(c(c1)C(=O)Nc1ccc(cc1Cl)[N+](=O)[O-])O,
Amodiaquine,SARS-COV-2,10.1101/2020.04.13.039917,,CCN(Cc1cc(ccc1O)Nc1ccnc2c1ccc(c2)Cl)CC,2165,,,,,,,,CCN(Cc1cc(ccc1O)Nc1ccnc2c1ccc(c2)Cl)CC,
Toremifene,SARS-COV-2,10.1101/2020.04.13.039917,,ClCCC(=C(c1ccccc1)c1ccc(cc1)OCCN(C)C)c1ccccc1,3005573,,,,,,,,ClCCC(=C(c1ccccc1)c1ccc(cc1)OCCN(C)C)c1ccccc1,
,,,,,,,,,,,,,,
,,,,,,,,,,,,,,